Development of a novel class of pharmacodynamic hybrids/no donors that targets cox-2 selectively and a machine-assisted flow procedure for the synthesis of meclinertant, a neurotensin receptor probe by Battilocchio, Claudio
  
 
 
Development of a Novel Class of Pharmacodynamic 
Hybrids/NO Donors that Targets COX-2 Selectively and a 
Machine-Assisted Flow Procedure for the Synthesis of 
Meclinertant, a Neurotensin Receptor Probe 
 
 
 
 
 
 
 
 
 
 
PhD candidate in Pharmaceutical Sciences 
Claudio Battilocchio 
Sapienza University of Rome 
Abstract 
The work described below is divided into two parts. 
 In the first chapter, the development of a novel class of pharmacodynamic hybrids is discussed. 
These compounds are endowed with analgesic/anti-inflammatory properties along with their 
ability to release nitric oxide which makes them an important contribution to the development 
of effective COX-Inhibiting Nitric Oxide Donors.  
In the second chapter, the synthesis of an important neurotensin receptor antagonist (SR 
48692, Meclinertant) is described.  The synthesis of Meclinertant is achieved with the use of 
machine-assisted flow protocols through a robust, reliable and scalable route. 
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Abbreviations 
 
AA Arachidonic acid 
ACHC Aza-bis(cyclohexanecarbonitrile)  
AcOH Acetic acid 
ASA Acetyl salicylic acid 
Boc Tertbutyloxy carbonyl 
BPR Back pressure regulator 
CBz Benzyloxy carbonyl 
CFC Continuous flow coil 
CINODs COX Inhibiting Nitric Oxide Donors 
CMC Carboxymethyl cellulose 
cNOS Constitutive Nitric Oxide Synthase 
COX-1 Cyclooxygenase-1 
COX-2 Cycloxygenase-2 
CV  Cardiovascular 
DCM Dichloromethane 
DIPEA Diisopropyl ethyl amine 
DMAP Dimethylamino pyridine 
DMC Dimethyl carbonate 
DMF Dimethyl formamide 
DMI Dimethyl imidazole 
DMSO Dimethylsulfoxide 
DSC Differential scanning calorimetry 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Et2O Diethyl ether 
FBS Fetal bovine serum 
GAG Glycosaminoglycans 
GC Guanilate cyclase 
GI Gastrointestinal 
GTN Glyceryl Trinitrate 
HOBt 1H-Hydroxybenzotriazole 
HRMS High resolution mass spectrometry 
HWB Human Whole Blood 
IL-β Interleukin-β 
iNOS Inducible Nitric Oxide Synthase 
ISDN Isosorbide nitrate 
LC-MS Liquid chromatography-mass spectrometry 
LPS Lipopolysaccharide 
MeOH Methanol 
Na2EDTA Edetate disodium 
NIS N-iodosuccinimide 
NMR Nuclear magnetic resonance 
NO Nitric Oxide 
NOBA 4-Nitroxybutanol 
Nox Nitrates and nitrites 
NSAIDs Non Steroidal Anti-inflammatory Drugs 
OA Osteoarthritis 
ODQ 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one  
PBS Phosphate buffer saline 
PFA Perfluoroalkoxy polymer 
PG Prostaglandin 
PGE2 Prostaglandin E2 
PTC Phase transfer catalyst 
PTSA Para-Toluene sulfonic acid 
PyBop Benzotriazol-1-yl-oxy tripoyrrolidinophosphonium hexafluorophosphate 
SGF Simulated gastric fluid 
TEA Triethylamine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin liquid chromatography 
TMS Tetramethyl silane 
tNSAIDs traditional Non Steroidal Anti-inflammatory Drugs 
 
 
 
 
Flow chemistry symbols 
 
 Polymer tubing 
 
Switching valve or T-piece 
 
Pump 
 
Reactor (coiled polymer tubing) 
   
Pressure chamber 
 Column  
 Backpressure regulator (related to specified pressure) 
 
Functionalised monolithic reactor 
 
Polyme supported reagent 
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Introduction 
Non-Steroidal Anti-inflammatory Drugs. Acetyl salicylic acid (ASA) was first synthesised in 
1853 by the French chemist Charles Frédéric Gerhardt (Figure 1).1 However, years later (1899) 
a German chemist named Felix Hoffmann, who worked for Bayer, rediscovered Gerhardt's 
molecule. Hoffmann then convinced Bayer to market the new wonder drug under the name of 
Aspirin which was patented on February 27, 1900.2 Since then, Aspirin has been one of the most 
popular over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) used as pain reliever 
and anti-inflammatory drug for fever, headache, migraine and acute pain.  
 
 
 
Figure 1. Charles Fréderic Gerhardt, Felix Hoffmann and Aspirin (its chemical structure and products 
marketed by Bayer at the beginning of the 20th century) 
 
NSAIDs are a chemically heterogeneous class of molecules sharing the biochemical feature of 
blocking the synthesis of prostanoids (prostaglandins, thromboxanes and prostacyclins) 
(Figure 2). Prostanoids are important biologically active autacoids generated through the 
arachidonic acid (AA) cascade by a class of enzymes defined prostaglandin-H synthases which 
are most popularly known as Cyclooxygenases-1 (COX-1) and Cyclooxygenases-2 (COX-2). 
These autacoids play an important role in maintaining homeostatic functions in the human body 
as they are involved in cytoprotection of gastric mucosa, renal physiology, blood flow 
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regulation, gestation. Additionally they are implicated in a number of pathological 
conditions such as inflammation, cardiovascular diseases and cancer.3,4 
 
 
Figure 2. Structures of prostaglandins, prostaclyclins and tromboxanes 
 
Though COX-1 and COX-2 both exhibit cyclooxygenase and peroxidase activities, different 
catalytic and transcriptional pathways are involved in their regulation in the human body 
(Figure 3).5, 6 
 
 
 
Figure 3. Crystallographic structures of COX-1/flurbiprufen complex and COX-2/DuP-697 complex 
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Remarkably, COX-2 requires considerably lower levels of hydroperoxides to initiate 
cyclooxygenase catalysis than those required by COX-1 and COX-2 exerts its activity at lower 
levels of free AA than COX-1. Another important difference is related on the regulation of the 
expression of the two isoenzyme genes. COX-1 has the structural features of an “housekeeping” 
gene while COX-2 appears as an immediate early gene.7, 8 Moreover, both mRNA and protein of 
COX-1 are more stable than those of COX-2.9 Thus, COX-1 is constitutively expressed in almost 
all tissues and is responsible for physiological functions such as gastrointestinal cytoprotection, 
platelet aggregation and vascular smooth muscle tone modulation.10 On the other hand, COX-2, 
the second isoform, was identified as an inducible enzyme, highly expressed in response to 
interleukin-1β (IL-1β) and other inflammatory stimuli.10 However, this strict separation of the 
function of COX-1 and COX-2, as constitutive and inducible, respectively, is now considered 
naïve. In-depth knowledge of COX-isoform biology has shown that COX-1 can be up-regulated in 
some circumstances (such as cell differentiation) and COX-2 can be constitutively expressed in 
physiologic conditions.11 The only thing that appears clear is that COX-2 is the isoform directly 
involved in mediating and enhancing the inflammatory/hyperalgesic stimulus.  
According to US National Center for Health Statistics, over 50 % of prescriptions for NSAIDs in 
the last decade were related to diseases of the musculoskeletal system and connective tissue, 
including arthritis. In addition, NSAIDs are widely used as analgesics in various pathologies for 
the treatment of mild to moderate pain and may be combined with opioids to treat moderate to 
severe pain (Figure 4). 
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Figure 4. Structures of some NSAIDs 
 Most of the “Big Pharmas” are leaving the area of research for new pain treatments, since they 
consider this area too challenging, and despite a substantial investment there has been minimal 
progress in developing new efficacious and safe analgesics.12 Indeed, the use of NSAIDs is 
hampered by side-effects which include gastrointestinal (GI) disorders ranging from minor 
dyspepsia to major ulcers, kidney effects and cardiovascular (CV) effects.13 The GI side-effects 
(known as NSAID-induced gastropathy) are the most relevant problem in long-term NSAIDs 
administration.12,13 NSAIDs are widely used worldwide and since gastroduodenal erosions and 
ulcerations are estimated to affect up to half of chronic NSAIDs users, this GI adverse effect has a 
major world health implication. The development of COX-2 selective NSAIDs  or coxibs was 
meant to circumvent these side effects, by selectively inhibiting the isoenzyme involved in the 
production of pro-inflammatory mediators (Figure 5).14  
 
Figure 5. Structures of some coxibs 
Though clinical trials have shown a reduction of gastrointestinal and renal side effects, an 
unexpected CV toxicity emerged during the coxibs post marketing outcome studies. Many 
subsequent studies were carried out to define the CV risks associated with coxibs and 
traditional NSAIDs (tNSAIDs). Though the increased cardiovascular morbidity was firstly 
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highlighted in large clinical trials investigating the safety of coxibs, later it appeared in studies 
involving tNSAIDs as well.15 
Renal side-effects of NSAIDs are less common, sometimes transient and often reversible upon 
drug withdrawal. However these side-effects, both in terms of incidence and severity, increase 
in patients with risk factors such as diabetes, heart failure, renal dysfunction and in the elderly. 
These side-effects seem to be common to coxibs and tNSAIDs and range from electrolytes 
retention/reduced glomerulal filtration to nephritic syndrome and chronic renal failure .16 
Additionally, recent studies underlined that the relation between inhibition of COXs and 
pharmacological effect (both therapeutic and adverse) could be more composite than it has 
been considered so far. This complex relation would generate from the finding that COX 
enzymes are homodimeric enzymes that act as conformational heterodimers.17   
Molecular hybridisation and nitric oxide. The complexity of many pathologies often requires a 
multi-target strategy in order to get different and complementary pharmacodynamic 
mechanisms. The use of pharmacological cocktails is usually used to accomplish this task, in 
order to get different effects within the same administration, although one of the main 
drawbacks is related to poor compliance. In the last few years a novel strategy has been adopted 
to overcome the administration of cocktails. The aim of this strategy is to generate molecular 
entities that can activate different targets, reduce the toxicity or change the bioavailability of the 
parent drug in order to increase the therapeutic efficacy of the parent drug itself. The concept of 
molecular hybridisation is related to the concept of multiple ligands where conjugation or 
overlapping of two or more molecular portions, gives rise to drugs able to recognise more than 
one receptor.18 
In recent years, many research groups have focused their efforts on the discovery and 
development of molecular hybrids characterised by a nitric oxide (NO) releasing moiety.18 While 
at high concentrations NO is cytotoxic and is part of the immune system, at low concentrations it 
has important functions in the overall homeostasis of the organism. In the GI tract, NO 
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modulates the blood flow contributing to mucosal defence against luminal irritants and it also 
modulates mucus and bicarbonate secretion. It has a striking role in mucosal healing processes 
and modulates vascular permeability. Furthermore, NO is known to be a cardioprotective agent 
due to its vascular activity. Increasing evidence suggests a considerable modulating effect of 
nitric oxide as a pleiotropic agent.19 
The role of NO in osteoarthritis (OA) has been recently reviewed.20 Although NO is one of the 
pro-inflammatory factors associated with OA, its role in the joint is more complicated than 
previously understood and recent evidences point for protective roles of NO generated by the 
constitutive isoenzyme form of nitric oxide synthase (cNOS) in the joint. This suggests that NO-
donors could be an asset in the OA treatment. Thus, while incubation of chondrocytes with a fast 
liberating NO donor such as glyceryl trinitrate (GTN) induces apoptosis, incubation with small 
amounts of NO or with diazenium diolates (a slow NO-donor) does not induce apoptotic cell 
death and has beneficial effects in chondrocytes, increasing alkaline phosphatase activity and 
collagen type X synthesis.21 There is a body of evidence that the degenerative activity due to an 
increase of NO concentration could be a result of an increase in peroxy-nitrite concentration. In 
chondrocytes NO and peroxynitrite have opposite effects in the nuclear factor-kappa B (NF-kB) 
activation. When cells are treated with a soft NO-donor, the number of cells with activated NF-kB 
decreased, while addition of peroxy-nitrite gives rise to a dramatic increase in NF-kB activation. 
Also other cells in the joint are differently influenced by different NO concentrations and/or 
peroxy-nitrite presence. Exposure of osteoblast cells to low NO levels have protective effects 
while exposure to high concentrations induced apoptotic cell death. 
Increasing evidence suggests that there is considerable cross talk between NO and 
prostaglandin (PG) biosynthesis.22 Indeed, the amount of NO released by cNOS or inducible NOS 
(iNOS) and the redox state of the cell system play a relevant role in the modulation of COX 
enzymes leading to opposite responses. A mass of experimental evidences has recently shown 
that low concentrations of NO down-regulate PG biosynthesis, mainly via inhibition of COX-2 
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activation. NO donors added exogenously to lyphopolysaccarides-treated microglia, endothelial 
and J774 cells inhibit PG release and reduced COX-2 expression in vitro and in vivo.23 
Accordingly, a beneficial role played by NO can be recognised for arthritis and other COX-
mediated diseases. However, as in the cases of the treatment of CV and GI side-effects, the NO 
concentration and then the kinetic for its release is fundamental to make the difference between 
a protective/therapeutic effect and a deleterious effect. The release should be slow and the NO 
concentration should be maintained within the nanomolar levels, such as those liberated by 
cNOS, while agents which liberate in the short time micromolar levels of NO are expected to give 
rise to iNOS-like effects, in addition to possible hypotensive effects. 
Generation of exogenous nitric oxide. Inorganic nitrates and nitrites are metabolised in vivo to 
form NO.24 However the kinetic, the site, and the concentration of NO liberation cannot be 
controlled when these inorganic nitrates are administered. Organic nitrates are characterised 
with a more complex fate in the organism. For instance glyceryl trinitrate (GNT) has been 
therapeutically used for the treatment of angina since 1878. GNT and its congeners (i.e., 
isosorbide nitrate, ISDN) are absorbed almost unchanged and rapidly converted into the 
organism by enzyme-dependent mechanisms into their metabolites and NO (Figure 6).  
 
 
 
Figure 6. Glyceryl nitrate and isosorbide dinitrate structures 
Two main biological pathways are responsible for the generation of NO from organic nitrates, 
the first involving an interaction with endogenous thiol-containing compounds (cysteine or 
glutathione, to form intermediate nitrosothiols), the other being a completely enzymatic redox 
reaction.25 
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CINODs and Naproxcinod. An interesting class of pharmacodynamics hybrids is represented by 
COX Inhibiting Nitric Oxide Donors, namely CINODs. This class of molecules was firstly 
developed with the aim to cut down the GI side effects related to the administration of NSAIDs, 
through the conjugation of existing tNSAIDs with a nitric oxide releasing moiety. This kind of 
strategy was first explored by NicOx through the development of two representative drugs of 
the CINODs family:  NO-flurbiprofen (HTC-1026) and Naproxcinod (AZD3582) (Figure 7).26 
 
 
 
Figure 7. Structure of CINODs, NO-Flurbiprofen and Naproxcinod 
Naproxcinod is the first drug of the CINODs class at the latest clinical trial. The phase III studies 
confirmed that Naproxcinod dosed at 375mg was comparable to 500mg dose of Naproxen in 
relieving signs and symptoms of OA and it was well-tolerated with most adverse effect being 
mild-to-moderate.27 A large clinical program of 37 studies was conducted for Naproxcinod with 
about 6,500 patients and three large pivotal studies, where safety was completely assessed in 
4,000 patients. Interestingly, even though GI side-effect related to Naproxcinod appeared only 
slightly better than those of Naproxen, an improved CV safety appeared during these studies.28 
Naproxcinod (750mg twice a day) reduced systolic blood pressure compared to Naproxen. In 
addition, the difference in mean change from baseline in systolic blood pressure between 
Naproxen and Naproxcinod was 6.5 mmHg in favour of Naproxcinod in patients with 
hypertension. The findings that Naproxcinod does not induce any increase of blood pressure, as 
with Naproxen and other NSAIDs, prompted NicOx to adjust the strategy focusing their drug for 
treating pain and inflammation in patients with congestive heart failure, liver disease, cirrhosis, 
pre-existing renal disease, elderly with renal impairment, chronic renal failure or essential 
hypertension.29 
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Naproxcinod is the ester of Naproxen with 4-(nitroxy)butanol (NOBA). In order to exert its 
analgesic and anti-inflammatory activity Naproxen must be liberated from Naproxcinod, which 
in this case acts as prodrug (Figure 8).  
 
 
 
Figure 8. Conversion of Naproxcinod through two main metabolic pathways 
In the blood and intestine Naproxcinod is converted into naproxen by esterases and only a 
modest amount of unchanged drug is found in plasma after oral administration. In humans 
about 9-20% of the dose appears to be taken up as intact substance. The circulating 
Naproxcinod is further metabolised with a half-life of about 3 hrs.30 Accordingly, Naproxcinod is 
converted mainly in the GI and for the remaining part in the organism into Naproxen which 
acting as COX inhibitor gives rise to the analgesic and anti-inflammatory actions. Though 
Naproxcinod in theory can release NO according to two independent mechanisms (Figure 8), 
one involving NO liberation from the intact drug to give rise to the alcohol metabolite, while the 
other implies Naproxcinod hydrolysis into Naproxen and the NO releasing moiety NOBA, the 
extensive GI hydrolysis excludes the first mechanism as the main NO releasing pathway. Since 
plasma nitrate levels were found to be significantly elevated after single and repeated doses of 
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Naproxcinod, it should be deduced that the main source of NO is the organic nitrate NOBA, 
which is mainly liberated and adsorbed in the GI. A common pathway for NO generation 
between Naproxcinod and GNT was defined and later NO-flurbiprofen was shown to be 
characterised by the same kinetic of NO-release, highlighting the NOBA moiety as the active 
metabolite of Naproxcinod responsible for NO activity. Accordingly, Naproxcinod is mainly 
converted in the GI into two active metabolites: Naproxen responsible for analgesic and anti-
inflammatory activity and NOBA responsible for NO related effects including the CV effects. The 
high in vivo metabolism of Naproxcinod into these metabolites can be at least in part 
responsible for some discrepancies found between in vitro and in vivo studies and explain some 
deviations from expectations seen with Naproxcinod. Moreover, NOBA, like GNT, acts as a 
relatively fast NO releaser (CV effects are seen up to 3hrs from drug administration) while the 
duration of action of naproxen is 7-10 hrs.31 This does not completely match the 
pharmacokinetics of the NO-release with the COX inhibition and could give rise in the long term 
use of the drug to a more limited CV protection than that expected on the basis of the present 
data. 
Rationale and aims. It appears at the present that only COX inhibition by NSAIDs represents an 
efficacious and cost effective therapy for the treatment of mild-to-moderate pain and 
inflammation. On the other hand GI side-effects seriously impact the long term use of traditional 
NSAIDs (tNSAIDs), while CV adverse effects hamper a widespread use of coxibs. Naproxcinod 
clinical data highlighted how the combination of a NO-donor moiety with a tNSAIDs, even 
though not giving rise to substantial improvement in GI toxicity of Naproxen, improved the CV 
safety. 
Accordingly, the combination of a COX-2 inhibitor with an NO-donor should provide a drug 
endowed with strong analgesic and anti-inflammatory properties, sparing the GI and endowed 
with the appropriate CV safety. The novelty in developing a class of molecules that would exert 
both COX inhibition and NO donor actions, without the need to be hydrolysed is based on the 
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idea of providing a drug endowed with chimeric pharmacokinetic properties, assuring COX-2 
inhibition and NO suitable concentration at the same time and in the same compartment. In 
addition, the NO-releasing properties could improve the CV-protective properties and gain an 
advantage of those favourable effects exerted by low NO concentrations on inflammatory and 
cartilage degradation processes, as discussed above. The scaffold present in the original COX-2 
inhibitors of Rottapharm S.p.A., patented  and granted, was used as scaffold for the design of 
dual COX-2-inhibitors/NO-donors (Figure 9).32 
 
 
 
Figure 9. Core structure of the selective COX-2 scaffold by Rottapharm S.p.A.; Site A corresponds to the 
site which is likely to interact with Tyr-385 of the catalytic pocket, whereas Site B is responsible for 
interaction with the side pocket of the enzyme; it was suggested that the side chain of the molecule could 
be involved in selective interactions as well 
Though several examples describe the “hybridisation” of NSAIDs, few of those involve the 
modification of a coxib-like structure, namely a selective COX-2 inhibitor.33 
Selective COX-Inhibiting Nitric Oxide Donors. We followed the pioneering strategy adopted by 
NicOx. Nonetheless our idea was to conjugate the COX-2 structure identified previously 
(Rottapharm S.p.A.) with a nitric oxide releasing moiety to give access to new molecular entities 
endowed with reduced toxicity (CV and GI) and enhanced pharmacodynamic properties (Figure 
2), where the molecule itself would present chimeric pharmacodynamic properties. The 
chemical manipulation was focused mainly on position 3 of the pyrrole core in order to retain 
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COX-2 inhibitory properties both in terms of potency and selectivity and to introduce an NO-
releasing moiety with appropriate characteristics. It has been speculated that the addition of a 
polar substituent on the heterocyclic core could improve the selectivity and the affinity for the 
alternative binding site in COX-2 (through engagement of H-bond interactions with the close 
Arg513 side chain which is present only in this isoform), due to dynamic interactions between 
the enzyme pocket and the ligand. The development of this novel panel of compounds was 
based on the dynamical features of this ligand-binding mechanism, where the polarity of the 
side chain is considered extremely important for selectivity. Three main classes of compounds 
were explored for COX-inhibitory activity and NO-releasing properties (Figure 10). 
 
Figure 10. Structures of compounds belonging to the four generations of Selective COX-2 
Inhibiting/Nitric Oxide Donors 
Aiming at achieving a full understanding of all the dynamic interaction of these molecules with 
the human body and the role of the NO-release at any level, nitro-free derivatives were also 
synthesised and tested.  
Stepwise approach to solubility and metabolic stability. When dealing with drug discovery 
and development, the concept of “bioavailability” is always to be considered of great 
importance. The bioavailability of any xenobiotic introduced in the human body is mainly 
determined by two parameters: solubility and metabolic stability. The former is determined by 
the amphiphilic character of biological membranes: in other words, balanced ratios between 
lipophilicity/hydrophilicity represent ideal conditions to allow the drug to reach the blood 
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 29 of 195 
 
stream and then the target. The latter is important in the sense that any alteration of the 
molecular structure could lead to inactivation of the biological properties or to an improvement 
of its toxicity. Moreover, as explained before, in the case of “pharmacodynamic hybrids” (as 
Selective COX-2 Inhibitors/Nitric Oxide Donors) the metabolic stability would provide a drug 
endowed with chimeric pharmacokinetic properties. It was reasoned that a stepwise approach 
would be more useful for a broader achievement ensuring COX-2 inhibition and NO-releasing 
properties. The starting point was a generation of molecules (acetic acid esters) that are 
characterised by low stability and solubility; the molecular structure was then adjusted 
stepwise in order to increase the solubility at first (glycine esters) and then stability (acetic acid 
and glycine amides).  
Solubility in phosphate buffered saline (PBS) and simulated gastric fluid (SGF). Since this kind of 
molecules (if marketed) would be administered “per os”, it is reasonable to check out the 
eventual solubility in the gastric and in the body fluids environment. To fulfil these goals, SGF 
(pH 1.5) without pepsin and PBS buffer were used.34 
Metabolic stability in phosphate buffered saline, simulated gastric fluid and rat plasma. After 
administration of any drug “per os”, this should be soluble enough to interact with the human 
body and then be absorbed. Metabolism is a crucial parameter that has to be considered when 
developing novel molecular entities since any metabolic action on a xenobiotic can dramatically 
change its therapeutic profile. To assess the sensitivity of these four classes of 
“pharmacodynamic hybrids”, SGF, PBS and rat plasma were used: the formers to assess the 
stability before absorption, the latter after absorption in the blood stream.35 
Biological and pharmacological evaluation. The evaluation of stability and solubility were always 
accompanied by biological and pharmacological issues related to every generation of molecules. 
Each compound was screened for activity and selectivity towards both cyclooxygenases (1 and 
2). To correlate the physical chemical (solubility and metabolic stability) data and the in vitro 
data, ex vivo and in vivo tests were carried out. It is extremely interesting to notice how in vitro 
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and in vivo testing could show discrepancies that could be explained by means of 
pharmacokinetics. Cell-based assay. Both nitro-oxy and nitro-free compounds were subjected to 
biological evaluation through in vitro testing. The in vitro estimation of the title compounds was 
performed to assess their inhibitory activity on both COX-1 and COX-2. Abdominal constriction 
test. In the attempt to screen the analgesic activity, the writhing test was performed on 
compounds that were selected on the basis of the activity displayed in the cell-based assay. This 
test is extremely indicative when trying to predict the antinociceptive activity of any molecule. 
Paw pressure and oedema test. The carrageenan-induced inflammation test was used to assess 
the analgesic and anti-inflammatory activities of these compounds. This model of inflammation 
is based on determination of the animal threshold response to pain induced in the paw by the 
application of a uniformly increasing pressure. The measurement of the edema (carrageenan-
induced) volume after administration of the compound is used to predict the actual 
antiedemigenic activity. Human whole blood assay. The selectivity towards the COX-2 isoform 
displayed through the cell-based assay cannot be considered completely reliable, because the 
use of exogenous AA in the assay for COX-1 activity in vitro (in the murine 
monocyte/macrophage J774 cell line) can interfere with the COX-1 isoform leading to a 
conformation change within the enzyme binding site. The human whole blood assay (HWB) is 
an important tool to assess selectivity towards COX-isoenzymes in humans. This information is 
very important to predict the clinical consequences of the administration of any drug as the in 
vivo degree of inhibition of COX-1 and COX-2 depends on the dose.36 Nitric Oxide release. The 
evaluation of nitric oxide release is of utmost importance, for the development of the hybrids. 
The nitric oxide dependency, when vasorelaxation was observed, was evaluated via 
administration of a guanilate cyclase (GC) inhibitor, namely 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ). Incubation of selected compounds with liver homogeneate allowed 
to study the kinetic of release and the “species” which is responsible for the actual vasorelaxing 
effect.  
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Acetic esters derivatives: the first generation 
(Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; Alfonso, S.; Rovini, M.; Valenti, S.; Giorgi, G.; Calderone, 
V.; Testai, L.; Martelli, A.; Sautebin, L.; Rossi, A.; Papa, G.; Ghelardini, C.; Di Cesare Mannelli, L.; Giordani, A.; 
Anzellotti, P.; Bruno, A.; Patrignani, P.; Anzini, M. J. Med. Chem. 2011, 54, 77659-7771. Ref. 38). 
A first class of molecules with significant analgesic and anti-inflammatory properties was 
identified (Figure 11). These compounds were obtained by simple “conjugation” of selective 
COX-2 structures32 with nitrooxy alkyl chains of different lengths (two, three and four carbons) 
in order to investigate the influence of the NO-donor moiety size on nitric oxide release and 
COX-2 inhibition.  
 
Figure 11. Chemical structure of the first generation of compounds 
Considering that the nitro-oxy alkyl chains would be metabolised in vivo, the 
corresponding nitro-free derivatives were also synthesised and tested accordingly.  
Chemistry. Access to the pyrrole core (14a-e) is given via a Stetter reaction between methyl-
vinyl ketone and p-methylthiobenzaldehyde (11), an oxidation of compound (12) by means of 
Oxone and a final Paal-Knorr condensation with a selection of anilines. Then a regioselective 
acylation with titanium tetrachloride/ethoxalylchloride, followed by reduction with 
triethylsilane/trifluoracetic acid and hydrolysis in basic conditions afforded the acid derivatives 
(17a-e).32 A final coupling of the acids with diols (18a-c) gave access to esters (2a-o), whereas 
the use of nitroxyalcohols (19a-c) as coupling partners afforded esters (1a-o). Nitro-oxy 
alcohols (19a-c) were obtained from diols (18a-c) using a simple nitrating overnight 
procedure.37 
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Scheme 1. Synthesis of compounds (1a-o) and (2a-o) 
. 
 
In vitro assay. This first class of esters (similar to Naproxcinod and NO-flurbiprofen) displayed 
selective low micro and nanomolar COX-2 inhibition (Table 1). Interestingly, these compounds 
were potent and selective COX-2 inhibitors as nitroesters (before releasing NO and/or to be 
hydrolyzed to the corresponding acid) and this represents the first striking difference in 
comparison with Naproxcinod.30, 31 The corresponding alcohols (potential metabolites formed 
after NO release) are also effective in inhibiting COX-2, even although the presence of the nitro-
oxy group is associated with higher extents of inhibition and selectivity. The data showed that 
substitution on the phenyl ring at N1 had an influence on selectivity and potency. Indeed, 
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activity could be modulated from low nanomolar (19 nM, 1d) to low micromolar (0.12 µM, 1g) 
simply by moving a fluorine substituent from position 3 to position 4. Side-chain length also had 
an impact on COX-2 activity as well (see: 1e, IC50 is 7.3 nM, vs. 1d and 1f, respectively 19 nM and 
69 nM). 
 
Table 1. Cycloxygenases inhibition for compounds (1) and (2) 
 
Compd R n 
COX-1 
inhibitio
n (%) 
COX-1 
IC50 
COX-2 
inhibition 
(%) 
COX-2 
IC50 
S.I.a 
1a H 2 19 >10 100 0.0430 >232 
1b H 3 27 >10 90 0.0420 >238 
1c H 4 10 >10 87 0.0900 >100 
1d 3-F 2 36 >10 96 0.0190 >526 
1e 3-F 3 75 1.1 97 0.0073 >150 
1f 3-F 4 10 >10 98 0.0690 >100 
1g 4-F 2 0 >10 100 0.1200 >344 
1h 4-F 3 28 >10 91 0.0372 >268 
1i 4-F 4 19     >10 92 0.0760 >100 
1j 4-SCH3 2 0 >10 100 0.0170 >588 
1k 4-SCH3 3 0 >10 99 0.0270 >370 
1l 4-SCH3 4 10 >10 82 0.1200 >100 
1m 4-OCH3 2 53 6.4 97 0.1700 >37.6 
1n 4-OCH3 3 0 >10 90 0.0024 >41667 
1o 4-OCH3 4 5 >10 87 0.1400 >100 
2a H 2 22 >10 100 0.096 >100 
2b H 3 0 >10 100 >10 n.c. 
2c H 4 2 >10 93 0.1100 >100 
2d 3-F 2 33 >10 80 0.0850 >100 
2e 3-F 3 0 >10 85 0.0230 >250 
2f 3-F 4 17 >10 89 0.0920 >100 
2g 4-F 2 21 >10 100 0.0390 >100 
\2h 4-F 3 0 >10 100 0.0560 >100 
2i 4-F 4 7 >10 96 0.1920 >100 
2j 4-SCH3 2 62 3.18 87 0.0850 37 
2k 4-SCH3 3 36 >10 85 0.2600 >30 
2l 4-SCH3 4 24 >10 80 0.9800 >10 
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2m 4-OCH3 2 5 >10 84 1.1000 >9 
2n 4-OCH3 3 27 >10 93 0.7000 >10 
2o 4-OCH3 4 33 >10 92 0.9000 >10 
Celecoxib - - 64 3.84 100 0.0610 >63 
a Selectivity index: IC50 COX-1 vs. IC50 COX-2 ratio. 
Stability and solubility assessment. Investigations on the chemical and enzymatic (esterases) 
sensitivity of these compounds highlighted the same problem described for Naproxcinod.31 The 
series of compounds were unstable at both neutral and acid pH values (PBS and SGF) (Table 2). 
Due to this chemical sensitivity, compounds belonging to this generation are likely to be cleaved 
into the acid and the NO-donor (NOBA or a NOBA analogue) under biological conditions, exactly 
as happens with naproxcinod, the only difference being the selectivity. 
 
Table 2. Stability assessment for compounds (1d) and (1e) 
Compound Time 
Parent molecule remained (%) 
PBS (pH 7.4) SGF (pH 1.5) Rat Plasma 
1d 
30 min 74.1 80.2 0.00 
60 min 53.6 65.7 0.00 
120 min 0.15 42.8 0.00 
1e 
30 min 88.10 87.40 0.10 
60 min 73.20 75.20 0.00 
120 min 62.90 61.00 0.00 
 
Moreover, these compounds were found to be poorly soluble both in PBS and SGF (Table 3). 
 
Table 3. Solubility assessment for compounds (1d) and (1e) 
Compound 
PBS (pH 7.4) 
µM 
SGF (pH 1.5) 
µM 
1d 1.6 <1 
1e 1.1 <1 
 
Vasorelaxing activity. Compounds (1a-o) were found to possess good vasorelaxing properties 
that were dependent on the nitric oxide pathway (nitric oxide release) (Table 4).  
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Table 4. NO-releasing efficacy and potency for compound (1a-o) and GTN 
 
Compound Emax pIC50 ODQ 
1a 65 ± 2 5.76 ± 0.08 + 
1b 44 ± 8 < 5 + 
1c 33 ± 5 < 5 + 
1d 69 ± 4 6.48 ± 0.06 + 
1e 39 ± 1 < 5 + 
1f 29 ± 1 < 5 + 
1g 58 ± 5 5.47 ± 0.07 + 
1h 41 ± 2 < 5 + 
1i 30 ± 3 < 5 + 
1j 65 ± 1 6.34 ± 0.06 + 
1k 41 ± 8 < 5 + 
1l 28 ± 5 < 5 + 
1m 77 ± 2 6.75 ± 0.05 + 
1n 41 ± 11 < 5 + 
1o 33 ± 3 < 5 + 
GTN 73 ± 2 6.90 ± 0.07 + 
 
The vasorelaxing activity of these molecules can be appreciated more when plotting the data in 
a graph (Figure 12). In the presence of ODQ no vasorelaxing activity was detected. This 
suggestes the mechanism is dependent on nitric oxide release. 
 
Figure 12. Representative concentration-response curves relative to the vasorelaxing effects evoked by 
compounds (1d) and 1g), in the absence (control, black squares) or in the presence (white circles) of 1 
µM ODQ 
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While the NO-releasing properties showed no dependence on the substitution pattern of the N1 
aromatic ring, varying the side chain length did alter the activity. This is probably due to 
differing solubilities of the compounds. Indeed, the vasorelaxing activity seems to increase with 
the reduction of the side chain length. The experimental evidence suggests that the NO-release 
occurs through a modulated “slow donating process” which is preferred for hybrid drugs 
(Figure 13).  
 
Figure 13. Time-dependent increase of the concentrations of NOx (nitrites + nitrates) following the 
incubation of 1 mM of (1d)  in rat hepatic homogenate, containing the opportune cofactors 
 
Whole human blood assay. In the ex vivo human whole blood (HWB) assay, the compounds 
showed a drop in inhibitory potency and selectivity toward COX-2 (Table 5 and Figure 14) 
when compared to the cell-based results.  
Table 5. Ex-vivo HWB assay for compounds (1d) and (2d) and reference compound Celecoxib 
 
Compound COX-1 IC50 (μM)a COX-2 IC50 (μM)a S. I.b 
1d 9.6 (6.3 – 14.6) 3.2 (2 – 5.5) 3 
2d 12.2 (7 – 21) 1.7 (0.94 – 3) 7.3 
Celecoxib 12.47 (8.6 -17.9) 0.54 (0.29 – 0.52) 23 
aIC50 values of COX-1 and COX-2 are reported as mean of three different experiments performed in duplicate and in brackets 95% 
confidence intervals (CI)  are shown. 
b Selectivity Index. 
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Figure 14. Inhibition of (1d) and (2d) on COX-1 and COX-2 activity in vitro in human whole blood; results 
are expressed as average percent of inhibition (N=3, MEAN+SEM) from three separate experiments 
In vivo testing. The results of the writhing test for (1d-f) and (2d-f) underlined a striking 
dependence on the side-chain length. Indeed, activity of the compounds decreased with the 
increase of the side chain size. Compounds (1d) and (2d) display a 70% of activity at their max 
dosage, compounds (1e) and (2e) displayed only by a lower activity (nearly 40% of writhes 
reduction), while (1f) and (2f) present a mere analgesic activity (around 20% of writhes 
reduction) (Table 6 and Figure 15).  
Table 6. Writhes reduction evoked in the mice by administration of compound (1d-f) and (2d-f) after 
treatment of intraperitoneal acetic acid 0.1% solution 
 
Compounda n° mice 
Dose po 
 µmol/kg-1 
n° writhes 
writhes 
reduction 
CMC 43 - 32.6+2.1 - 
1d 
12 42 17.1+2.3* 48% 
12 84 9.4+2.5* 71% 
1e 
18 41 25.7+2.8^ 30% 
10 82 24.9+2.2* 32% 
1f 
12 39 28.3+2.8^ 18% 
15 78 26.4+2.1* 27% 
2d 
8 7 26.9+3.0* 26% 
8 23 17.4+2.9* 48% 
8 46 16.2+2.8* 51% 
8 70 8.9+2.1* 73% 
2e 
10 45 25.3+2.8 30% 
10 90 20.6+2.2* 40% 
2f 
13 42 26.8+2.2* 26% 
12 84 26.0+2.9* 24% 
Celecoxib 10 26 13.4+2.6* 60% 
^P<0.05; *P < 0.01 versus vehicle treated mice. 
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Figure 15. Percentage of writhes reduction of compounds belonging to the first generation 
The results of the carrageenan-induced hyperalgesia and edema show good pharmacological 
profiles (Table 7). Compound (2d) is worthy of particular note since it displayed an 80% 
reduction of hyperalgesia 30 minutes after the treatment, when administered at a dose of 30 
mgkg-1. Comparison of (2d) with celecoxib showed similar features, with the main difference 
being a faster onset of the effect for (2d). The related nitroxy derivative (1d) displayed the same 
fast effect but its efficacy was abated after 60 minutes. This could be due to different metabolic 
pathways for the two compounds.  
Table 7. Paw pressure test and edema for compounds (1d-f) and (2d-f) with reference compound 
Celecoxib 
 
Pre-
treatment 
Treatmen
t 
Dose 
µmol/K
g 
Paw Pressure 
Edema 
Volume 
(mL) 
Before 
treatmen
t 
After Treatment 
30 min 60 min 120 
min 
Saline CMC 32 62.6+2.1 62.5+1.8 63.4+2.2 62.7+2.5 1.33+0.07 
Carrageenan CMC 28 61.9+2.0 33.7+2.6 35.1+2.3 34.8+2.3 2.44+0.08 
Carrageenan 1d 42 32.6+2.7 40.1+3.4 35.3+2.8 N.D. 2.52+0.06  
Carrageenan 1d 84 29.8+3.1 54.1+3.7 38.7+3.1 N.D. 2.17+0.08  
Carrageenan 1d 210 31.9+3.0 57.2+3.5 36.5+3.8 N.D. 1.88+0.08  
Carrageenan 1e 41 62.5+3.1 43.2+3.2 45.1+3.2 40.7+2.6 2.05+0.08 
Carrageenan 1e 82 63.2+3.3 45.5+3.7 44.9+4.1 36.8+3.8 1.96+0.09 
Carrageenan 1f 39 62.4+3.1 39.2+4.3 40.1+2.7 33.7+2.6 2.15+0.08 
Carrageenan 1f 78 61.4+3.3 41.5+3.6 43.7+4.8 37.9+4.0 2.00+0.08 
Carrageenan 2d 70 31.8±2.5 55.7±3.1 52.3±2.8 39.3±3.5 2.51±0.05 
Carrageenan 2d 45 62.6+3.1 41.2+3.0 45.8+3.1 36.4+3.1 N.D. 
Carrageenan 2e 90 61.3+3.0 43.1+3.6 48.8+3.3 44.4+3.3 N.D. 
Carrageenan 2f 84 61.1+3.2 40.1+3.0 43.3+3.2 39.4+2.3 N.D. 
Carrageenan Celecoxib 26 61.5±3.4 54.3±3.9 57.1±4.0 54.9±3.6 1.36±0.07 
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Conclusions. The slow donating properties, good selective inhibition towards COX-2 and the 
acceptable in vivo activity are an excellent starting point for this novel class of compounds. 
However, the extremely low solubility and the high sensitivity to enzymatic and non-enzymatic 
metabolic routes were considered major problems which needed to be overcome. The high in 
vivo metabolism of these molecules could be responsible of the discrepancies between the 
biological (in vitro) and pharmacological data (in vivo), indicating that the pharmacokinetic 
behaviour  plays a crucial role in the fate of this class of molecules. 
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Glycine esters derivatives: improving solubility 
(Biava, M.; Battilocchio, C.; Poce, G.; Alfonso, S.; Consalvi, S.; Porretta, G.C.; Schenone, S.; Calderone, V.; 
Martelli, A.; Testai, L.; Ghelardini, C.; Di Cesare Mannelli, L.; Sautebin, L.; Rossi, A.; Giordani, A.; Patrignani, 
P.; Anzini, M. Eur. J. Med. Chem. 2012, 58, 287–298. Ref. 40) 
Poor solubility can be caused by either high crystallinity of the molecule (due to zwitterion 
formation, insoluble salts, strong H-bonding networks, etc) or hydrophobicity. Hence high 
values of logP (absence of an ionisable moiety, high molecular weight) are undesirable.34,35 In 
the case of molecules belonging to the first generation of esters, the problem was the latter 
(Figure 15). Indeed, a rapid calculation of the cLogP for all compounds highlighted values 
between 3.25 to 4.50.  
 
Figure 15. CLogP calculated for compound 1d using ChemDraw software (version 12.0) 
Formulation strategies represent a fashionable and successful way to improve the solubility and 
bioavailability of active compounds; nevertheless, the study of these systems adds further 
parameters which results in added complexity and expense in the early stages of development.34 
It was therefore decided to improve the solubility through chemical modification of the 
identified core (Figure 16).  
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Figure 16. Chemical structure of compounds belonging to the second generation 
The introduction of an amino group would represent an effective improvement in order to give 
access to molecules endowed with higher solubility and higher diffusion within the hydrophilic 
environment of the cartilage. It was decided that the second generation of esters would be 
characterised by a meta-fluoro or para-fluoro substituent at the N-phenyl ring, for a higher 
degree of interaction shown in the first generation.32,38 Since we expected that the NO release 
could give rise to the nitro-free intermediates as metabolites, we decided to further synthesise 
and analyse the activity of these molecules to better understand the biological profile of this 
class of derivatives. 
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Scheme 2. Synthesis of the second generation of compounds 
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Chemistry. These molecules were prepared using a route to a common core, namely (21a-b) 
and then following two different approaches for the generation of nitro-oxy and nitro-free 
compounds (Scheme 2). As for compounds belonging to the first generation, the synthesis 
commences with a Stetter reaction between the para-methythiobenzaldehyde (11) and methyl 
vinyl ketone in the presence of a thiazolium salt catalyst. The compound obtained (12) is then 
oxidised by means of Oxone and subsequently a Paal-Knorr reaction affords the 1,5-
diarylpyrroles (14b-c). Regioselective acylation of the pyrroles is achieved by a titanium-
catalysed Friedel-Crafts reaction to obtain compounds (15b-c). The installation of the amino 
functionality was first attempted using a direct reductive-amination with ammonium acetate 
and screening different boron hydrides: unfortunately, we did not obtain very good results with 
yields ranging between 30 to 50%.39 Moreover, the long reaction time and the need to column 
the final mixture discouraged us from pursuing this approach further. However, we found that 
formation of the oxime, its subsequent reduction to the amine and protection were easily 
achieved without the use of chromatography, giving the products (22a-b) and (25a-b) in very 
good yields. Hydrolysis of these ethyl esters under mild conditions and subsequent coupling 
gave access to compounds (26a-f) and (27a-f). A final deprotection step yielded nitro-free 
compounds (4a-f) and nitro-oxy compounds (3a-f). As shown in the scheme above, the 
installation of the α-functionality is obtained using the same approach (oxime formation, 
reduction and protection) but employing two different protection strategies for the nitroxy and 
nitro-free derivatives. The tert-butyl-oxy carbonyl (Boc) protecting group was selected for the 
synthesis of the nitro-oxy compounds (3a-f), whose deprotection in mild acid conditions did not 
affect the stability of the nitro-oxy side chain. On the other side, the benzyl-oxy carbonyl (Cbz) 
group was used for the route to the nitro-free derivatives since a late stage double-deprotection 
was envisaged to yield compounds (4a-f). Indeed, compounds (27a-f) represent a double 
protected scaffold where catalytic hydrogenation can eliminate both the nitroxy and Cbz 
functionalities. 
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Solubility assessment. As shown in Table 8, the introduction of an ionisable moiety within the 
scaffold hugely increased the solubility as expected. However, it was clear that even though 
changes on that position were tolerated, alteration of activity could occur.  
 
Table 8. Solubility assessment for compounds (3d-f) (second generation) 
 
Compound 
PBS (pH 7.4) 
µM 
SGF (pH 1.5) 
µM 
3d 89.0 >200 
3e 80.0 >200 
3f 70.8 >200 
 
Analysis of the solubility profiles underlines a 200-fold improvement of solubility in SGF and 
around 100-fold in PBS(Figure 17). 
 
Figure 17. Solubility of (3d) and (1d) in both SGF and PBS 
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In vitro testing. As anticipated, the introduction of an ionisable moiety resulted in reduction of 
the activity in the cell based-assay. Indeed, this second generation of esters is endowed with 
lower extents of inhibition towards both COX-1 and -2. This can be clearly seen in Table 9, 
where activities of compounds range in the millimolar values, while first generation compounds 
exhibited low millimolar/nanomolar inhibition. 
 
Table 9. In vitro activity for compounds (3a-f) and (4a-f) 
 
Compound R N 
% inhib 
COX-1 
(10 µM) 
% inhib 
COX-2 
(10 µM) 
IC50 
(COX-1) 
(µM) 
IC50 
(COX-2) 
(µM) 
COX-1/ 
COX-2 
(S.I.)a 
3a 3-F 2 0 89 >10 1.10 >10.00 
3b 3-F 3 0 95 >10 0.82 >12.20 
3c 3-F 4 1 82 >10 1.00 >10.00 
3d 4-F 2 0 80 >10 1.89 >10.00 
3e 4-F 3 5 100 >10 1.51 >6.62 
3f 4-F 4 15 59 >10 1.41 >1.35 
4a 3-F 2 14 92 >10 1.09 >10.00 
4b 3-F 3 23 100 >10 0.76 >13.16 
4c 3-F 4 10 100 >10 0.22 >45.45 
4d 4-F 2 23 100 >10 1.45 >10.00 
4e 4-F 3 30 79 >10 1.19 >8.40 
4f 4-F 4 23 100 >10 1.50 >6.67 
a Selectivity index: IC50 COX-1 vs. IC50 COX-2 ratio. 
However, an average micromolar activity is still present in all compounds and selectivity 
towards the COX-2 isoenzyme is maintained. Amongst the nitro-oxy derivatives, (3b) proved to 
exert the best inhibition towards COX-2 (IC50 0.82 uM) while the nitro-free compound (4c) 
inhibited COX-2 isoform at the lowest IC50 value (0.22 uM).  
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In vivo testing. The results of the writhing test highlight that even though the introduction of 
the amino group in the original scaffold reduced the in activity in the cell-based assay, an 
appreciable analgesic activity is still detected in vivo (Table 10).  
Table 10.  Writhing reduction for compounds (3d-e) in comparison with their first generation 
homologues (1e-f)  
Compound n° mice 
Dose po 
 µmol/kg-1 
n° writhes 
writhes 
reduction 
CMC 43 - 32.6+2.1 - 
3e 
13 5.5 26.9±2.6 19% 
10 18.4 21.3±2.5 36% 
12 36.8 18.1±3.0 46% 
14 73.6 13.5±2.0 59% 
3f 
13 35.9 24.5±3.2 27% 
15 71.8 19.8±2.4 41% 
1e 
18 41 25.7+2.8^ 30% 
10 82 24.9+2.2* 32% 
1f 
12 39 28.3+2.8^ 18% 
15 78 26.4+2.1* 27% 
Celecoxib 10 26 13.4+2.6 60% 
^P<0.05; *P < 0.01 versus vehicle treated mice. 
Comparing the activities of compounds (3e) and (3f) it can be speculated that the side chain 
length inversely relates to the analgesic/anti-inflammatory potency of these molecules as 
observed in the first generation of compounds. Besides the outcast (3d) (not active), 
compounds (3e) and (3f) present higher activities than the parent compounds of the first 
generation. We hypothesise that although the molecular interactions of the amino derivatives 
are less favourable (cell-based assay), the solubility enhancement gained with the introduction 
of an ionisable group causes an overall increase in in vivo activity (Figure 18). 
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 47 of 195 
 
  
Figure 18. Comparison of writhes reduction between (3e) and (1e) (40 mgkg-1 dosage) 
As for the carrageenan-induced inflammation test, the data were collected every 15 min until 
activity of compounds was not detected anymore (Table 11).  
 
Table 11.  Activity of compounds 3e in comparison with (1d-e) in the carrageenan induced inflammation 
test  
Pre-
treatment 
i.pl. 
Treatment 
p.o. 
Dose 
(mg/
kg) 
Before 
treat. 
Paw-pressure 
Edema 
volume 
(mL) 
After treatment  
15 min 30 min 45 min 60 min  
Saline CMC 
- 61.2±2.5 65.6±3.4 58.9±3.8 61.4±4.1 63.6±4.0 1.44±0.05 
Carrageenan CMC 
- 36.1±3.3 32.8±2.9 30.6±3.2 31.8±2.2 34.8±3.1 2.71±0.08 
Carrageenan 3e 
20 
33.8± 
2.8 
40.2± 3.6 
(25%) 
43.7± 3.7 
(44%) 
38.3±3.1 
(27%) 
37.1±3.0 
(15%) 
2.58±0.05 
(15%) 
Carrageenan 
3e 40 32.9±3.0 
45.4±3.2 
(40%) 
50.2±4.4 
(70%) 
45.6±4.3 
(53%) 
37.5±2.8 
(16%) 
2.11±0.09 
(45%) 
Carrageenan 
1d 20 35.7±3.1 
38.7±3.3 
(18%) 
40.1±3.4 
(35%) 
38.7±3.4 
(29%) 
35.2±2.8 
(10%) 
2.52±0.06 
(17%) 
Carrageenan 
1d 40 29.8±3.1 
48.3±3.3 
(50%) 
54.1±3.7 
(80%) 
49.7±3.0 
(60%) 
38.7±3.1 
(23%) 
2.17±0.08 
(40%) 
Carrageenan 
1e 40 33.5±2.6 
41.2±2.2 
(40%) 
42.3±3.8 
(41%) 
40.7±2.6 
(40%) 
37.9±3.0 
(17%) 
2.35±0.07 
(35%) 
Carrageenan Celecoxib 
10 31.7±2.7 
45.7±4.2 
(45%) 
52.9±3.1 
(75%) 
48.3±3.4 
(56%) 
42.5±2.9 
(39%) 
2.53±0.05 
(17%) 
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A good extent of activity was already present after just 15 min. The results concerning (3e) 
show the maximum activity after 30 min (70% pressure reduction at 40 mgkg-1) and then after 
45 min (53% reduction) a decrease in activity. The same trend is observed for (1d) and (1e) 
(first generation), indicating that the pharmacokinetics plays a similar role whether or not an 
amino group is present on the side chain.37 As observed in the writhing test, the solubility 
enhancement of compound (3e) seems to be favourable as this compound is more active than 
the corresponding parent molecules (1e) (Figure 19).38  
 
Figure 19. Comparison of paw pressure reduction between (9e) and (13e) (40mgkg-1 dosage) 
The same cannot be said for (3d) which showed complete lack of activity (data not reported). 
Moreover, (3e) is endowed with an activity which is very close to that displayed by (1d).38 
Vasorelaxing effect. The vasorelaxing efficacy of compounds belonging to the second 
generation is definitely improved and can be accounted for by the enhanced solubility due to the 
introduction of the amino moiety (Table 12). Nevertheless, compound (1d) (first generation) is 
endowed with the best potency profile.38  
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Table 12.  Vasorelaxing activity of compounds (3d-e) in comparison with their first generation 
homologues (1d-f) 
Compound E max pIC50 +ODQ 1µM 
1d 69.0±4.0 6.48±0.06 + 
1e 39.0±1.0 n.c. + 
1f 30±1.0 n.c. + 
3d 80.0±1.9 5.95±0.05. ~ 
3e 84.0±2.0 5.66±0.03 ~ 
3f 93.0±1.3 5.81±0.01 ~ 
 
These compounds show a unique behaviour because their vasorelaxing properties are not 
completely NO-dependent. This is shown in Figure 19, where the vasorelaxing activity is 
partially detected even when ODQ is present (especially for 3f), suggeting a different 
mechanism. Investigation of this alternative mechanism is outside the scope of this research 
dissertation. 
 
Figure 20. Response vs. concentration curves for the vasorelaxing activity of (3d-f) 
Stability assessment. Even though the introduction of the amino group doesn’t reduce the 
activity in vivo, the drop of activity in the cell-based assay (which may exclude the activity on 
COXs), the potential interaction with other vasorelaxing routes (other than the NO-dependent 
one) and the “high” metabolic sensitivity to esterases (Table 13) could be considered negative 
features of this compound series. 
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Table 13.  Stability assessment for compound 3e 
Compound Time 
Parent molecule remained (%) 
PBS (pH 7.4) SGF (pH 1.5) 
Rat 
Plasma 
3e 
30 min 75.0 100 0.00 
60 min 75.0 100 0.00 
120 min 75.0 100 0.00 
 
In a stability assessment, (13e) exhibited a moderate stability in PBS and high stability in SGF, 
meaning that the introduction of the α-amino moiety reduces the sensitivity to non-enzymatic 
hydrolysis.  
Conclusions. This class of molecules proved to be more soluble and the vasorelaxing effect 
associated with their administration was far better than for the previous class of compounds. 
However, the reduced interaction with the enzyme in vitro (IC50 ranging in the millimolar 
concentration) and the absence of substantial increase of the in vivo activity led us to undertake 
further structural modifications of these molecules. 
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Three generations of amides: improving stability whilst keeping solubility 
(Biava, M.; Battilocchio, C.; Poce, G.; Alfonso, S.; Consalvi, S.; Porretta, G.C.; Schenone, S.; Calderone, V.; 
Martelli, A.; Testai, L.; Ghelardini, C.; Di Cesare Mannelli, L.; Sautebin, L.; Rossi, A.; Giordani, A.; Patrignani, 
P.; Anzini, M. J. Med. Chem. Submitted for publication Ref. 41) 
The chemical and enzymatic sensitivities of the first two generations of esters were speculated 
to be responsible for the gap between the biological and pharmacological issues.38, 40, 41 
Another class of compounds was generated through bioisosteric replacement of the ester 
moiety with the amide one. We had previously identified a need to generate more stable and 
soluble derivatives in order to enhance the pharmacokinetics. In particular, we designed and 
developed a subclass of “linear” acetic amides (first generation amides), “serine/homoserine” 
acetic amides (second generation amides) and glycine amides (third generation amides) 
(Figure 21).  
 
 
Figure 21. Structures of amides 
Due to the presence of an amino group which is protonated at physiological pH, the glycine 
derivatives were expected to better penetrate into the cartilage. Indeed, positively charged 
compounds are reported to better diffuse into the cartilage matrix due to electrostatic 
interaction with the negatively charged GAG-sulphates.42 
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The substitution pattern of compounds was based on the results obtained during the previous 
studies, where it was clearly underlined that a fluorine substituent on the N1 phenyl ring (meta 
or para) was associated to the best bio-pharmacological profiles.32,38,40 In the glycine amides 
series, only the meta fluoro substituent was selected. 
The phenyl ring in C5 of the central core presented a methansulfonyl group which has been 
proven to be responsible for selectivity towards COX-2. In order to understand the importance 
of the NO release (nitric oxide dependent effects), nitro-free derivatives were synthesised and 
tested accordingly. 
Chemistry. The first generation of amides was obtained as shown in the scheme below (scheme 
3). Access to the acetic acid derivative (17b-c) was achieved through a first Stetter “umpolung” 
reaction, followed by an oxidation using oxone, a Paal-Knorr condensation to get to the pyrrole 
ring (14b-c), a titanium-catalysed regioselective acylation, a reduction with triethylsilane and a 
final saponification.32,38,40 The nitro-oxy compounds (5a-d) were obtained using EDCI as 
activating agent, DMAP as covalent nucleophilic catalyst and then the nitro-oxyalkyl amines 
(29a-b). The nitro-oxyalkyl amines (29a-b) were obtained via nitration of amino alcohols (28a-
b) employing fuming nitric acid in dichloromethane and then precipitated as nitrated salts after 
addition of acetic anhydride.43 The nitro-free derivatives (6a-d) are obtained via a EDCI/HOBt 
coupling system in order to discriminate the nucleophilicity of the oxygen and the nitrogen. 
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Scheme 3. Synthesis of acetic acid derivatives bearing a non-ionisable side chain 
 
A second generation of amides was obtained following the same route to the acid derivatives 
(17b-c) as shown in the previous scheme. Activation of the acid derivative with benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and subsequent reaction with 
the amino acid (30a-b and 31a-b) gave access to the final molecules (nitro-oxy 7a-d and nitro-
free 8a-d). Compounds (31a-b) were obtained following the same nitrating procedure 
described for compounds (29a-b) (scheme 3).43 The amino acids (30a-b) used were racemic 
serine and homoserine (scheme 4). 
 
Scheme 4. Synthesis of acetic acid derivatives bearing an amino acid side chain 
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Glycine derivatives were prepared using a common route to derivative (21a) and then following 
two different strategies for the generation of nitro-oxy and nitro-free compounds (scheme 5).40 
Starting from the intermediate (15b) already described in the previous schemes, the installation 
of the amino functionality was achieved via oxime formation and then reduction to the glycine 
ethyl ester to afford (21a). A subsequent protection using two different protecting groups (Boc 
for 22, Cbz for 25), hydrolysis of the ethyl ester and coupling gave access to compounds (32a-b) 
and (33a-b). A final deprotection step yielded nitro-free (10a-b) and nitro-oxy compounds (9a-
b).  
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Scheme 5. Synthesis of acetic acid derivatives bearing an amino acid side chain 
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Solubility assessment. As expected the replacement of the ester functionality with the amide 
one gave rise to more soluble molecules. 
 
Table 14. Solubility assessment in SGF and PBS for compounds (1d), (3e), (5a), (5c), (7c) and (9a) 
 
Compound SGF (pH 1.5) (µM) PBS (pH 7.4) (µM) 
1d <1 1.6 
3e >200 80.0 
5a 150.0 >200 
5c 147.0 >200 
7c 112.0 90.5 
9a >200 >200 
 
Surprisingly, the introduction of a carboxylic acid moiety (compound 3c) was endowed with a 
lower extent of solubility (Table 14). This could be due to a participation of the carboxylic acid 
moiety to intramolecular H-bonding networks that stabilise the folding of the molecule leading 
to reduced solubility. On the other side “linear” amides showed good solubility in both SGF and 
PBS. However, the best solubility profile was displayed by the glycine amide (9a) whose 
solubility was higher than 200µM.  
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Stability in simulated gastric fluid (SGF-without pepsin), phosphate buffered solution (PBS) 
and rat plasma. Stability studies on (1d) and (3e) revealed the expected sensitivity of these 
structures to any metabolic pathway. However, it is interesting pointing out that the presence of 
the amino moiety, probably due to its steric hindrance or electronics conferred more stability, 
especially in SGF (100% of parent compound detected after 120 minutes). The effect of the 
bioisosteric replacement reduced dramatically the metabolic liability. The presence of an amide 
bond was indeed responsible of better stability especially for compounds belonging to the first 
and third subclass of amides (5a and 9a) (Table 15). In our conditions, compound (5a) was 
insensitive to any form of metabolic stress, whereas compound (9a) is relatively more sensitive 
in rat plasma (even though after 120 min of incubation 77% of the compound can still be 
detected). 
 
Table 15. Stability assessment in SGF and PBS for compounds (1d), (3e), (5a), (7a) and (9a) 
Compound Time 
Parent molecule remained (%) 
PBS (pH 7.4) SGF (pH 1.5) Rat Plasma 
1d 
30 min 74.1 80.2 0.00 
60 min 53.6 65.7 0.00 
120 min 0.15 42.8 0.00 
3e 
30 min 75.0 100 0.00 
60 min 75.0 100 0.00 
120 min 75.0 100 0.00 
5a 
30 min 100 100 100 
60 min 100 100 100 
120 min 100 100 100 
7a 
30 min 75.0 100 71.4 
60 min 50.0 93.8 57.1 
120 min 37.5 87.5 28.6 
9a 
30 min 100 100 94 
60 min 100 100 93 
120 min 100 100 77 
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The higher profile of sensitivity of the serine derivative (7a) could be explained by intra-
molecular interactions due to the presence of the carboxylic acid moiety, that could ease any 
chemical transformation on the side chain (enzyme mediated or not). 
In vitro COX-2 inhibition. Linear derivatives (5a-d and 6a-d) displayed an average inhibition 
towards COX-2 of 0.2-0.3 µM. Surprisingly, derivatives 6b and 6d (which are nitro-free 
compounds p-fluoro substituted) exhibited inhibitions in the nanomolar range that could be due 
to a non-specific cooperation between the N1 substitution and the hydroxyl chain, allowing very 
strong and effective interactions with the enzyme. As for the nitro-oxy amino acid derivatives, 
the data clearly show that serine derivatives are more active in vitro than the homoserine ones. 
The nitro-free compounds (8a) and (8d) displayed outstanding inhibitions against the COX-2 
isoform. Low COX-2 inhibitory potencies and high selectivity values are obtained within the 
third generation of amides (9a-b and 10a-b), demonstrating that the negative effect obtained in 
vitro with the previous class of glycine esters was due probably to a mismatch-interaction 
rather than to the presence of the amino group itself (Table 16). 
Table 16. In vitro COXs inhibition and selectivity for compounds (5a-d), (6a-d), (7a-d), (8a-d), (9a-b) 
and (10a-b) 
 
Compound R X n 
% inhib 
COX-1  
(10 µM) 
% inhib 
COX-2 
(10 µM) 
IC50 
(COX-1) 
(µM) 
IC50 
(COX-2) 
(µM) 
COX-1/ 
COX-2 
(S.I.)a 
5a 3-F NO2 2 0 95 >10 0.300 >33 
5b 3-F NO2 3 0 100 >10 0.250 >40 
5c 4-F NO2 2 0 100 >10 0.240 >42 
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5d 4-F NO2 3 0 100 >10 0.310 >32 
6a 3-F H 2 0 95 >10 0.240 >34 
6b 3-F H 3 21 100 >10 0.045 >220 
6c 4-F H 2 0 95 >10 0.300 >33 
6d 4-F H 3 17 100 >10 0.068 >147 
7a 3-F NO2 1 0 100 >10 0.140 >70 
7b 3-F NO2 2 27 43 >10 n.d. n.d. 
7c 4-F NO2 1 0 100 >10 0.310 >32 
7d 4-F NO2 2 6 89 >10 1.600 >6.2 
8a 3-F H 1 23 100 >10 0.057 >167 
8b 3-F H 2 16 79 >10 n.d. n.d. 
8c 4-F H 1 23 100 >10 0.160 >62.5 
8d 4-F H 2 16 79 >10 0.086 >116 
9a - NO2 2 10 90 >10 0.054 >185 
9b - NO2 3 10 86 >10 0.140 >71 
10a - H 2 10 25 >10 n.d. n.d. 
10b - H 3 10 83 >10 0.047 >200 
a Selectivity index: IC50 COX-1 vs. IC50 COX-2 ratio. 
Writhes reduction in the acetic acid-induced abdominal constrictions in mice. All 
compounds showed very good activity in reducing the abdominal writhes induced by acetic acid 
(Table 17). Compounds belonging to the first generation of amides were endowed with a 
higher extent of reduction compared to the serine/homoserine derivatives. In particular, 
compound (5c) displayed a 78% of reduction when dosed at 20 mg/kg. On the other side, the 
introduction of the amino moiety (which is associated to great stability and solubility, as shown 
before) gave access to a compound with outstanding properties. Derivative (9a) was active at 3 
mg/kg with a reduction of writhes around 18%; the reduction extent increases with the dose 
and reached 56% when the compound was administered at 10 mg/kg and reached a plateau of 
80% when the dose was above 20 mg/kg, meaning that the maximum efficacy of this molecule 
had been reached already at 20 mg/kg. It is worth mentioning that nitro-free derivatives (6c) 
and (8a) displayed a lower extent of inhibition in this test when compared to the related nitro-
oxy compounds (5c) and (9a) and this could account for a direct NO dependent effect. The only 
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exception was the couple (7c)/(8c) where the nitro-free compounds were more active than the 
nitro-oxy ones and this could be explained by different metabolic pathways of 
activation/disactivation.  
Table 17. Writhes reduction for compounds 5a-d,  6c, 7a-d, 8c, 9a and 9b 
Compound 
n° 
mice 
Dose 
po 
 mg/kg-
1 
n° writhes 
after 30 
min 
writhes 
reduction 
CMC 43 - 32.6+2.1 - 
5a 
10 10 26.8±2.1 18% 
9 20 20.6±3.0 37% 
10 40 14.7±2.1 56% 
5b 
10 10 33.2±3.5 0% 
10 20 29.8±3.6 12% 
10 40 22.9±2.2 31% 
5c 
10 10 12.2+ 2.3 62% 
10 20 7.4+1.3 78% 
10 40 8.1+1.2 75% 
5d 
10 3 33.3+3.2 0% 
9 10 20.4+2.2 37% 
10 20 21.6+2.8 34% 
6c 
10 10 20.7±3.5 37% 
11 20 12.6±2.7 62% 
9 40 12.5±2.2 62% 
7a 
10 10 28.3+ 2.5 12% 
10 20 17.1+3.1 46% 
10 40 16.4+2.9 48% 
7b 
10 10 33.4+3.6 0% 
10 20 29.2+2.4 9% 
10 40 25.2+3.3 22% 
7c 
10 10 33.1+ 3.5 0% 
10 20 23.2+2.3 28% 
11 40 16.3+3.2 50% 
7d 
9 10 22.8+3.0 31% 
11 20 14.6+2.7 56% 
10 40 14.7+2.8 56% 
8c 
9 10 23.7+3.0 28% 
10 20 13.4+2.8 59% 
10 40 12.9+2.1 62% 
9a 
10 3 25.1±2.3 18% 
10 10 14.2±2.9 56% 
10 20 6.7±2.0 80% 
11 40 6.5±2.1 81% 
9b 
11 3 31.6+2.1 3% 
10 10 30.5±2.6 6% 
10 20 21.4±3.7 34% 
9 40 18.8±3.1 43% 
Celecoxib 13 10 13.5±3.0 61% 
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Reduction of hyperalgesia in the carrageenan induced inflammation and edema reduction. 
Compound (5c) and (9a) were selected for a further assessment of their in vivo profile through 
the carrageenan-induced edema and hyperalgesia. Surprisingly, the data on the carrageenan 
induced inflammation showed that (5c) was associated with a good but not outstanding activity. 
Indeed, at 40 mg/kg the maximum activity was reached after 60 minutes with a reduction of 
hyperalgesia equating to 60%. A mere activity was found when testing the compound for its 
anti-edemigenic properties (10%). On the other hand, compound (9a) proved to be highly 
active with a reduction of hyperalgesia of 80% after just 30 minutes. The activity is maintained 
after 60 minutes (70%) and after 90 minutes a good reduction was still displayed (50%). After 2 
hours, a residual analgesic activity could still be detected (26% reduction). An anti-edemigenic 
effect was observed with the administration of this compound at 20mg/kg. In these conditions 
the edema volume was reduced by about 76% (Table 18).  
 
 
 
 
 
 
 
 
 
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 62 of 195 
 
Table 18. Hyperalgesia and edema reduction in the carrageenan induced inflammation for compounds 
(5c) and (9a) in comparison with celecoxib 
Pretreat. 
(i.pl.) 
Comp. 
Dose 
(mg/kg
) 
Before 
treatm
ent 
Paw-pressure 
Edema 
volume 
(mL) After treatment 
30min 60 min 90 min 120 min 
Saline CMC - 
61.2±2.
5 
61.6±3.4 58.9±3.8 61.4±4.1 61.4±4.1 1.44±0.05 
Carrageenan CMC - 
36.1±3.
3 
32.8±2.9 30.6±3.2 31.8±2.2 31.8±2.2 2.71±0.08 
Carrageenan 
5c 20 
33.8± 
2.9 
40.7±3.5 
(28%) 
42.8 ±3.4 
(30%) 
37.8 ± 2.6 
(20%) 
32.7± 2.6 
(0%) 
2.63 ± 0.05 
(4%) 
Carrageenan 5c 40 
32.9±3.
3 
44.2±4.0
(32%) 
48.3±4.6 
(60%) 
41.5 ± 3.7 
(29%) 
31.5± 2.6 
(0%) 
2.50 ± 0.09 
(10%) 
Carrageenan 9a 20 
33.8± 
2.9 
55.2±3. 
(80%) 
52.1±4.2 
(70%) 
47.3±3.7 
(50%) 
39.5±3.0 
(26%) 
1.79±0.09 
(76%) 
Carrageenan Celecoxib 10 
33.8± 
2.9 
55.2±3. 
(80%) 
54.9±4.2 
(78%) 
49.3±3.4 
(60%) 
45.3±3.0 
(40%) 
1.83±0.07 
(70%) 
 
Ex vivo nitric oxide releasing properties. All nitro-oxy compounds showed NO-dependent 
vasorelaxing properties (Table 19). Derivatives belonging to the second subclass of amides 
(serine and homoserine derivatives, 7a-d) were associated to a mere vasorelaxing effect. 
Compounds (5a-c) were endowed with very good efficacy and potency but the vasorelaxing 
activity of these compounds was lower than for the ester (3e). However, the introduction of the 
amide functionality within the glycine skeleton gave rise to a class of compounds with 
outstanding vasorelaxing properties (9a and 9b).  
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Table 19. Vasorelaxing properties for compounds (5a-c), (7a-c) and (9a-b) in comparison with 
Naproxcinod, (1d) and (3e) 
Compound E max pIC50 +ODQ 1µM 
Naproxcinod 68.0±3.0 6.33±0.06 + 
1d 69.0±4.0 6.48±0.06 + 
3e 80.0±1.9 5.95±0.05. + 
5a 49.0±2.0 n.c. + 
5b 69.0±8.0 5.78±0.07 + 
5c 68.0±0.5 5.31±0.05 + 
7a 18.0±9.0 n.c. + 
7b 25.0±2.0 n.c. + 
7c 25.0±1.9 n.c. + 
7d 42.0±9.0 n.c. + 
9a 74.1±1.0 5.38±0.20 + 
9b 86.0±2.0 5.38±0.03 + 
 
The kinetic of NO release was also investigated for compounds (5c) and (9a). The concentration 
over time curve of both compounds described a class of molecules which were endowed with a 
slow kinetic of NO release, which is absolutely important for the development of this kind of 
hybrids (Figure 22).  
 
Figure 22. Time-dependent increase of the concentrations of NOx (nitrites + nitrates) following the 
incubation of 1 mM (5c) and (9a) in rat hepatic homogenate, containing the opportune cofactors 
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The first difference between the two compounds is that nitrated species were released faster 
with compound (5c). More interestingly, the other difference between the two compounds is 
that the overall amount of nitrated species for (5c) was generated by a direct release of nitrates, 
whilst for (9a) both nitrates and nitrites could be detected.  
Human whole blood assay. Compounds (5c) and (9a) were tested in the human whole blood 
assay.36 Along with the nitro-oxy amides (5c) and (9a) the  respective nitro-free derivatives (6c 
and 10a) were studied in the human whole blood assay. Compound (9a)  inhibited  COX-2  
activity in a  concentration-dependent fashion with an IC50 value of 21.23 µM  (Table 20).  
Table 20. COX-1 and COX-2 IC50 values for (9a) and (10a) in the HWB assay 
Compd n R 
COX-1 IC50 μM (95% CI) 
 
COX-2 IC50 μM (95% CI) 
 
S.I. 
 
9a 2 NO2 >100 21.23 (15.17- 29.71) >5 
10a 2 H > 100 144 (66-311) <1 
Celecoxib   12.47 (8.6 -17.9) 0.54 (0.29 – 0.52) 23 
 
At 100µM, this compound inhibited COX-2 activity by 80.2%, while it inhibited only marginally 
COX-1 activity (Figure 23).  
 
Figure 23. Inhibition/concentration curves for (9a) and (10a) in the HWB assay 
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COX-2 activity of the nitro-free derivative (10a) was characterised by an unusual concentration-
response curve. In fact, up to 100 µM, COX-2 activity was inhibited in a concentration-
dependent fashion reaching a maximal inhibitory effect of 43%.  At 100 µM, COX-1 activity was 
only marginally inhibited.  
Compound (5c) caused a concentration dependent inhibition of COX-1 and COX-2 activities with 
a respective IC50 of 0.8 and 3.2 µM, respectively. Surprisingly, this compound was 4-fold more 
potent towards COX-1 than COX-2.  Its nitro-free derivative (6c) inhibited COX-1 and COX-2  
activities with  similar  IC50 values of 1.9 and 1.4 µM, respectively  (Figure 24 and Table 21).   
 
Figure 24. Inhibition/concentration curves for (5c) and (6c) in the HWB assay 
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Table 21. COX-1 and COX-2 IC50 values for (1c) and (2c) in the HWB assay 
Compd n R 
COX-1 IC50 μM (95% 
CI) 
 
COX-2 IC50 μM (95% 
CI) 
 
S.I. 
 
5c 2 NO2 0.8 (0.5 - 1.3) 3.2 (1.8 - 5.6) 
0.23 
6c 2 H 1.9 (1.1 - 3.3) 1.4 (0.9 - 2.3) 1.33 
Celecoxib   12.47 (8.6 -17.9) 0.54 (0.29 – 0.52) 23 
 
As shown in Table 21, (5c) and (6c) inhibited COX-1 activity with similar IC50 values. The IC50 
values for the inhibition of  COX-2  activity by (5c) and its derivative were not significantly 
different. 
Conclusions. The replacement of the ester moiety with an amide one gave access to a stable and 
soluble class of hybrid compounds. Nitro-oxy derivatives highlighted a very good COX-2 
inhibiting feature both in rats and in humans. The NO-dependent vasorelaxing properties and 
the slow kinetic release of NO make these compounds an ideal class of pharmacodynamic 
hybrids. Among all derivatives, (5a) is endowed with an outstanding in vivo profile (comparable 
and in some extent superior to celecoxib). It is quite interesting to observe in the HWB assay 
that (5a) is a selective inhibitor of COX-2 and that its potential metabolite (6a) is endowed with 
very low affinity towards COX-2. This finding could mean that (5a) can efficiently inhibit COX-2 
and release NO whereas, when transformed to its metabolite, it loses its activity towards COX-2.  
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Conclusions  
A novel class of molecules that inhibits selectively COX-2 has been developed. These molecules 
proved to be effective nitric oxide donors and the biopharmacological tests have shown them to 
be potential analgesic and anti-inflammatory agents.  
Further work will focus on developing methabolically stable analogues (Figure 25). The future 
plan is to conjugate the identified molecular core with an adamantyl group. It has been proven 
that the adamantyl moiety, beyond increasing the partition coefficient of molecules when 
introduced, positively modulates the activity of therapeutics. One of the most outstanding 
features displayed by this group is the metabolic stabilization towards hydrolytic enzymes due 
to its steric hindrance. 
The 2-aminoadamantane 2-carboxylic acid core is a very challenging moiety to achieve. 
Although in the literature two synthetic pathways are described, both of them have been proven 
problematic in our hands. Though commercially available, this amino acid is extremely 
expensive. We developed a novel economic and scalable synthesis for this amino acid which is 
described in the following section.    
 
Figure 25. Representative structure of adamantyl-bearing molecules  
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Experimental procedures 
Chemistry. All chemicals used were of reagent grade. Yields refer to purified products and are 
not optimized. A CEM Discovery microwave system apparatus was used for the Stetter and 
Paal−Knorr reactions. Melting points were determined in open capillaries on a Gallenkamp 
apparatus and are uncorrected. Microanalyses were performed on a Perkin-Elmer 240C or a 
Perkin-Elmer series II CHNS/O analyzer 2400 instrument. Sigma-Aldrich silica gel 60 (230−400 
mesh) was used for column chromatography. Merck TLC plates (silica gel 60 F 254) were used 
for thin-layer chromatography (TLC). Sigma-Aldrich aluminum oxide (activity II−III, according 
to Brockmann) was used for chromatographic purifications. Sigma-Aldrich Stratocrom 
aluminum oxide plates with a fluorescent indicator were used for TLC to check the purity of the 
compounds. 13C-NMR and 1H-NMR spectra were recorded with a Bruker AC 400 spectrometer in 
the indicated solvent (TMS as the internal standard). The values of the chemical shifts are 
expressed in ppm and the coupling constants (J) in hertz. The purity of the title compounds was 
assessed by means of a Waters Alliance 2695 instrument equipped with an UV−vis Waters PDA 
996 as the detector and working at 333 nm. Millennium Empower with Windows XP was used. 
A Phenomenex LUNA C8, 5μm (150 mm×4.6 mm) column (code 00F-4249-E0) at 40°C was used 
as the chromatographic column at a flow rate of 1.0 mL/min. The eluent was (A) a 65/15/20 
(v/v/v) 10 mM (pH 2.5) KH2PO4/ MeOH/acetonitrile mixture or (B) a 15/75/10 (v/v/v) 10 mM 
(pH 2.5) KH2PO4/MeOH/acetonitrile mixture. A gradient from 100% A to 100% B was run in 25 
min, and then isocratic conditions at 100% B were maintained for an additional 10 min. Using 
the analytical conditions reported above, the retention times of the compounds range between 
7.44 and 17.25 min. All the synthesized compounds were generally more than 95% pure. 
Elemental analyses were determined at the ISS (Istituto Superiore della Sanita’) and are in 
accordance with the theoretical values within a tolerance of ±0.3%. 
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1-[4-(Methylthio)phenyl]pentane-1,4-dione (12).  
 
4-Methyl-thiobenzaldehyde (11) (11.97 mL, 90 mmol), triethylamine (19.5 mL, 600 mmol), 
methyl vinyl ketone (5.8 mL, 90 mmol), and 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium 
bromide (14 mmol) were microwave irradiated in a 80 mL vessel for 15 min (150 W, 70°C, 170 
psi). The mixture obtained was treated with 2 N HCl (10 mL) until pH 2 was reached. After 
extraction with ethyl acetate, the organic layer was washed with aqueous sodium bicarbonate 
and water. The organic fractions were dried over sodium sulfate, filtered, and concentrated to 
give a crude orange liquid. After crystallization from cyclohexane, intermediate (12) was 
isolated. White needles (78% yield), m.p. 75 °C; 1H-NMR  (400 MHz, CDCl3) δ (ppm): 7.87 (d, 2H, 
J = 8.0 Hz), 7.26 (d, 2H, J = 8.0 Hz), 3.23 (t, 2H, J = 7 Hz), 2.87 (t, 2H, J = 7.0 Hz), 2.52 (s, 3H), 2.25 
(s, 3H); Anal. (C12H14O2S) C, H. 
1-[4-(Methylsulfonyl)phenyl]pentane-1,4-dione (13). 
 
A solution of Oxone (61.4 mmol) in water (150 mL) was added dropwise over 15 min to a 
solution of (12) (35 mmol) in methanol (250 mL). The reaction mixture was stirred for 2 h at 
room temperature, then diluted with water (400 mL) and extracted with dichloromethane. The 
organic layer was washed with brine (200 mL), water (200 mL) and dried over sodium sulfate. 
Filtration and concentration under reduced pressure, give access to compound (13). White 
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crystalline solid (>92% yield), m.p. 138-140 °C; 1H NMR (400 MHz, CDCl3) δ (ppm): 8.16 (d, 2H, J 
= 8.0 Hz), 8.06 (d, 2H, J = 8.0 Hz), 3.28 (t, 2H, J = 7.0 Hz), 3.08 (s, 3H), 2.96 (t, 2H, J = 7.0 Hz), 2.26 
(s, 3H); Anal.(C12H14O4S) C, H. 
1-Phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrole (14a).  
 
Following the Paal−Knorr condensation conditions, p-(methylthio)aniline (2.28 mmol) and p-
toluenesulfonic acid (0.17 mmol) were added to a solution of compound (13) (2.28 mmol) in 
ethanol (2 mL). were added. The flask was inserted into the cavity of the microwave system 
apparatus and heated (150 W for 45 min, temperature 160°C, pressure 150 psi). The reaction 
mixture was cooled to room temperature and subsequently concentrated. The crude material 
was purified by chromatography on aluminum oxide using cyclohexane/ethyl acetate, 3:1 (v/v), 
as the eluent to give the expected 1,5-diarylpyrroles solids in satisfactory yields. Yellowish 
needles (79% yield), mp 105−110°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.78 (d, 2H, J =8.6 Hz), 
7.26 (d, 2H, J = 8.5 Hz), 7.13-7.06 (m, 5H), 6.39 (d, 1H, J = 5.0 Hz), 6.11 (d, 1H, J = 5.0 Hz), 3.01 (s, 
3H), 2.08 (s, 3H); Anal.(C18H17NO2S) C, H, N. 
1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrole (14b). Yellowish 
needles (76% yield), m.p. 106−110 °C. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.80 (d, 2H, J = 8.6 
Hz), 7.48 (d, 2H, J = 8.5 Hz), 7.20 (m, 1H), 7.04 (m, 2H), 6.41 (d, 1H, J = 5.0 Hz), 6.12 (d, 1H, J = 5.0 
Hz), 3.06 (s, 3H), 2.09 (s, 3H); Anal.(C18H16NO2SF) C, H, N. 
1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrole (14c). Yellowish 
needles (78% yield), m.p. 110−112 °C. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.71 (d, 2H, J =8.6 
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Hz), 7.46 (d, 2H, J = 8.5 Hz), 7.23 (d, 2H, J = 8.6 Hz), 7.02 (d, 2H, J = 8.5 Hz), 6.38 (d, 1H, J = 3.0 
Hz), 6.11 (d, 1H, J = 3.0 Hz), 3.01 (s, 3H), 2.06 (s, 3H); Anal.(C18H16NO2SF) C, H, N.  
1-[(4-Methylthio)phenyl]-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrole (14d). 
Yellowish needles (79% yield), m.p. 100−103 °C. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.77 (d, 
2H, J =8.6 Hz), 7.46 (d, 2H, J = 8.5 Hz), 7.17 (d, 2H, J = 8.6 Hz), 6.98 (d, 2H, J = 8.5 Hz), 6.39 (d, 1H, 
J = 3.0 Hz), 6.11 (d, 1H, J = 3.0 Hz), 3.01 (s, 3H), 2.51 (s, 3H), 2.06 (s, 3H); Anal.(C19H19NO2S2) C, 
H, N. 
1-[(4-Methoxy)phenyl]-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrole (14e). 
Yellowish needles (78% yield), m.p. 105−108 °C. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.78 (d, 
2H, J =8.6 Hz), 7.47 (d, 2H, J = 8.5 Hz), 7.20 (d, 2H, J = 8.6 Hz), 7.01 (d, 2H, J = 8.5 Hz), 6.40 (d, 1H, 
J = 3.0 Hz), 6.13 (d, 1H, J = 3.0 Hz), 3.88 (s, 3H), 3.06 (s, 3H), 2.09 (s, 3H); Anal.(C19H19NO3S) C, H, 
N. 
Ethyl 2-[1-phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]glyoxylate 
(15a). 
 
Ethoxalyl chloride (4.82 mmol) and TiCl4 (4.82 mmol) were added in sequence to a solution of 
pyrrole (14a) (4.82 mmol) in dry dichloromethane (5 mL), at 0°C under inert atmosphere. The 
solution was stirred for 4 h at room temperature and then quenched with ice water. The 
mixture was extracted with chloroform, and the organic layer washed with brine, dried under 
sodium sulfate and evaporated in vacuo to afford an oily mixture. Purification of this mixture by 
chromatography on silica gel employing petroleum ether/chloroform/ ethyl acetate, 4:3:1 
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(v/v/v), as the eluent gave a solid which, after recrystallization from hexane, afforded the 
expected product. Yellowish needles (77% yield), m.p. 105−110°C; 1H-NMR (400 MHz, CDCl3) δ 
(ppm): 7.75 (d, 2H, J = 8.6 Hz), 7.49 (d, 2H, J = 8.5 Hz), 7.18-7-10 (m, 5H), 6.49 (s, 1H), 4.12 (q, 
2H, J = 7.0 Hz), 3.09 (s, 3H), 2.11 (s, 3H), 1.43 (t, 3H, J = 7.0 Hz); Anal.(C22H21NO5S) C, H, N. 
Ethyl 2-[1-[(3-fluoro)phenyl]-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]glyoxylate (15b). Yellowish needles (79% yield), m.p. 115-113 °C; 1H-NMR (400 MHz, 
CDCl3) δ (ppm): 7.86 (d, 2H, J = 8.4 Hz), 7.43 (d, 2H, J = 8.4 Hz), 7.20 (m, 1H), 7.12 (m, 3H), 6.48 
(s, 1H), 4.12 (q, 2H, J = 7.1 Hz), 3.08 (s, 3H), 2.11 (s, 3H), 1.39 (t, 3H, J = 7.1 Hz); 
Anal.(C22H20NO5SF) C, H, N. 
Ethyl 2-[1-[(4-fluoro)phenyl]-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]glyoxylate (15c). Yellowish needles (77% yield), m.p. 113-115 °C, 1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.79 (d, 2H, J = 8.5 Hz), 7.56 (d, 2H, J = 8.5 Hz), 7.20 (m, 2H), 7.10 (m, 2H), 6.98 (s, 1H), 
4.12 (q, 2H, J = 7.1 Hz), 3.04 (s, 3H), 2.10 (s, 3H), 1.40 (t, 3H, J = 7.1 Hz); Anal.(C22H20NO5SF) C, H, 
N. 
Ethyl 2-[1-[(4-methylthio)phenyl]-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]glyoxylate (15d). Yellowish needles, mp 105−110°C (yield 73%). 1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.60 (d, 2H, J  = 8.6 Hz), 7.25 (d, 2H, J = 8.5 Hz), 7.17 (d, 2H,J= 8.6 Hz), 7.03−6.99 (m, 
3H,), 4.10 (q, 2H, J = 7.0 Hz), 3.00 (s, 3H), 2.54 (s, 3H), 2.09 (s, 3H), 1.55 (t, 3H, J = 7.0 Hz); 
Anal.(C23H23NO5S2) C, H, N. 
Ethyl 2-[1-[(4-methoxy)phenyl]-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]glyoxylate (15e). Yellowish needles (yield 71%), mp 100−103°C. 1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.84 (d, 2H, J = 8.6 Hz), 7.50 (d, 2H,J = 8.5 Hz), 7.23 (d, 2H, J = 8.6 Hz), 7.11 (d, 2H, J = 
8.6 Hz), 6.99 (s, 1H), 4.11 (q, 2H, J = 7.0 Hz), 3.88 (s, 3H), 3.00 (s, 3H), 2.09 (s, 3H), 1.45 (t, 3H, J = 
7.0 Hz); Anal.(C23H23NO6S) C, H, N. 
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Ethyl 2-[1-pheny-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetate (16a).   
 
Triethylsilane (0.75 mL, 4.7 mmol) was added slowly to a solution of 1,5-diarylpyrrol-3-
glyoxylic ester (15a) (2.3 mmol) in trifluoroacetic acid (9 mL, 0.12 mol), stirred at 0°C under 
nitrogen atmosphere. The mixture was reacted for 2 h at room temperature and then the pH 
adjusted to 12m using a 40% aqueous ammonia solution. The mixture obtained was extracted 
with chloroform. The organic solution was dried over sodium sulfate, filtered, and evaporated in 
vacuo. The resulting residue was purified by chromatography on silica gel using petroleum 
ether/chloroform/ethyl acetate, 4:3:1 (v/v/v), as the eluent to give a solid which, after 
recrystallization from ethanol, afforded compound (16a) Yellowish needles (77% yield), m.p. 
123−127°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.88 (d, 2H, J = 8.6 Hz), 7.47 (d, 2H, J = 8.5 Hz), 
7.20-7.13 (m, 5H), 6.46 (s, 1H), 4.10 (q, 2H, J = 7.0 Hz), 3.51 (s, 2H), 3.00 (s, 3H), 2.54 (s, 3H), 
2.09 (s, 3H), 1.55 (t, 3H, J = 7.0 Hz); Anal.(C22H23NO4S) C, H, N. 
Ethyl-2-methyl-1-[3-(fluoro)-phenyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-acetate 
(16b). Yellowish needles (73% yield), m.p. 133 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.90 (d, 
2H, J = 8.4 Hz), 7.50 (d, 2H, J = 8.4 Hz), 7.23 (m, 1H), 7.10 (m, 3H), 6.32 (s, 1H), 4.12 (q, 2H, J = 7.1 
Hz), 3.38 (s, 2H), 3.04 (s, 3H), 2.10 (s, 3H), 1.34 (t, 3H, J = 7.1 Hz). Anal.(C22H22NO4SF) C, H, N. 
Ethyl-2-methyl-1-[4-(fluoro)-phenyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-acetate 
(16c). Yellowish needles (71% yield), m.p. 133 °C, 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.99 (m, 
2H), 7.76 (m, 2H), 7.20 (m, 2H), 7.00 (m, 2H), 6.30 (s, 1H), 4.12 (q, 2H, J = 7.1 Hz), 3.39 (s, 2H), 
2.84 (s, 3H), 2.16 (s, 3H), 1.30 (t, 3H, J = 7.1 Hz); Anal.(C22H22NO4SF) C, H, N. 
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Ethyl-2-methyl-1-[4-(methylthio)-phenyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
acetate (16d). Yellowish needles (76% yield), m.p. 123-127 °C; 1H-NMR (400 MHz, CDCl3) δ 
(ppm): 7.83 (d, 2H, J = 8.6 Hz), 7.49 (d, 2H, J = 8.5 Hz), 7.21 (d, 2H, J = 8.6 Hz), 7.05 (d, 2H,J= 8.5 
Hz), 6.43 (s, 1H), 4.10 (q, 2H, J = 7.0 Hz), 3.51 (s, 2H), 3.00 (s, 3H), 2.54 (s, 3H), 2.09 (s, 3H), 1.40 
(t, 3H, J = 7.0 Hz); Anal.(C23H25NO4S2) C, H, N. 
Ethyl-2-methyl-1-[4-(methoxy)-phenyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
acetate (16e). Yellowish needles (70% yield), m.p. 118-122 °C; 1H-NMR (400 MHz, CDCl3) δ 
(ppm): 7.85 (d, 2H, J = 8.6 Hz), 7.48 (d, 2H, J = 8.5 Hz), 7.22 (d, 2H, J = 8.6 Hz), 7.03 (d, 2H, J = 8.5 
Hz), 6.42 (s, 1H), 4.11 (q, 2H, J = 7.0 Hz), 3.49 (s, 2H), 3.87 (s, 3H), 3.04 (s, 3H), 2.10 (s, 3H), 1.39 
(t, 3H, J = 7.0 Hz); Anal.(C23H25NO5S) C, H, N. 
2-[1-Phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrol-3yl]acetic acid (17a). 
 
Sodium hydroxide solution (1N, 4.83 mL)  was added to a solution of ethyl 1,5-diarylpyrrole-
3-acetic ester (16a) (0.67 mmol) in methanol (4.83 mL). The resulting mixture was refluxed for 
1.5 h, cooled, and concentrated in vacuo. The residue was solubilized in water (5 mL) and then 
acidified with concentrated HCl. The precipitate was filtered off to give the expected acid as a 
white solid. White needles (>95% yield), m.p. 147−152°C; 1H NMR (400 MHz, CDCl3) δ (ppm): 
11.00 (br s, 1H), 7.60 (d, 2H, J = 8.6 Hz), 7.25 (d, 2H, J = 8.5 Hz),7.17 (d, 2H, J = 8.6 Hz), 7.00 (d, 
2H, J = 8.5 Hz), 6.49 (s, 1H), 3.02 (s, 3H), 2.55 (s, 3H), 2.10 (s, 3H). Anal.(C20H19NO4S) C, H, N. 
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2-[1-(3-fluoro)phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrol-3yl]acetic acid 
(17b). White needles (>95% yield), m.p. 166−170°C; 1H NMR (400 MHz, CDCl3) δ (ppm): 11.20 
(br s, 1H), 7.72 (d, 2H, J = 8.6 Hz), 7.25 (d, 2H, J = 8.5 Hz), 7.20 (m, 1H), 7.07-7.00 (m, 2H), 6.45 
(s, 1H), 3.02 (s, 3H), 2.10 (s, 3H); Anal.(C20H18NO4SF) C, H, N. 
2-[1-(4-fluoro)phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrol-3yl]acetic acid 
(17c). White needles (>95% yield), m.p. 170−175°C; 1H NMR (400 MHz, CDCl3) δ (ppm): 11.17 
(br s, 1H), 7.71 (d, 2H, J = 8.6 Hz), 7.26 (d, 2H, J = 8.5 Hz), 7.22 (m, 2H), 7.09 (m, 2H), 6.44 (s, 1H), 
3.07 (s, 3H), 2.11 (s, 3H); Anal.(C20H18NO4SF) C, H, N. 
2-[1-(4-methylthio)phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrol-3yl]acetic 
acid (17d). White needles (>95% yield), m.p. 147−152°C; 1H NMR (400 MHz, CDCl3) δ (ppm): 
11.00 (br s, 1H), 7.70 (d, 2H, J = 8.6 Hz), 7.25 (d, 2H, J = 8.5 Hz),7.17 (d, 2H, J = 8.6 Hz), 7.00 (d, 
2H, J = 8.5 Hz), 6.49 (s, 1H), 3.02 (s, 3H), 2.55 (s, 3H), 2.10 (s, 3H); Anal.(C21H21NO4S2) C, H, N. 
2-[1-(4-methoxy)phenyl-2-methyl-5-[4-(methylsulfonyl)-phenyl]-1H-pyrrol-3yl]acetic 
acid (17e). White needles (>95% yield), m.p. 139−143°C; 1H NMR (400 MHz, CDCl3) δ (ppm): 
11.09 (br s, 1H), 7.69 (d, 2H, J = 8.6 Hz), 7.28 (d, 2H, J = 8.5 Hz),7.19 (d, 2H, J = 8.6 Hz), 7.02 (d, 
2H, J = 8.5 Hz), 6.47 (s, 1H), 3.86 (s, 3H), 3.10 (s, 3H), 2.10 (s, 3H); Anal.(C21H21NO5S) C, H, N. 
2-(Nitroxy)ethyl 2-[1-phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (1a). 
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Nitro-oxy alcohol (19a) (0.3 mmol), DMAP (0.1 mmol), and EDCI (0.2 mmol) were added in 
sequence to a solution of 1,5-diarylpyrrole-3-acetic acid (17a) (0.1 mmol) in dichloromethane 
(5 mL), under nitrogen atmosphere. After 3h stirring, the reaction was quenched with water and 
extracted with chloroform. The organic layer was washed with 1 N HCl, sodium bicarbonate 
saturated solution, brine and dried over sodium sulfate. After filtration and concentration of the 
organic phase a crude material was obtained. The material was then purified by 
chromatography on silica gel using petroleum ether/chloroform/ethyl acetate, 4:4:1 (v/v/v), as 
the eluent to give the desired product in good yield. White needles (yield 80%), mp 124-126 °C; 
FT-IR (neat, cm-1): 1740, 1622, 1277, 1153, 881; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.63 (d, 
2H, J = 8.6 Hz), 7.36-7.40 (m, 3H), 7.11-7.15 (m, 4H), 6.48(s, 1H), 4.67-4.70 (m, 2H), 4.37-4.42 
(m, 2H), 3.53 (s, 2H), 2.96 (s, 3H), 2.04 (s, 3H). 13C-NMR (100 MHz, CDCl3)  δ(ppm): 10.98, 32.26, 
44.50, 60.77, 69.90, 112.78, 113.79, 115.50, 120.20, 124.35, 130.60, 130.59, 131.39, 134.67, 
137.22, 138.01, 139.45, 176.88; MS-ESI = 459.12 m/z [M + H+]; HPLC: >98% (Rt=13.87 min.)  
3-(Nitroxy)propyl 2-[1-phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (1b). Obtained with the same procedure as (1a) using (19b) as alcohol. White 
needles (yield 77%), mp 116-118 °C; FT-IR (neat, cm-1): 1737, 1285, 1152, 1633, 877; 1H-NMR 
(400 MHz, CDCl3)  δ (ppm): 7.62 (d, 2H,  J = 8.5 Hz), 7.38-7.40 (m, 3H), 7.12-7.16 (m, 4H), 6.49(s, 
1H), 4.52 (t, 2H, J = 6.4), 4.23 (t, 2H,  J = 6.0 Hz), 3.51 (s, 2H), 2.97 (s, 3H), 2.06-2.15 (m, 5H).13C-
NMR (400 MHz, CDCl3)  δ (ppm): 11.03, 27.45, 32.26, 44.50, 60.77, 69.90, 112.78, 113.79, 
115.50, 120.20, 124.35, 130.60, 130.59, 131.39, 134.67, 137.22, 138.01, 139.45, 176.88;  
Anal.(C23H24N2O7S) C, H, N; MS-ESI: m/z 473.15 [M + H+]; HPLC: >98% (Rt=14.31 min.). 
3-(Nitroxy)butyl 2-[1-phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (1c). Obtained with the same procedure as (1a) using (19c) as alcohol. White 
needles (yield 59%), mp 110-112 °C; FT-IR (neat, cm-1): 1734, 1630, 1282, 1150, 866; 1H-NMR 
(400 MHz, CDCl3)  δ (ppm): 7.69 (d, 2H,  J = 8.5 Hz), 7.42-7.39 (m, 3H), 7.12-7.16 (m, 4H), 6.49(s, 
1H), 4.69 (t, 2H, J = 6.4), 4.26 (t, 2H,  J = 6.0 Hz), 3.51 (s, 2H), 2.97 (s, 3H), 2.10 (s, 5H), 1.99-1.85 
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(m, 4H).13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.09, 27.45, 31.03, 32.29, 44.50, 60.77, 69.92, 
112.81, 113.79, 115.50, 120.24, 124.35, 131.60, 130.59, 131.39, 134.67, 137.22, 138.01, 139.45, 
176.79. Anal. (C24H26N2O7S) C, H, N; MS-ESI: m/z 487.14 [M + H+]; HPLC: >98% (Rt=15.01 min.). 
2-(Nitroxy)ethyl 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1d). Obtained with the same procedure as (1a). Yellowish needles (89% 
yield), mp 130-133 °C; FT-IR (neat, cm-1):  1738, 1625, 1280, 1144, 843; 1H-NMR (400 MHz, 
CDCl3)  δ (ppm): 7.70 (d, 2H,  J  = 8.6 Hz), 7.38-7.36 (m, 1H), 7.14-7.10 (m, 3H), 6.91-6.87 (m, 
2H), 6.49 (s, 1H), 4.68 (t, 2H,  J = 7.0 Hz), 4.20 (t, 2H,  J = 6.8 Hz), 3.50 (s, 2H), 3.00 (s, 3H), 2.09 
(s, 3H). 13C-NMR (100 MHz, CDCl3)  δ(ppm): 10.93, 32.22, 44.46, 60.69, 69.88, 112.78, 113.87, 
115.55, 120.13, 124.33, 127.07, 130.59, 130.66, 131.44, 131.90, 137.20, 138.02, 139.40, 166.69, 
177.00; Anal.(C22H21FN2O7S) C, H, N; MS-ESI: m/z 477.14 [M + H+]; HPLC: >97% (Rt=13.95 min.)  
3-(Nitroxy)propyl 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1e). Obtained with the same procedure as (1a) using (19b) as alcohol. 
Yellowish needles (92% yield), mp 120-125 °C; FT-IR (neat, cm-1):  1742, 1630, 1281, 1150, 870; 
1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.69 (d, 2H,  J = 8.6 Hz), 7.40-7.38 (m, 1H), 7.18 (d, 2H, J = 
8.6 Hz), 7.12-7.10 (m, 1H), 6.95-6.93 (m, 2H), 6.48 (s, 1H), 4.69 (t, 2H, J  = 7.0 Hz), 4.25 (t, 2H, J = 
6.8 Hz), 3.50 (s, 2H), 3.00 (s, 3H), 2.09-2.04 (m, 5H). 13C-NMR (400 MHz, CDCl3)  δ(ppm): 10.94, 
26.42, 32.19, 44.45, 60.70, 69.82, 112.77, 113.85, 115.53, 120.12, 124.30, 127.07, 130.58, 
130.64, 131.41, 131.88, 137.15, 138.00, 139.55, 166.71, 177.06; Anal.(C23H23FN2O7S) C, H, N; MS-
ESI: m/z 513 [M + Na+];  HPLC: >97% (Rt=14.50 min.)  
4-(Nitroxy)butyl 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1f). Obtained with the same procedure as (1a) using (19c) as alcohol. 
Yellowish needles (yield 89%), mp 113-115 °C. FT-IR (neat, cm-1): 1739, 1633, 1280, 1144, 865; 
1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.70 (d, 2H, J = 8.6 Hz), 7.40-7.37 (m, 1H), 7.14-7.10 (m, 
3H), 6.91-6.87 (m, 2H), 6.49 (s, 1H), 4.70 (t, 2H, J = 7.0 Hz), 4.17 (t, 2H, J = 6.8 Hz), 3.50 (s, 2H), 
3.00 (s, 3H), 2.09 (s, 3H), 2.01-1.92 (m, 4H). 13C-NMR (100 MHz, CDCl3)  δ(ppm): 10.94, 26.42, 
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30.11, 32.20, 44.50, 60.71, 69.88, 112.79, 113.80, 115.51, 120.12, 124.30, 127.07, 130.58, 
130.64, 131.41, 131.90, 137.65, 138.11, 139.51, 166.67, 177.10; Anal.(C24H25FN2O7S) C, H, N; MS-
ESI: m/z 505.20 [M + H+]. HPLC: >98% (Rt=15.05 min.)  
2-(Nitroxy)ethyl 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1g).  Obtained with the same procedure as (1a). White needles, mp 110-
112 °C, (yield 78%); FT-IR (neat, cm-1): 1745, 1634, 1283, 1155, 890; 1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.64 (d, 2H, J = 8.6 Hz), 7.25-7.15 (m, 6H), 6.47 (s, 1H), 4.68 (t, 2H, J = 6.2 Hz), 4.32 (t, 
2H, J = 6.2 Hz), 3.52 (s, 2H), 3.00 (s, 3H), 2.03 (s, 3H); 13C-NMR (100 MHz, CDCl3)  δ(ppm): 10.99, 
32.17, 44.50, 60.30, 69.91, 112.96, 113.50, 116.00, 120.13, 124.30, 127.08, 130.59, 131.31, 
131.92, 137.16, 138.01, 166.67, 177.08; Anal.(C22H21FN2O7S) C, H, N; MS-ESI: m/z 477.14 [M + 
H+]; HPLC: >98% (Rt =14.01 min.)  
3-(Nitroxy)propyl 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1h).  Obtained with the same procedure as (1a) using (19b) as alcohol. 
White needles, mp 126-128 °C, (yield 81%). FT-IR (neat, cm-1): 1739, 1626, 1277, 1144, 871; 1H-
NMR (400 MHz, CDCl3) δ (ppm): 7.64 (d, 2H, J = 8.6 Hz), 7.06-7.15 (m, 6H), 6.47 (s, 1H), 4.69 (t, 
2H, J = 7.1 Hz), 4.21 (t, 2H, J = 7.0 Hz), 3.49 (s, 2H), 2.96 (s, 3H), 2.00-2.13 (m, 5H); 13C-NMR (100 
MHz, CDCl3)  δ(ppm): 11.00, 26.44, 32.20, 44.49, 60.33, 69.90, 112.97, 113.49, 116.01, 120.12, 
124.30, 127.07, 130.58, 131.30, 131.90, 137.15, 138.00, 166.60, 176.99; Anal. (C23H23FN2O7S) C, 
H, N; MS-ESI: m/z 491.11 [M + H+]. HPLC: >96% (Rt = 14.89 min.)  
4-(Nitroxy)butyl 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1i).  Obtained with the same procedure as (1a) using (19c) as alcohol. 
White needles (yield 81%), mp 116-118 °C; FT-IR (neat, cm-1): 1739, 1626, 1277, 1144, 871; 1H-
NMR (400 MHz, CDCl3) δ (ppm): 7.68 (d, 2H, J = 8.6 Hz), 7.06-7.15 (m, 6H), 6.47 (s, 1H), 4.71 (t, 
2H, J = 7.1 Hz), 4.16 (t, 2H, J = 7.0 Hz), 3.49 (s, 2H), 2.96 (s, 3H), 2.09 (s, 3H), 2.01-1.92 (m, 4H); 
13C-NMR (100 MHz, CDCl3)  δ(ppm): 11.02, 26.50, 31.00, 32.23, 44.55, 60.39, 69.90, 113.00, 
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113.49, 116.00, 120.12, 124.30, 127.07, 130.58, 131.30, 131.90, 137.15, 138.00, 166.55, 177.01; 
Anal. (C24H25FN2O7S) C, H, N; MS-ESI: m/z 505.13 [M + H+]. HPLC: >98% (Rt = 15.09 min.)  
2-(Nitroxy)ethyl 2-[1-(4-methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1j). Obtained with the same procedure as (1a). Yellow powder (yield 
70%), mp 118−123°C; FT-IR (neat, cm-1): 1738, 1628, 1280, 1144, 862; 1H-NMR (400 MHz, 
CDCl3) δ(ppm): 7.80 (d, 2H, J = 8.6 Hz), 7.24 (d, 2H, J = 8.5 Hz), 7.17 (d, 2H, J = 8.6 Hz), 6.99 (d, 
2H, J = 8.5 Hz), 6.51 (s, 1H), 4.73 (t, 2H, J = 6.3 Hz), 4.27 (m, 2H, J = 6.3 Hz), 3.50 (s, 2H), 3.00 (s, 
3H), 2.55 (s, 2H), 2.10 (s, 3H). 13C-NMR (400 MHz, CDCl3) δ (ppm): 10.89, 29.79, 32.21, 
44.60,60.41, 69.90, 112.96, 113.50, 115.89, 120.67, 125.39, 127.00, 130.59, 130.70, 131.30, 
131.80, 136.10, 138.00, 177.03; Anal.(C23H24N2O7S2) C, H, N; MS-ESI: m/z 505 [M + H+]. HPLC: 
>98% pure (tR= 14.19 min). 
3-(Nitroxy)propyl 2-[1-(4-methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1k). Obtained with the same procedure as (1a) using (19b) as alcohol. 
Yellowish needles (yield 68%), mp 118-122 °C; FT-IR (neat, cm-1): 1737, 1632, 1281, 1142, 865; 
1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.69 (d, 2H, J  = 8.6 Hz), 7.30 (d, 2H,  J  = 8.6 Hz), 7.12 (d, 2H,  
J  = 8.6 Hz), 6.96 (d, 2H, J = 8.6 Hz), 6.56 (s, 1H), 4.66 (t, 2H, J = 7.0 Hz), 4.18 (t, 2H, J = 6.9 Hz), 
3.59 s, 2H), 3.09 (s, 3H), 2.53 (s, 3H), 2.50 (s, 3H), 2.10 (m, 2H); 13C-NMR (100 MHz, CDCl3)  
δ(ppm): 10.89, 26.44, 29.79, 32.20, 44.63, 60.40, 69.87, 112.99, 113.54, 115.91, 120.67, 125.39, 
127.02, 130.55, 130.70, 131.30, 131.77, 136.11, 138.07, 177.07; Anal.(C24H26N2O7S2) C, H, N; MS-
ESI: m/z 519 [M + H+]. HPLC: >97% (Rt = 17.25 min.)  
4-(Nitroxy)butyl 2-[1-(4-methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (1l). Obtained with the same procedure as (1a) using (19c) as alcohol. 
Yellowish needles, mp 112-115 °C (yield 68%). FT-IR (neat, cm-1):  1741, 1626, 1282, 1149, 866; 
1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.68 (d, 2H, J  = 8.6 Hz), 7.30 (d, 2H,  J  = 8.6 Hz), 7.12 (d, 2H,  
J  = 8.6 Hz), 6.96 (d, 2H, J = 8.6 Hz), 6.46 (s, 1H), 4.66 (t, 2H, J = 7.0 Hz), 4.18 (t, 2H, J = 6.9 Hz), 
3.56 (s, 2H), 3.09 (s, 3H), 2.53 (s, 3H), 2.10 (s, 3H), 2.00-1.93 (m, 4H); 13C-NMR (100 MHz, CDCl3)  
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δ(ppm): 10.98, 26.44, 29.82, 30.98, 32.20, 44.63, 60.40, 69.91, 113.01, 113.54, 115.91, 120.67, 
125.39, 127.02, 130.55, 130.68, 131.29, 131.75, 136.13, 138.09, 177.07; Anal.(C25H28N2O7S2) C, 
H, N; MS-ESI: m/z 519 [M + H+]. HPLC: >97% (Rt = 17.25 min.)  
2-(Nitroxy)ethyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (1m). Obtained with the same procedure as (1a). Yellowish needles (yield 
78%), mp 120-125 °C; FT-IR (neat, cm-1): 1742, 1629, 1280, 1144, 867; 1H-NMR (400 MHz, 
CDCl3)  δ(ppm): 7.70 (d, 2H, J = 8.6 Hz), 7.20 (d, 2H, J = 8.5 Hz), 7.10 (d, 2H, J = 8.6 Hz), 6.89 (d, 
2H, J = 8.5 Hz), 6.50 (s, 1H), 4.68 (t, 2H, J = 6.3 Hz), 4.24 (t, 2H, J = 6.0 Hz), 3.60 (s, 3H), 3.50 (s, 
2H), 3.01 (s, 3H), 2.10 (s, 3H); 13C-NMR (400 MHz, CDCl3)  δ (ppm): 13C-NMR (400 MHz, CDCl3)  δ 
(ppm): 11.04, 32.35, 44.70, 54.09, 60.42, 69.83, 112.87, 113.40, 115.67, 120.60, 125.44, 127.10,  
130.59, 130.70, 131.20, 131.70, 138.10, 138.17, 177.06; Anal.(C23H24N2O8S) C, H, N; MS-ESI: m/z 
489 [M + H+]. HPLC: >96% (Rt = 14.12 min.)  
3-(Nitroxy)propyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (1n). Obtained with the same procedure as (1a) using (19b) as alcohol. 
Yellowish powder (yield 69%), mp 115-119 °C; FT-IR (neat, cm-1): 1742, 1630, 1281, 1150, 870; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.67 (d, 2H, J = 8.6 Hz), 7.18 (d, 2H, J = 8.5 Hz), 7.07 (d, 2H, J 
= 8.6 Hz), 6.92 (d, 2H, J = 8.5 Hz), 6.49 (s, 1H), 4.67 (t, 2H, J = 7.0 Hz), 4.24 (t, 2H, J = 6.8 Hz), 3.85 
(s, 3H), 3.52 (s, 2H), 3.00 (s, 3H) 2.12-2.03 (m, 5H). 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.00, 
26.09, 32.36, 44.70, 54.10, 60.44, 69.90, 112.90, 113.40, 115.66, 120.61, 125.42, 127.10, 130.61, 
130.68, 131.20, 131.72, 138.11, 138.15, 177.06; Anal.(C24H26N2O8S) C, H, N; MS-ESI: m/z 503 [M 
+ H+]. HPLC: >98% (Rt = 15.08 min.). 
4-(Nitroxy)butyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (1o). Obtained with the same procedure as (1a) using (19c) as alcohol. 
Yellowish powder (yield 69%), mp 105-108 °C. FT-IR (neat, cm-1): 1741, 1632, 1281, 1152, 870; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.69 (d, 2H, J = 8.6 Hz), 7.18 (d, 2H, J = 8.5 Hz), 7.07 (d, 2H, J 
= 8.6 Hz), 6.92 (d, 2H, J = 8.5 Hz), 6.47 (s, 1H), 4.68 (t, 2H, J = 7.0 Hz), 4.23 (t, 2H, J = 6.8 Hz), 3.84 
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(s, 3H), 3.50 (s, 2H), 3.00 (s, 3H) 2.10 (s, 3H), 2.01-1.92 (m, 4H); 13C-NMR (100 MHz, CDCl3)  δ 
(ppm): 11.02, 26.09, 30.18, 32.38, 44.76, 54.16, 60.49, 69.92, 112.90, 113.40, 115.66, 120.60, 
125.42, 127.10, 130.61, 130.56, 131.18, 131.72, 138.11, 138.15, 177.02; Anal.(C25H28N2O8S) C, H, 
N; MS-ESI: m/z 503 [M + H+]. HPLC: >98% (Rt = 15.08 min.). 
2-Hydroxyethyl 2-[1-phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (2a). Obtained with the same procedure as (1a) using ethylene glycol as alcohol. 
White needles (66% yield), mp 121-123 °C; 1H-NMR (400 MHz, CDCl3) δ(ppm): 7.62 (d, 2H, J = 
8.6 Hz), 7.35-7.40 (m, 3H), 7.09-7.14 (m, 4H), 6.50 (s,1H), 4.24 (t, 2H, J = 6.9 Hz), 3.85 (t, 2H, J = 
6.9 Hz), 3.77 (br s, 1H), 3.54 (s, 2H), 2.96 (s, 3H), 2.05 (s, 3H). 13C-NMR (400 MHz, CDCl3)  δ 
(ppm): 10.98, 32.26, 44.50, 60.77, 66.30, 112.79,113.78, 115.50, 120.20, 124.35, 130.60, 130.59, 
131.39, 134.67, 137.20, 138.00, 139.45, 176.85.  
3-Hydroxypropyl 2-[1-Phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (2b). Obtained with the same procedure as (1a) using propylene glycol as alcohol. 
White needles (62% yield), mp 108-110 °C; 1H-NMR (400 MHz, CDCl3) δ(ppm): 7.62 (d, 2H, J = 
8.6 Hz), 7.37-7.40 (m, 3H), 7.12-7.16 (m, 4H), 6.50 (s,1H), 4.28 (t, 2H, J = 6.8 Hz), 3.71 (t, 2H, J = 
6.7 Hz), 3.52 (s, 2H), 2.97 (s, 3H), 2.06 (s, 3H), 1.86-1.95 (m, 2H), 1.83 (br s, 1H); 13C-NMR (400 
MHz, CDCl3)  δ(ppm): 11.00, 27.45, 32.27, 44.51, 60.78, 65.99, 112.78, 113.80, 115.50, 120.20, 
124.35, 130.60, 130.59, 131.39, 134.67, 137.22, 138.01, 139.46, 176.80.  
4-Hydroxybutyl 2-[1-Phenyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3yl]acetate (2c). Obtained with the same procedure as (1a) using propylene glycol as alcohol. 
White needles (53% yield), mp 108-110 °C; 1H-NMR (400 MHz, CDCl3) δ(ppm): 7.65 (d, 2H, J = 
8.6 Hz), 7.37-7.41 (m, 3H), 7.12-7.18 (m, 4H), 6.48 (s,1H), 4.34 (t, 2H, J = 6.8 Hz), 4.12 (t, 2H, J = 
6.7 Hz), 3.52 (s, 2H), 3.07 (s, 3H), 2.08 (s, 3H), 1.90-1.77 (m, 5H); 13C-NMR (400 MHz, CDCl3)  
δ(ppm): 11.01, 27.43, 30.22, 32.29, 44.50, 60.78, 65.85, 112.78, 113.86, 115.50, 120.20, 124.35, 
130.60, 130.59, 131.39, 134.55, 137.20, 138.01, 139.40, 176.78.  
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2-Hydroxyethyl 2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3 yl]acetate (2d). Obtained with the same procedure as (1a) using ethylene glycol as 
alcohol. Yellowish powder (77% yield), mp 115-120 °C; 1H-NMR (400 MHz, CDCl3)  δ(ppm): 7.71 
(d, 2H, J  = 8.6 Hz), 7.19-7.10 (m, 6H), 6.46 (s, 1H), 4.33 (t, 2H,  J  = 6.8 Hz), 4.12 (t, 2H, J = 6.8 Hz), 
3.47 (s, 2H), 3.04 (s, 3H), 2.09 (s, 3H), 2.08(s broad, 1H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 
10.89, 32.42, 44.60, 60.49, 66.03, 112.72, 113.67, 115.63, 120.03, 124.93, 127.15, 130.86, 
130.57, 131.44, 131.90, 137.20, 138.02, 139.40, 166.69, 177.00.  
3-Hydroxypropyl 2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2e). Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. Yellowish powder (81% yield), mp 110-113 °C; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 
7.68 (d, 2H, J = 8.6 Hz), 7.37-7.36 (m, 1H), 7.15-7.11 (m, 3H), 6.90-6.88 (m, 2H), 6.50 (s, 1H), 
4.24 (t, 2H,  J  = 6.8 Hz), 3.83 (t, 2H,  J  = 6.5 Hz), 3.50 (s, 2H), 3.00 (s, 3H), 2.10-2.03 (m, 5H),1.50 
(s broad, 1H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 10.94, 27.13, 32.22, 44.46, 60.69, 66.45, 
112.78, 113.87, 115.55, 120.13, 124.30, 127.07, 130.60, 130.70, 131.44, 131.88, 137.20, 138.03, 
139.40, 166.70, 177.01.  
3-Hydroxypropyl 2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2f). Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. Yellowish powder (58% yield), mp 110-113 °C; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 
7.70 (d, 2H, J = 8.6 Hz), 7.37-7.35 (m, 1H), 7.15-7.10 (m, 3H), 6.90-6.88 (m, 2H), 6.48 (s, 1H), 
4.33 (t, 2H,  J  = 6.8 Hz), 4.13 (t, 2H,  J  = 6.5 Hz), 3.50 (s, 2H), 3.00 (s, 3H), 2.10 (s, 3H), 1.92-1.76 
(m, 4H), 1.50 (s broad, 1H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 10.99, 27.13, 31.08, 33.00, 
44.61, 60.70, 67.05, 112.80, 113.88, 115.61, 120.10, 124.30, 127.17, 130.61, 130.70, 131.44, 
131.88, 137.20, 138.03, 139.22, 166.73, 177.02.  
2-Hydroxyethyl 2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2g).  Obtained with the same procedure as (1a) using ethylene glycol as 
alcohol. White needles,  mp 129-131 °C, (yield 76%). 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.68 
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(d, 2H,  J  = 8.3 Hz), 7.08-7.17 (m, 6H), 6.52 (s, 1H), 4.25 (t, 4H,  J  = 6.8 Hz), 4.11 (t, 2H, J = 6.8 
Hz), 3.80 (br s, 1H), 3.50 (s, 2H), 2.99 (s, 3H), 2.01 (s, 3H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 
10.95, 32.21, 44.50, 60.30, 66.33, 112.89, 113.50, 116.01, 120.13, 124.31, 127.08, 130.59, 
131.31, 131.92, 137.16, 138.01, 166.70, 177.02.  
3-Hydroxypropyl 2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2h).  Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. White needles, mp 112-115 °C, (yield 75%). 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.62 
(d, 2H, J = 8.3 Hz), 7.12-7.16 (m, 6H), 6.50 (s, 1H), 4.25 (t, 2H,  J  = 6.9 Hz), 3.75 (t, 2H, J = 6.5 Hz), 
3.50 (s, 2H), 2.98 (s, 3H), 2.05 (s, 3H), 1.84-1.94 (m, 2H), 1.80 (br s, 1H); 13C-NMR (400 MHz, 
CDCl3)  δ (ppm): 11.01, 26.40, 32.10, 44.4, 60.33, 66.23, 112.97, 113.49, 116.01, 120.12, 124.30, 
127.07, 130.58, 131.30, 131.91, 137.15, 138.00, 166.57, 176.95.  
3-Hydroxypropyl 2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2i).  Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. White needles, mp 106-108 °C, (yield 75%). 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.68 
(d, 2H, J = 8.3 Hz), 7.17-7.14 (m, 6H), 6.44 (s, 1H), 4.28 (t, 2H, J = 6.9 Hz), 4.12 (t, 2H, J = 6.5 Hz), 
3.50 (s, 2H), 2.98 (s, 3H), 2.05 (s, 3H), 1.92-1.81 (m, 4H), 1.79 (br s, 1H); 13C-NMR (400 MHz, 
CDCl3)  δ (ppm): 11.01, 26.42, 31.00, 32.11, 44.51, 60.33, 66.23, 112.91, 113.45, 116.09, 120.10, 
124.30, 127.11, 130.43, 131.30, 131.90, 137.15, 138.00, 166.52, 176.09.  
2-Hydroxyethyl 2-[1-(4-Methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3-yl]acetate (2j). Obtained with the same procedure as (1a) using ethylene glycol as 
alcohol. Yellow powder, mp 110−112 °C (yield 55%). 1H-NMR (400 MHz,CDCl3) δ(ppm): 7.80 (d, 
2H, J = 8.6 Hz), 7.24 (d, 2H, J = 8.5 Hz), 7.17 (d, 2H, J= 8.6 Hz), 7.00 (d, 2H, J= 8.5 Hz), 6.48 (s, 1H), 
4.25 (t, 2H,J= 6.8 Hz), 3.89 (t, 2H,J = 6.8 Hz), 3.52 (s, 2H), 2.55 (s, 3H), 2.07 (s, 3H), 2.01 (br s, 
1H); 13C-NMR (400 MHz, CDCl3) δ (ppm): 10.89, 29.79, 32.20, 44.54, 60.40, 66.29, 112.96, 
113.50, 115.90, 120.67, 125.39, 127.01, 130.63, 130.71, 131.27, 131.80, 136.10, 138.00, 177.00.  
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3-Hydroxypropyl 2-[1-(4-Methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2k). Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. Yellow solid, mp104-107 °C (yield 53 %). 1H-NMR (400 MHz, CDCl3) δ(ppm): 7.79 (d, 
2H, J = 8.6 Hz), 7.34 (d, 2H, J = 8.6 Hz), 7.12 (d, 2H, J = 8.6 Hz), 6.96 (d, 2H, J = 8.6 Hz), 6.46 (s, 
1H), 4.26 (t, 2H, J = 6.8 Hz), 3.85 (t, 2H, J = 6.6 Hz), 3.50 (s, 2H), 3.09 (s, 3H), 2.50 (s, 3H), 2.19 (s, 
3H), 2.09 (m, 2H), 2.02 (br s, ,1H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 10.89, 26.44, 29.79, 
32.20, 44.63, 60.40, 67.00, 112.90, 113.53, 115.93, 120.67, 125.39, 127.02, 130.56, 130.70, 
131.30, 131.77, 136.10, 138.00, 177.01.  
3-Hydroxybutyl 2-[1-(4-methylthiophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetate (2l). Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. Yellow solid, mp100-103 °C (yield 50 %). 1H-NMR (400 MHz, CDCl3) δ(ppm): 7.69 (d, 
2H, J = 8.6 Hz), 7.34 (d, 2H, J = 8.6 Hz), 7.12 (d, 2H, J = 8.6 Hz), 6.96 (d, 2H, J = 8.6 Hz), 6.45 (s, 
1H), 4.26 (t, 2H, J = 6.8 Hz), 4.10 (t, 2H, J = 6.6 Hz), 3.50 (s, 2H), 3.09 (s, 3H), 2.50 (s, 3H), 2.19 (s, 
3H), 2.01-1.85 (m, 5H); 13C-NMR (400 MHz, CDCl3)  δ(ppm): 10.97, 26.39, 29.79, 30.12, 32.30, 
44.61, 60.40, 67.02, 112.91, 113.53, 115.90, 120.69, 125.40, 127.00, 130.56, 130.70, 131.30, 
131.77, 136.10, 138.10, 176.98.  
2-Hydroxyethyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (2m).  Obtained with the same procedure as (1a) using ethylene glycol as 
alcohol. Yellowish powder (yield 59%),  mp 105-110 °C; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 
7.60 (d, 2H, J = 8.6 Hz), 7.18 (d, 2H, J = 8.5 Hz), 7.00 (d, 2H, J = 8.6 Hz), 6.96 (d, 2H, J = 8.5 Hz), 
6.43 (s, 1H), 4.30 (t, 2H, J = 6.8 Hz), 3.82 (t, 2H, J = 6.8 Hz), 3.58 (s, 3H), 3.47 (s, 2H), 2.40 (br,s, 
1H), 2.37 (s, 3H), 2.01 (s, 3H); 13C-NMR (400 MHz, CDCl3)  δ (ppm): 11.04, 32.35, 44.70, 54.09, 
60.42, 66.77, 112.85, 113.34, 115.67, 120.56, 125.44, 127.10, 130.59, 130.70, 131.20, 131.72, 
138.11, 138.20, 177.01.  
3-Hydroxypropyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (2n).  Obtained with the same procedure as (1a) using propylene glycol as 
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 85 of 195 
 
alcohol. Yellow solid (yield 52%), mp 103-110 °C; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.67 (d, 
2H, J  = 8.6 Hz), 7.18 (d, 2H, J = 8.5 Hz), 7.07 (d, 2H, J = 8.6 Hz), 6.92 (d, 2H, J = 8.5 Hz), 6.49 (s, 
1H), 4.25 (t, 2H, J = 6.8 Hz), 3.83 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.52 (s, 2H), 3.00 (s, 3H), 2.12-
2.05 (m, 5H), 1.70 (s broad, 1H). 13C-NMR (400 MHz, CDCl3)  δ(ppm): 11.01, 26.08, 32.34, 44.71, 
54.10, 60.45, 66.80, 112.91, 113.40, 115.66, 120.61, 125.42, 127.10, 130.66, 130.70, 131.20, 
131.72, 138.11, 138.15, 177.04.  
3-Hydroxypropyl 2-[1-(4-methoxyphenyl)-2-methyl-5-[4-(methylsulfonyl)pheny]-1H-
pirrol-3yl]acetate (2o).  Obtained with the same procedure as (1a) using propylene glycol as 
alcohol. Yellow solid (yield 52%), mp 97-100 °C; 1H-NMR (400 MHz, CDCl3)  δ (ppm): 7.68 (d, 
2H, J  = 8.6 Hz), 7.18 (d, 2H, J = 8.5 Hz), 7.07 (d, 2H, J = 8.6 Hz), 6.92 (d, 2H, J = 8.5 Hz), 6.46 (s, 
1H), 4.25 (t, 2H, J = 6.8 Hz), 4.09 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.52 (s, 2H), 3.00 (s, 3H), 2.10 (s, 
3H), 2.00-1.90 (m, 4H), 1.70 (s broad, 1H). 13C-NMR (400 MHz, CDCl3)  δ(ppm): 11.00, 26.11, 
30.12, 32.30, 44.70, 54.11, 60.45, 66.85, 112.91, 113.40, 115.66, 120.61, 125.42, 127.10, 130.66, 
130.70, 131.20, 131.72, 138.11, 138.15, 177.00.  
2-Nitroxyethanol (19a). 
 
 
Nitric acid (65% w/v, 16 mmol), glacial acetic acid (97 mmol), and acetic anhydride (97% w/v, 
59 mmol) were carefully added in sequence to a solution of ethylene glycol (18a, 20 mmol) in 
ethyl acetate (100 mL). The mixture was allowed to react overnight and then quenched with 
20% KOH solution. The pH was adjusted to 12−13, and the aqueous phase was extracted with 
ethyl acetate (3×100 mL), washed with NaCl saturated solution, and dried over Na2SO4. After 
filtration, the organic layers were concentrated in vacuo, and the crude product was purified by 
chromatography on silica gel, using petroleum ether/chloroform/ethyl acetate, 3:1:1 (v/v/v), as 
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eluent, to obtain the expected nitroester in good yield. Yellowish oil (70% yield); FT-IR (neat, 
cm-1): 1623, 850; 1H-NMR (400 MHz, CDCl3) δ (ppm): 4.67 (t, 2H, J = 6.9 Hz), 4.20 (t, 2H, J = 6.9 
Hz), 2.10 (br s, 1H); MS-ESI: m/z 108.19 [M + H+]. 
3-Nitroxypropanol (19b). Obtained with the same procedure as (11a) using 1,3-propandiol 
(18b). Colorless oil (68% yield); FT-IR (neat, cm-1): 1638, 881 ; 1H-NMR (400 MHz, CDCl3)  δ 
(ppm): 4.71 (t, 2H, J = 6.9 Hz), 4.18 (t, 2H, J = 6.9 Hz), 2.00 (br s, 1H), 1.91 (m, 2H); MS-ESI: m/z 
122.39 [M + H+]. 
4-Nitroxybutanol (19c). Obtained with the same procedure as (11a) using butylene glycol as 
alcohol. Colorless oil (55% yield); FT-IR (neat, cm-1): 1640, 867; 1H-NMR (400 MHz, CDCl3)  δ 
(ppm): 4.62 (t, 2H, J = 6.9 Hz), 4.19 (t, 2H, J = 6.9 Hz), 2.09-2.01 (m, 5H); MS-ESI: m/z 136.22 [M 
+ H+]. 
2-(Nitroxy)ethyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (3a).  
 
An excess of trifluoroacetic acid (4mL) was added dropwise at 0 °C to a solution of (24a) (0.40 
mmol) in dioxane (2 mL). The solution was microwave irradiated at 60 °C for 40 minutes 
(power 150 W, pressure 170 psi). The reaction mixture was poured into ice/water (20 mL) and 
the pH adjusted to 12-13 (using ammonia solution) and the mixture extracted with chloroform. 
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The organic layer was then dried over sodium sulfate. The filtration and concentration of the 
organic phase gave a crude material, which was purified through column chromatography 
(alumina) using  MeOH/DCM 1:20 (v/v) to obtain the product as a yellowish powder. Yellowish 
powder, m.p. 137°C (83% yield); FT-IR (neat, cm-1): 3340, 2889, 1738, 1681, 1590, 1300, 1145, 
1091, 890;  1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J = 8.5 Hz), 7.39 (m, 1H), 7.18 (d, 2H, 
J = 8.5 Hz), 7.10 (m, 1H), 7.03 (m, 2H), 6.60 (s, 1H), 4.66 (t, 2H, J = 7.2 Hz), 4.48 (s, 1H), 4.38 (t, 
2H, J = 7.2 Hz), 3.05 (s, 3H), 2.20 (s, 3H), 1.90 (s br., 2H); 13C-NMR (100 MHz, CDCl3):  δ (ppm) 
171.44, 158.57, 148.78, 144.00, 139.50, 138.56, 137.66, 135.54, 131.92, 128.90, 128.66, 126.20, 
123.44, 122.59, 117.11, 74.58, 64.11, 61.03, 43.00, 11.11; Anal. (C22H22FN3O7S) C, H, N; ESI-Mass: 
m/z 528.122 [M + Na]+. 
3-(Nitroxy)propyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetate (3b). Obtained following the procedure as 
(3a). Yellowish powder, m.p. 117°C (73% yield); FT-IR (neat, cm-1): 3340, 2887, 1738, 1681, 
1592, 1300, 1149, 1091, 891; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J = 8.5 Hz), 7.39 
(m, 1H), 7.18 (d, 2H, J = 8.5 Hz), 7.10 (m, 1H), 7.03 (m, 2H), 6.60 (s, 1H), 4.67 (t, 2H, J = 7.2 Hz), 
4.48 (s, 1H), 4.38 (t, 2H, J = 7.2 Hz), 3.07 (s, 3H), 2.23 (s, 3H), 1.98 (m, 2H), 1.90 (s br., 2H); 13C-
NMR (100 MHz, CDCl3)  δ (ppm): 171.44, 158.57, 148.78, 144.00, 139.50, 138.56, 137.66, 
135.54, 131.92, 128.90, 128.66, 126.20, 123.44, 122.59, 117.11, 74.58, 64.11, 61.03, 43.00, 
27.69, 11.11; Anal. (C23H24FN3O7S) C, H, N; MS-ESI: m/z 528.122 [M + Na]+.  
4-(Nitroxy)butyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (3c). Obtained following the procedure as (3a). Yellowish powder 
(57% yield), m.p. 113 °C; FT-IR (neat, cm-1): 3350, 2892, 1740, 1693, 1580, 1292, 1150, 1088, 
870; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.68 (d, 2H, J = 8.4 Hz), 7.42 (m, 1H), 7.18 (d, 2H, J = 8.4 
Hz), 7.10 (m, 1H), 7.05 (m, 2H), 6.61 (s, 1H), 4.70 (t, 2H, J = 7.2 Hz), 4.50 (s, 1H), 4.37 (t, 2H, J = 
7.2 Hz), 3.12 (s, 3H), 2.20 (s, 3H), 2.03 (m, 4H), 1.90 (s br., 2H); 13C-NMR (100 MHz, CDCl3):  δ 
(ppm) 171.39, 158.60, 148.90, 144.05, 139.54, 138.56, 137.66, 135.50, 131.91, 128.88, 128.60, 
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126.20, 123.44, 122.59, 117.18, 74.70, 64.10, 61.20, 43.88, 25.69, 23.44, 11.09; Anal. 
(C24H26FN3O7S) C, H, N; MS-ESI: m/z 542.137 [M + Na]+. 
2-(Nitroxy)ethyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (3d). Obtained following the procedure as (3a). Yellowish powder 
(85% yield), m.p. 133°C; FT-IR (neat, cm-1): 3339, 2896, 1738, 1685, 1590, 1299, 1147, 1090, 
880; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.73 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.4 Hz), 7.12 (d, 
2H, J = 8.4 Hz), 7.04 (m, 2H), 6.60 (s, 1H), 4.67 (t, 2H, J = 7.2 Hz), 4.50 (s, 1H), 4.37 (t, 2H, J = 7.2 
Hz), 3.00 (s, 3H), 2.20 (s, 3H), 1.80 (s br., 2H); 13C-NMR (100 MHz, CDCl3):  δ (ppm) 171.33, 
159.91, 147.33, 146.80, 141.53, 135.00, 130.32, 129.22, 128.76, 126.19, 123.45, 122.50, 117.09, 
74.34, 64.08, 60.98, 43.07, 11.06; Anal. (C22H22FN3O7S) C, H, N; MS-ESI: m/z 528.122 [M+Na]+. 
3-(Nitroxy)propyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetate (3e). Obtained following the procedure as 
(3a). Yellowish powder, m.p. 121°C (75% yield); FT-IR (neat, cm-1): 3344, 2890, 1736, 1685, 
1590, 1302, 1147, 1090, 880; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.70 (d, 2H, J = 8.4 Hz), 7.29 
(d, 2H, J = 8.4 Hz), 7.11 (d, 2H, J = 8.4 Hz), 7.08 (m, 2H), 6.61 (s, 1H), 4.65 (t, 2H, J = 7.2 Hz), 4.50 
(s, 1H), 4.39 (t, 2H, J = 7.2 Hz), 3.01 (s, 3H), 2.20 (s, 3H), 1.95 (m, 2H), 1.80 (s br., 2H); 13C-NMR 
(100 MHz, CDCl3):  δ (ppm) 171.33, 159.91, 147.33, 146.80, 141.53, 135.00, 130.32, 129.22, 
128.76, 126.19, 123.45, 122.50, 117.09, 74.34, 64.08, 60.98, 53.07, 27.62, 11.06; Anal. 
(C23H24FN3O7S) C, H, N; MS-ESI: m/z 528.122 [M+Na]+. 
4-(Nitroxy)butyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (3f). Obtained following the procedure as (3a).Yellowish powder, m.p. 
102 °C (58% yield); FT-IR (neat, cm-1): 3347, 2894, 1742, 1689, 1587, 1298, 1157, 1099, 877; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.69 (d, 2H, J = 8.5 Hz), 7.25 (d, 2H, J = 8.5 Hz), 7.15 (d, 2H, J 
= 8.5 Hz), 7.07 (m, 2H), 6.60 (s, 1H), 4.68 (t, 2H, J = 7.2 Hz), 4.48 (s, 1H), 4.39 (t, 2H, J = 7.2 Hz), 
3.07 (s, 3H), 2.23 (s, 3H), 2.01 (m, 4H), 1.90 (s br., 2H); 13C-NMR (100 MHz, CDCl3):  δ (ppm) 
171.31, 159.90, 147.40, 146.71, 141.50, 135.02, 130.32, 129.67, 128.80, 126.21, 123.43, 122.51, 
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117.03, 74.34, 64.10, 60.90, 43.11, 24.62, 22.88, 11.16;  Anal. (C24H26FN3O7S) C, H, N; MS-ESI: 
m/z 542.137 [M+Na]+.  
2-Hydroxyethyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4a).  
 
Ammonium formate (0.081g, 1.3 mmol) and Pd/C (0.07g) were added to a solution of (27a) 
(0.32 mmol) in isopropanol (2 mL). The solution was microwave irradiated at 80 °C for 5 
minutes (power 150 W, pressure 170 psi). The reaction mixture was passed through Celite® 
and then poured into water (20 mL). The pH was adjusted to 10-12 (using NaOH 10% solution) 
and the mixture extracted with chloroform. The organic layer was then dried over Na2SO4. 
Filtration and concentration of the organic phase gave a material, which was identified to be the 
product without the need of any further purification. Yellowish powder, m.p. 118°C (>95% 
yield); FT-IR (neat, cm-1): 3345, 3322, 2858, 1741, 1590, 1300, 1145, 1090; 1H-NMR (400 MHz, 
DMSO-d6): δ (ppm) 7.71 (d, 2H, J = 8.4 Hz), 7.41 (m, 1H), 7.15 (d, 2H, J = 8.4 Hz), 7.05 (m, 1H), 
6.97 (m, 2H), 6.59 (s, 1H), 4.79 (t app., 1H), 4.40 (s, 1H), 4.13 (m, 2H), 3.56 (m, 2H), 3.11 (s, 3H), 
2.20 (s br., 2H), 2.19 (s, 3H); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 172.44, 158.57, 148.78, 
144.00, 139.50, 138.56, 137.66, 135.54, 131.92, 128.90, 128.66, 126.20, 123.44, 122.55, 117.11, 
64.09, 60.88, 58.80, 43.10, 11.01; Anal. C22H23FN2O5S (C, H, N); MS-ESI: m/z 468.107 [M+Na]+. 
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3-Hydroxypropyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4b). Obtained following the procedure as (4a), using (27b) as starting 
material. Yellowish powder (>95% yield), m.p. 110°C; FT-IR (neat, cm-1): 3345, 3322, 2858, 
1741, 1590, 1300, 1145, 1090; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.71 (d, 2H, J = 8.4 Hz), 
7.41 (m, 1H), 7.15 (d, 2H, J = 8.4 Hz), 7.05 (m, 1H), 6.97 (m, 2H), 6.59 (s, 1H), 4.79 (t app., 1H), 
4.40 (s, 1H), 4.13 (m, 2H), 3.56 (m, 2H), 3.11 (s, 3H), 2.20 (s br., 2H), 2.19 (s, 3H), 1.92 (m, 2H); 
13C-NMR (100 MHz, DMSO-d6) δ (ppm): 171.44, 158.57, 148.78, 144.00, 139.50, 138.56, 137.66, 
135.54, 131.92, 128.90, 128.66, 126.20, 123.44, 122.59, 117.11, 64.09, 60.88, 58.80, 43.10, 
27.60, 11.01; Anal. (C23H25FN2O5S)C, H, N; MS-ESI: m/z 483.137 [M + Na]+.  
4-Hydroxybutyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4c). Obtained following the procedure as (4a), using (27c) as starting 
material. Yellowish powder (>95% yield), m.p. 98°C; FT-IR (neat, cm-1): 3353, 3311, 2861, 1744, 
1590, 1300, 1147, 1092; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.74 (d, 2H, J = 8.5 Hz), 7.43 (m, 
1H), 7.15 (d, 2H, J = 8.5 Hz), 7.11 (m, 1H), 6.97 (m, 2H), 6.52 (s, 1H), 4.80 (t app., 1H), 4.39 (s, 
1H), 4.18 (m, 2H), 3.53 (m, 2H), 3.13 (s, 3H), 2.21 (s br., 2H), 2.18 (s, 3H), 1.86 (m, 4H); 13C-NMR 
(100 MHz, DMSO-d6) δ (ppm): 171.39, 158.60, 148.90, 144.05, 139.54, 138.56, 137.66, 135.50, 
131.91, 128.88, 128.60, 126.20, 123.44, 122.59, 117.18, 74.70, 64.10, 61.20, 43.34, 25.69, 23.44, 
11.09;  Anal. (C24H27FN2O5S) C, H, N; MS-ESI: m/z 497.152 [M+Na]+.  
2-Hydroxyethyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4d). Obtained following the procedure as (4a), using (27d) as starting 
material.Yellowish powder (>95% yield), m.p. 119°C; FT-IR (neat, cm-1): 3340, 3320, 2852, 
1736, 1593, 1302, 1140, 1098; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J = 8.4 Hz), 
7.70 (d, 2H, J = 8.4 Hz), 7.29 (d, 2H, J = 8.4 Hz), 7.08 (m, 2H), 6.56 (s, 1H), 4.78 (t app., 1H), 4.45 
(s, 1H), 4.15 (m, 2H), 3.57 (m, 2H), 3.06 (s, 3H), 2.24 (s br., 2H), 2.18 (s, 3H); 13C-NMR (100 MHz, 
DMSO-d6):  δ (ppm) 171.34, 159.87, 147.30, 146.78, 141.51, 135.00, 130.32, 129.25, 128.78, 
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126.20, 123.48, 122.53, 117.12, 64.10, 61.00, 58.88, 44.07, 11.06; Anal. (C22H23FN2O5S) C, H, N; 
MS-ESI: m/z 468.107 [M+Na]+.  
3-Hydroxypropyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4e). Obtained following the procedure as (4a), using (27e) as starting 
material. Yellowish powder (>95% yield), m.p. 107°C; FT-IR (neat, cm-1): 3340, 3320, 2852, 
1736, 1593, 1302, 1140, 1098; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J = 8.4 Hz), 
7.70 (d, 2H, J = 8.4 Hz), 7.29 (d, 2H, J = 8.4 Hz), 7.08 (m, 2H), 6.56 (s, 1H), 4.78 (t app., 1H), 4.45 
(s, 1H), 4.15 (m, 2H), 3.57 (m, 2H), 3.06 (s, 3H), 2.24 (s br., 2H), 2.18 (s, 3H), 1.90 (m, 2H); 13C-
NMR (100 MHz, DMSO-d6) δ (ppm): 171.30, 159.87, 147.30, 146.78, 141.51, 135.00, 130.32, 
129.25, 128.78, 126.20, 123.48, 122.53, 117.12, 64.10, 61.00, 58.88, 43.07, 27.62, 11.06; Anal. 
(C23H25FN2O5S) C, H, N; MS-ESI: m/z 483.137 [M+Na]+.  
4-Hydroxybutyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]acetate (4f). Obtained following the procedure as (4a) using (27f) as starting 
material. Yellowish powder, m.p. 101°C (>95% yield); ); FT-IR (neat, cm-1): 3349, 3324, 2861, 
1731, 1588, 1298, 1132, 1079; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.72 (d, 2H, J = 8.5 Hz), 
7.37 (d, 2H, J = 8.5 Hz), 7.15 (d, 2H, J = 8.5 Hz), 7.09 (m, 2H), 6.60 (s, 1H), 4.78 (t app., 1H), 4.41 
(s, 1H), 4.17 (m, 2H), 3.55 (m, 2H), 3.10 (s, 3H), 2.20 (s br., 2H), 2.19 (s, 3H), 1.89 (m, 4H); 13C-
NMR (100 MHz, DMSO-d6) δ (ppm): 171.31, 159.90, 147.40, 146.71, 141.50, 135.02, 130.32, 
129.67, 128.80, 126.21, 123.43, 122.51, 117.03, 74.34, 64.10, 60.90, 43.11, 24.62, 22.88, 11.16;  
Anal. (C24H27FN2O5S) C, H, N; MS-ESI: m/z 497.152 [M+Na]+.  
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 Ethyl 2-(hydroxyimino)-2-[2-methyl-5-[4-(methylsulfonyl)phenyl]-1-(3-fluorophenyl)-
1H-pyrrol-3-yl]acetate (20a). 
 
Hydroxylamine hydrochloride (6.07 g, 0.0874 mol) and sodium acetate (11.9g, 0.1456 mol) 
were added to a suspension of (15b) (25g, 0.0582 mol) in ethanol/1,4-dioxane (100 mL, 1:1 
v/v). The resulting solution was heated at 90 °C under stirring for 40 hours. The resulting 
mixture was concentrated in vacuo, extracted with ethyl acetate (500 mL) and then washed with 
water (100 mL). The organic phase was dried over sodium sulfate, filtered and concentrated to 
afford the oxime (20a) as yellowish solid. Yellowish solid (79% yield), m.p. 104 °C; 1H-NMR 
(400 MHz, DMSO-d6) δ (ppm): 7.73 (d, 2H, J = 8.5 Hz), 7.33 (m, 4H), 7.18 (d, 2H, J = 8.5 Hz), 6.55 
(s, 1H), 5.67 (s, 1H), 4.18 (q, 2H), 3.14 (s, 3H), 2.05 (s, 3H), 1.18 (t, 3H); 13C-NMR (100 MHz, 
DMSO-d6) δ (ppm): 170.10, 159.66, 149.51, 144.67, 141.33, 138.78, 135.00, 130.75, 129.20, 
128.22, 126.06, 123.40, 122.50, 120.66, 118.34, 115.37, 65.99, 43.10, 27.62, 11.06; Anal. 
(C22H21FN2O5S) C, H, N; MS-ESI: m/z 467.105 [M+Na]+.  
Ethyl 2-(hydroxyimino)-2-[2-methyl-5-[4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)-
1H-pyrrol-3-yl]acetate (20b). Obtained following the procedure as (20a), using compound 
(15c) as starting material. Yellowish solid (80% yield), m.p. 103 °C; 1H-NMR (400 MHz, DMSO-
d6) δ (ppm): 7.73 (d, 2H, J = 8.5 Hz), 7.33 (m, 4H), 7.18 (d, 2H, J = 8.5 Hz), 6.55 (s, 1H), 5.67 (s, 
1H), 4.18 (q, 2H, J = 7.4 Hz), 3.14 (s, 3H), 2.05 (s, 3H), 1.18 (t, 3H, J = 7.4 Hz); 13C-NMR (100 MHz, 
DMSO-d6):  δ (ppm) 170.02, 159.70, 149.49, 144.50, 141.33, 135.20, 130.25, 129.20, 128.22, 
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126.11, 123.45, 122.50, 118.03, 115.34, 65.84, 43.15, 27.60, 10.96; Anal. (C22H21FN2O5S) C, H, N; 
MS-ESI: m/z 467.105 [M + Na]+.  
Ethyl 2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3-yl]acetate (21a).  
 
Formic acid (100 mL) was added to a solution of the crude oxime (20a) in ethanol (100 mL) 
and the solution was cooled to °C. Then zinc dust (0.2522 mol) was added in portions over a 
period of 1h. The mixture was allowed to warm up to rt very slowly and then stirred for 19 h. 
Afterwards, zinc salts were filtered off and the solvents evaporated under reduced pressure. 
The residue obtained was dissolved in water and the pH adjusted to 10 with 10% NaOH solution 
and extracted with EtOAc. The combined organic fractions were dried over sodium sulfate, 
filtered and concentrated in vacuo to afford the crude product. The material was then purified 
by column chromatography (silica gel) eluting with MeOH/CHCl3 (1:20) (v/v) to afford the 
product. White powder (47% yield), m.p. 97 °C; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.73 (d, 
2H, J = 8.4 Hz), 7.32 (m, 4H), 7.19 (d, 2H, J = 8.4 Hz), 6.59 (s, 1H), 4.76 (app. t, 1H), 4.09 (q, 2H, J = 
7.4 Hz), 3.16 (s, 3H), 2.05 (s, 3H), 1.74 (s, broad 2H), 1.16 (t, 3H, J = 7.4 Hz); 13C-NMR (100 MHz, 
DMSO-d6) δ (ppm): 169.89, 159.27, 143.85, 140.59, 135.72, 130.93, 128.96, 128.13, 125.89, 
124.91, 123.92, 122.48, 117.02, 114.84, 108.04, 65.95, 57.99, 42.97, 27.31, 11.02; Anal. 
(C22H23FN2O4S) C, H, N; MS-ESI: m/z 453.126 [M+Na]+;  
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Ethyl 2-amino-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-
3-yl]acetate (21b). Obtained following the same procedure as (21a), using (20b) as starting 
material. White powder (50% yield), m.p. 95°C; 1H-NMR (400 MHz, DMSO-d6) δ (ppm):  7.73 (d, 
2H, J = 8.5 Hz), 7.30 (m, 4H), 7.18 (d, 2H, J = 8.5 Hz), 6.55 (s, 1H), 4.60 (s, 1 H), 4.04 (q, 2H, J = 7.3 
Hz), 3.14 (s, 3H), 2.05 (s, 3H), 1.74 (s broad, 2H), 1.18 (t, 3H, J = 7.3 Hz); 13C-NMR (100 MHz, 
DMSO-d6) δ (ppm): 169.77, 159.42, 144.50, 141.33, 135.20, 130.25, 129.20, 128.22, 126.11, 
123.45, 122.50, 115.34, 108.59, 65.84, 58.23, 43.33, 27.60, 10.96; Anal. (C22H23FN2O4S) C, H, N; 
MS-ESI: m/z 453.126 [M+Na]+.   
tert-Butyl (ethoxycarbonyl)-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]methyl carbamate (22a).  
 
Boc anhydride (1.01g, 0.004651 mol) was added to a solution of the amino ester (21a) (1g, 
0.002326 mol) in MeOH (15 mL) and the reaction mixture stirred for 18h. The mixture was then 
diluted with water, adjusted the pH to 2-3 with 1N HCl and extracted with EtOAc. The combined 
organic fractions were washed with water. Dried over sodium sulfate and evaporated to give the 
crude product. The residue was purified by column chromatography (silica gel) eluting with 
EtOAc/hexane (1:20) (v/v) to afford the desired product as white solid. White solid (67% yield), 
m.p. 109°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.69 (d, 2H, J = 8.4 Hz), 7.35 (m, 1H), 7,13 (d, 2H, 
J = 8.4 Hz), 7.09 (m, 1H), 6.90 (m, 2H), 6.59 (s, 1H), 5.65 (d, 1H, J = 7.8 Hz), 5.39 (d, 1H, J = 7.8 
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Hz), 4.13 (d, 2H, J = 6.8  Hz), 3.17(s, 3H), 2.06 (s, 3H), 1.44 (s, 9H), 1.14 (t, 3H, J = 6.8 Hz); 13C-
NMR (100 MHz, CDCl3) δ (ppm):  171.32, 168.35, 154.93, 139.72, 137.21, 135.81, 132.86, 
128.98, 127.84, 126.75, 122.47, 121.44, 118.92, 117.76, 117.58, 108.43, 81.46, 63.87, 53.96, 
43.82, 29.04, 27.27, 11.10; Anal. (C27H31FN2O6S) C, H, N; MS-ESI: m/z 553.597 [M+Na]+.  
tert-Butyl (ethoxycarbonyl)-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]methyl carbamate (22b). Obtained following the same procedure as (22a), 
using (21b) as starting material. White solid (63 % yield), m.p. 105°C; 1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.70 (d, 2H, J = 8.5 Hz), 7.20 (m, 4H), 7.05 (d, 2H, J = 8.5 Hz), 6.51 (s, 1H), 5.67 (d, 1H, J 
= 7.8 Hz), 5.40 (d, 1H, J = 7.8 Hz), 4.15 (q, 2H, J = 6.8 Hz), 3.15 (s, 3H), 2.05 (s, 3H), 1.45 (s, 9H), 
1,13 (t, 3H, J = 6.8  Hz); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 171.21, 163.43, 158.20, 140.28, 
139.37, 135.81, 132.96, 128.87, 127.93, 126.75, 122.47, 121.34, 118.92, 117.55, 81.68, 65.79, 
54.20, 44.25, 28.61, 27.22, 11.20; Anal. (C27H31FN2O6S) C, H, N; MS-ESI: m/z 553.597 [M+Na]+.  
N-tert-Butyl-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]-2-amino-acetic acid (23a).  
 
A solution of NaOH (0.005917) in water (3 mL) was added to a solution of the amino ester 
(22a) (0.002326 mol) in MeOH (15 mL), and the reaction mixture stirred for 17h. The mixture 
was then concentrated in vacuo, diluted with water (2mL) and the acid precipitated through the 
addition of HCl. The solid was collected to give the product as off white solid. White solid (64% 
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yield), m.p. 128 °C; 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.75 (s, 1H), 7.85 (d, 1H, J = 7.8 Hz), 
7.72 (d, 2H, J = 8.4 Hz), 7.37 (m, 1H), 7.16 (d, 2H, J = 8.4 Hz), 7.12 (m, 1H), 6.90 (m, 1H), 6.64 (s, 
1H), 5.10 (d, 2H, J = 7.8 Hz), 3,15 (s, 3H), 2.10 (s, 3H), 1.45 (s, 9H); 13C-NMR (100 MHz, DMSO-
d6) δ (ppm):  170.84, 169.17, 155.62, 140.23, 138.12, 136.04, 133.11, 129.01, 128.13, 126.88, 
123.98, 122.21, 117.45, 117.32, 116.82, 108.99, 82.31, 63.74, 55.05, 42.46, 29.00, 18.26, 10.90; 
Anal. (C25H27FN2O6S) C, H, N; ESI-Mass: m/z 525.147 [M+Na]+.  
N-tert-Butyl-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]-2-amino-acetic acid (23b). Obtained following the same procedure as (23a), using (22b) 
as starting material. White solid (60% yield), m.p. 120°C; 1H-NMR (400 MHz, DMSO-d6) δ 
(ppm): 12.70 (s, 1H), 7.81 (d, 1H, J = 7.8 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.35 (m, 4H), 7.15 (d, 2H, J = 
8.5 Hz), 6.63 (s, 1H), 5.09 (d, 1H, J = 7.8 Hz), 3.17 (s, 3H), 2.02 (s, 3H), 1.43 (s, 9H); 13C-NMR (100 
MHz, DMSO-d6) δ (ppm): 170.23, 162.38, 157.75, 140.28, 139.77, 136.23, 133.06, 128.71, 
127.86, 126.88, 121.98, 122.01, 119.32, 117.33, 82.01, 53.87, 44.15, 28.53, 11.11; Anal. 
(C25H27FN2O6S) C, H, N; MS-ESI: m/z 525.147 [M+Na]+.  
2-(Nitroxy)ethyl N-tert-butyl-(ethoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (24a). Obtained following the 
same procedure as (1a), using (23a) as carboxylic acid partner. White solid (71% yield), m.p. 
129°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.83 (d, 2H, J = 8.4 Hz), 7.41 (m, 1H), 7.11 (m, 3H), 
6.94 (m, 2H), 6.59 (s, 1H), 5.55 (d, 1H, J = 7.8 Hz), 5.30 (d, 1H, J = 7.8 Hz), 4.73 (t, 2H, J = 7.0 Hz), 
4.24 (t, 2H, J = 7.0 Hz), 3.05 (s, 3H), 2.17 (s, 3H), 1.40 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 
(ppm):  170.27, 168.88, 154.23, 141.40, 138.07, 136.29, 134.52, 130.01, 128.13, 126.68, 123.12, 
121.43, 117.32, 117.06, 118.11, 108.31, 81.93, 62.85, 60.56,  54.82, 43.83, 28.51, 27.31, 10.90; 
Anal. (C27H32FN3O9S) C, H, N; MS-ESI: m/z 614.14 [M+Na]+.  
3-(Nitroxy)propyl] N-tert-butyl-(ethoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (24b). Obtained following the 
same procedure as (1a), using (23a) and (19b) as coupling partners. White solid (71% yield), 
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m.p. 114°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.83 (d, 2H, J = 8.4 Hz), 7.40 (m, 1H), 7.12 (m, 
3H), 6.90 (m, 2H), 6.65 (s, 1H), 5.55 (d, 1H, J = 7.8 Hz), 5.30 (d, 1H, J = 7.8 Hz), 4.71 (t, 2H, J = 7.0 
Hz), 4.30 (t, 2H, J = 7.0 Hz), 3.05 (s, 3H), 2.17 (s, 3H), 1.99 (m, 2H), 1.40 (s, 9H); 13C-NMR (100 
MHz, CDCl3) δ (ppm):  170.27, 168.88, 154.23, 141.40, 138.07, 136.29, 134.52, 130.01, 128.13, 
126.68, 123.12, 121.43, 117.32, 117.06, 118.11, 108.31, 81.93, 62.85, 60.56,  54.82, 43.83, 28.51, 
27.31, 10.90; Anal. (C27H32FN3O9S) C, H, N; MS-ESI: m/z 628.174 [M+Na]+.  
4-(Nitroxy)butyl N-tert-butyl-(ethoxycarbonyl)-2-[1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]-2-amino-acetate (24c). Obtained following the 
same procedure as (1a), using (23a) and (19c) as coupling partners. White solid, m.p. 118°C 
(68% yield)  1H-NMR (400 MHz, CDCl3) δ (ppm): 7.83 (d, 2H, J = 8.5 Hz), 7.40 (m, 1H), 7.12 (m, 
3H), 6.90 (m, 2H), 6.65 (s, 1H), 5.55 (d, 1H, J = 7.8 Hz), 5.30 (d, 1H, J = 7.8 Hz), 4.70 (t, 2H, J = 7.6 
Hz), 4.11 (t, 2H, J = 7.6 Hz), 3.05 (s, 3H), 2.17 (s, 3H), 1.71 (m, 2H), 1.63 (m, 2H), 1.40 (s, 9H); 13C-
NMR (100 MHz, CDCl3) δ (ppm):  169.82, 167.54, 153.90, 142.04, 138.75, 135.81, 133.81, 
129.85, 128.00, 127.41, 122.31, 123.56, 117.20, 117.06, 117.33, 107.02, 79.68, 65.79, 62.09,  
54.82, 44.28, 27.94, 26.82, 22.54, 12.03; Anal. (C28H34FN3O9S) C, H, N; MS-ESI: m/z 642.190 
[M+Na]+.  
2-(Nitroxy)ethyl N-tert-butyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (24d). Obtained following the 
same procedure as (1a), using (23b) as carboxylic acid partner. White solid (76% yield), m.p. 
131°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.75 (d, 2H, J = 8.4 Hz), 7.35 (m, 4H), 7.13 (d, 2H, J = 
8.4 Hz), 6.59 (s, 1H), 5.59 (d, 1H, J = 6.8 Hz), 5.33 (d, 1H, J = 6.8 Hz), 4.69 (t, 2H, J = 7.0 Hz), 4.25 
(t, 2H, J = 7.0 Hz), 3.09 (s, 3H), 2.11 (s, 3H), 1.46 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 
171.24, 168.72, 155.24, 138.72, 135.83, 134.88, 132.50, 129.21, 127.17, 126.74, 123.02, 123.33, 
118.86, 117.32, 81.97, 64.05, 61.34, 52.94, 44.03, 29.50, 27.82, 11.24; Anal. (C27H32FN3O9S) C, H, 
N; MS-ESI: m/z 614.15 [M+Na]+.  
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3-(Nitroxy)propyl N-tert-butyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (24e). Obtained following the 
same procedure as (1a), using (23b) and (19b) as coupling partners. White solid (73% yield), 
m.p. 112°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.75 (d, 2H, J = 8.4 Hz), 7.35 (m, 4H), 7.15 (d, 2H, 
J = 8.4 Hz), 6.63 (s, 1H), 5.59 (d, 1H, J = 6.8 Hz), 5.33 (d, 1H, J = 6.8 Hz), 4.64 (t, 2H, J = 7.0 Hz), 
4.28 (t, 2H, J = 7.0 Hz), 3.05 (s, 3H), 2.15 (s, 3H), 1.98 (m, 2H), 1.46 (s, 9H); 13C-NMR (100 MHz, 
CDCl3) δ (ppm): 171.24, 168.72, 155.24, 138.72, 135.83, 134.88, 132.50, 129.21, 127.17, 126.74, 
123.02, 123.33, 118.86, 117.32, 81.97, 64.05, 61.34, 52.94, 44.03, 29.50, 27.82, 11.24; Anal. 
(C27H32FN3O9S) C, H, N; MS-ESI: m/z 628.174 [M+Na]+.  
4-(Nitroxy)butyl N-tert-butyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (24f). Obtained following the 
same procedure as (1a), using (23b) and (19c) as coupling partners. White solid (75% yield), 
m.p. 114°C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.75 (d, 2H, J = 8.5 Hz), 7.36 (m, 4H), 7.15 (d, 2H, 
J = 8.5 Hz), 6.65 (s, 1H), 5.59 (d, 1H, J = 6.8 Hz), 5.33 (d, 1H, J = 6.8 Hz), 4.65 (t, 2H, J = 7.6 Hz), 
4.10 (t, 2H, J = 7.6 Hz), 3.05 (s, 3H), 2.15 (s, 3H), 1.73 (m, 2H), 1.58 (m, 2H), 1.46 (s, 9H); 13C-
NMR (100 MHz, CDCl3) δ (ppm): 170.82, 169.04, 156.23, 139.01, 135.82, 134.65, 132.46, 129.02, 
126.89, 125.38, 124.21, 123.13, 118.15, 116.85, 109.95, 81.88, 65.82, 63.00, 53.28, 44.03, 25.24, 
23.82, 10.98; Anal. (C28H34FN3O9S) C, H, N; MS-ESI: m/z 642.19 [M+Na]+.  
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N-Benzyl-(ethoxycarbonyl)-[1-(3-fluorophenyl)-2-methyl-5-[4 (methylsulfonyl)phenyl]-
1H-pyrrol-3-yl] methylcarbamate (25a).  
 
To a biphasic solution of amino ester (21a) (0.002326 mol) in DCM (10 mL), sodium 
carbonate (0.0046 mol) and benzyl chloroformate (0.002352 mol) were added at 0 °C, the 
reaction mixture was allowed to warm up to rt and stirred for further 4h. The mixture was then 
diluted with water and the two phases separated. The organic fraction was washed with water 
(50 mL × 2), dried over sodium sulfate and evaporated to give the crude product. The residue 
was purified by column chromatography (silica gel) eluting with EtOAc/hexane (1:20) (v/v) to 
afford the desired product as white solid. White solid (61% yield), m.p. 97°C; 1H-NMR (400 MHz, 
DMSO-d6) δ (ppm):  8.01 (d, 1H, J = 7.8 Hz), 7.89 (d, 2H, J = 8.5 Hz), 7.59 (m, 6H), 7.46 (m, 3H), 
7.06 (m, 2H), 6.48 (s, 1H), 5.18 (d, 1H, J = 7.8 Hz), 5.15 (s, 2H), 4.16 (q, 2H, J = 6.8 Hz), 3.15 (s, 
3H), 2.04 (s, 3H), 1.17 (t, 3H, J = 6.8 Hz); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 170.23, 169.27, 
155.08, 140.24, 139.23, 137.21, 136.03, 132.78, 130.58, 129.05, 128.04, 127.70, 127.12, 126.65, 
124.55, 123.09, 119.25, 118.33, 117.67, 107.28, 67.98, 64.77, 54.05, 44.66, 15.62, 12.03; Anal. 
(C30H29FN2O6S) C, H, N; MS-ESI: m/z 587.163 [M + Na]+.  
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N-Benzyl-(ethoxycarbonyl)-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]methylcarbamate (25b). Obtained following the same procedure as (25a), 
using (24b) as starting material. White solid (65% yield), m.p. 95°C; 1H-NMR (400 MHz, DMSO-
d6) δ (ppm):  7.89 (d, 1H, J = 7.8 Hz), 7.74 (d, 2H, J = 8.5 Hz), 7.51 (m, 5H), 7.19 (m, 6H), 6.50 (s, 
1H), 5.16 (d, 1H, J = 7.8 Hz), 5.08 (s, 2H), 4.11 (q, 2H, J = 6.9 Hz), 3.10 (s, 3H), 2.00 (s, 3H), 1.15 (t, 
3H, J = 6.9 Hz); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 168.45, 159.71, 156.04, 142.96, 132.28, 
138.86, 137.12, 135.98, 133.27, 130.34, 127.96, 126.51, 126.23, 125.38, 123.91, 122.54, 118.07, 
117.44, 67.45, 64.31, 54.11, 43.89, 15.46, 12.01; Anal. (C30H29FN2O6S) C, H, N; MS-ESI: m/z 
587.163 [M+Na]+.  
N-(Benzyloxy)carbonyl-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]-2-amino-acetic acid (26a). Obtained following the same procedure as (23a), 
using (25a) as starting material. White solid (>95% yield), m.p. 127°C; 1H-NMR (400 MHz, 
DMSO-d6) δ (ppm): 12.81 (s, 1H), 7.89 (d, 1H, J = 7.8 Hz), 7.70 (d, 2H, J = 8.6 Hz), 7.52 (m, 1H), 
7.47 (m, 7H), 7.32 (d, 2H, J = 8.6 Hz), 7.21 (m, 1H), 6.64 (m, 1H), 5.11 (d, 1H, J = 7.8 Hz), 5.09 (s, 
2H), 3.15 (s, 3H), 2.09 (s, 3H); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 171.22, 168.97, 155.85, 
141.02, 139.18, 138.12, 136.58, 132.93, 128.56, 128.02, 127.90, 126.76, 126.54, 126.00, 124.21, 
124.00, 117.11, 116.50, 115.99, 106.97, 63.74, 55.05, 42.46, 11.02; Anal. C28H25FN2O6S (C, H, N); 
MS-ESI: m/z 559.132[M+Na]+.  
N-(Benzyloxy)carbonyl-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-
1H-pyrrol-3-yl]-2-amino-acetic acid (26b). Obtained following the same procedure as (23a), 
using (25b) as starting material. White solid (>95% yield), m.p. 130°C; 1H-NMR (400 MHz, 
DMSO-d6) δ (ppm): 12.81 (s, 1H), 7.81 (d, 1H, J = 7.8 Hz), 7.79 (d, 2 H, J = 8.5 Hz), 7.68-7.37 (m, 
9H), 7.16 (d, 2H, J = 8.5 Hz), 6.63 (s, 1H), 5.09 (d, 1H, J = 7.8 Hz), 5.06 (s, 2H), 3.21 (s, 3H), 2.03 
(s, 3H); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 171.03, 169.27, 156.98, 143.08, 140.23, 136.91, 
134.21, 133.09, 130.88, 127.97, 127.34, 126.32, 124.55, 122.91, 119.00, 118.23, 117.43, 106.99, 
63.21, 53.92, 43.71, 11.18; Anal. (C28H25FN2O6S) C, H, N; MS-ESI: m/z 559.13 [M+Na]+.  
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 101 of 195 
 
2-(Nitroxy)ethyl N-benzyl-(ethoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino acetate (27a). Obtained following the 
same procedure as (1a), using (26a) as carboxylic acid partner. White solid (66% yield), 115 °C; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J = 8.5 Hz), 7.52-7.46 (m, 1H), 7.46 (m, 7H), 7.30 
(d, 2H, J = 8.5 Hz), 7.21 (m, 1H), 6.64 (m, 1H), 5.52 (d, 1H, J = 7.8 Hz), 5.29 (d, 1H, J = 7.8 Hz), 5.10 
(s, 2H), 4.69 (t, 2H, J = 6.9 Hz), 4.29 (t, 2H, J = 6.9 Hz), 3.00 (s, 3H), 2.20 (s, 3H); 13C-NMR (100 
MHz, CDCl3) δ (ppm): 170.83, 169.04, 155.28, 142.47, 142.06, 138.07, 136.29, 134.31, 130.83, 
128.79, 127.64, 127.32, 127.13, 126.40, 124.08, 121.31, 117.51, 117.08, 116.92, 108.09, 67.20, 
63.04, 60.93, 54.82, 43.83, 28.51, 10.90; Anal. (C30H28FN3O9S) C, H, N; MS-ESI: m/z 648.17 
[M+Na]+.  
3-(Nitroxy)propyl N-benzyl-(ethoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino acetate (27b). Obtained following the 
same procedure as (1a), using (26a) and (19b) as coupling partners. White solid (66% yield), 
115 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J = 8.5 Hz), 7.52 (m, 1H), 7.47 (m, 7H), 
7.32 (d, 2H, J = 8.5 Hz), 7.21 (m, 1H), 6.64 (m, 1H), 5.50 (d, 1H, J = 7.8 Hz), 5.29 (d, 1H, J = 7.8 Hz), 
5.10 (s, 2H), 4.67 (t, 2H, J = 6.9 Hz), 4.29 (t, 2H, J = 6.9 Hz), 3.00 (s, 3H), 2.20 (s, 3H), 1.95 (m, 
2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 170.83, 169.04, 155.28, 142.47, 142.06, 138.07, 
136.29, 134.31, 130.83, 128.79, 127.64, 127.32, 127.13, 126.40, 124.08, 121.31, 117.51, 117.08, 
116.92, 108.09, 67.20, 63.04, 60.93, 54.82, 43.83, 28.51, 10.90; Anal. (C31H30FN3O9S) C, H, N; MS-
ESI: m/z 662.158 [M+Na]+.  
4-(Nitroxy)butyl N-benzyl-(ethoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino acetate (27c). Obtained following the 
same procedure as (1a), using (26a) and (19c) as coupling partners. White solid (64% yield), 
119 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J = 8.4 Hz), 7.55 (m, 1H), 7.47 (m, 7H), 
7.29 (d, 2H, J = 8.4 Hz), 7.21 (m, 1H), 6.64 (s, 1H), 5.48 (d, 1H, J = 7.7 Hz), 5.31 (d, 1H, J = 7.7 Hz), 
5.12 (s, 2H), 4.60 (t, 2H, J = 7.0 Hz), 4.07 (t, 2H, J = 7.0 Hz), 3.05 (s, 3H), 2.10 (s, 3H), 1.75 (m, 2H), 
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1.60 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm):  170.92, 169.00, 155.20, 142.45, 142.21, 
138.07, 136.29, 134.31, 130.83, 128.79, 127.64, 127.32, 127.03, 126.41, 124.08, 121.89, 117.51, 
117.08, 116.97, 108.09, 67.20, 63.44, 61.45, 54.82, 43.83, 27.33, 28.51, 10.91; Anal. 
(C32H32FN3O9S) C, H, N; MS-ESI: m/z 676.18 [M+Na]+. 
2-(Nitroxy)ethyl N-benzyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (27d). Obtained following the 
same procedure as (1a), using (26b) as carboxylic acid partner. White solid (62% yield), 118 °C; 
1H-NMR (400 MHz, CDCl3): δ (ppm) 7.70 (d, 2 H, J = 8.4 Hz), 7.54-7.49 (m, 9H), 7.16 (d, 2 H, J = 
8.4 Hz), 6.64 (s, 1H), 5.54 (d, 1H, J = 7.7 Hz), 5.32 (d, 1H, J = 7.7 Hz), 5.10 (s, 2H), 4.69 (t, 2H, J = 
6.8 Hz), 4.29 (t, 2H, J = 6.8 Hz), 3.00 (s, 3H), 2.20 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ (ppm):  
170.83, 168.72, 154.98, 143.23, 139.01, 135.82, 134.65, 132.43, 131.80, 127.98, 127.49, 127.29, 
127.17, 126.89, 123.45, 123.22, 119.05, 116.92, 115.88, 66.82, 66.24, 60.45, 44.03, 27.80, 11.24; 
Anal. (C30H28FN3O9S) C, H, N; MS-ESI: m/z 648.17 [M+Na]+.  
3-(Nitroxy)propyl N-benzyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate (27e). Obtained following the 
same procedure as (1a), using (26b) and (19b) as coupling partners. White solid, 118 °C (62% 
yield);  1H-NMR (400 MHz, CDCl3): δ (ppm) 7.69 (d, 2 H, J = 8.4 Hz), 7.55 (m, 9H), 7.16 (d, 2 H, J 
= 8.4 Hz), 6.64 (s, 1H), 5.54 (d, 1H, J = 7.7 Hz), 5.32 (d, 1H, J = 7.7 Hz), 5.10 (s, 2H), 4.66 (t, 2H, J = 
6.8 Hz), 4.39 (t, 2H, J = 6.8 Hz), 3.00 (s, 3H), 2.20 (s, 3H), 1.95 (m, 2H). 13C-NMR (100 MHz, 
CDCl3):  δ (ppm)  170.83, 168.72, 154.98, 143.23, 139.01, 135.82, 134.65, 132.43, 131.80, 
127.98, 127.49, 127.29, 127.17, 126.89, 123.45, 123.22, 119.05, 116.92, 115.88, 66.82, 66.24, 
60.45, 44.03, 27.8, 11.24. ESI-Mass: m/z 662.158 [M + Na]+; Anal. C31H30FN3O9S (C, H, N). 
4-(Nitroxy)butyl N-benzyl-(ethoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-
(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino acetate (27f). Obtained following the 
same procedure as (1a), using (26b) and (19c) as coupling partners. White solid (61% yield), 
121 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.65 (d, 2 H, J = 8.5 Hz), 7.53 (m, 9H), 7.17 (d, 2 H, J = 
Chapter 1: Development of a Novel Class of Pharmacodynamic Hybrids/NO Donors that Targets COX-2 Selectively 
 
Page 103 of 195 
 
8.5 Hz), 6.64 (s, 1H), 5.55 (d, 1H, J = 7.6 Hz), 5.34 (d, 1H, J = 7.6 Hz), 5.12 (s, 2H,), 4.65 (t, 2H, J = 
7.0 Hz), 4.11 (t, 2H, J = 7.0 Hz), 3.05 (s, 3H), 2.15 (s, 3H), 1.73 (m, 2H), 1.58 (m, 2H); 13C-NMR 
(100 MHz, CDCl3) δ (ppm): 171.00, 168.66, 154.99, 143.21, 139.34, 135.04, 134.09, 132.40, 
131.81, 128.22, 127.39, 127.21, 127.07, 126.09, 123.31, 123.20, 118.95, 117.55, 116.09, 66.67, 
66.04, 60.05, 44.03, 27.81, 27.55, 11.21; Anal. (C32H32FN3O9S) C, H, N; MS-ESI: m/z 676.18 
[M+Na]+. 
N-[2-(Nitroxy)ethyl] 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (5a). 
 
Nitroxyethylamine (29a, nitrate salt) (0.3 mmol), DMAP (0.1 mmol), and EDCI (0.2 mmol) 
were added in sequence to a solution of 1,5-diarylpyrrole-3-acetic acid (17b) (0.1 mmol) in 
dichloromethane (5 mL), under nitrogen atmosphere. An excess of triethylamine (TEA, 0.35 
mmol) was added dropwise and the reaction was stirred at rt for 3h. Then the mixture was 
quenched with water and extracted with chloroform. The organic layer was washed with 1N 
HCl, NaHCO3 saturated solution, brine and dried over Na2SO4. After filtration and concentration 
of the organic phase a crude material was obtained. The material was then purified by 
chromatography on silica gel/alumina (1:1) using petroleum ether/chloroform/ethyl acetate, 
4:4:1 (v/v/v), as the eluent to give the desired product in good yield. Yellow powder (yield 
80%), mp 133°C.; FT-IR (neat, cm-1): 3300, 1640, 1595, 1520, 1278, 865; 1H-NMR (400 MHz, 
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CDCl3) δ (ppm): 7.71 (d, 2H, J = 8.6 Hz), 7.18 (m, 6H), 6.40 (s, 1H), 6.12 (s broad, 1H), 4.59 (t, 2H, 
J = 7.6 Hz), 3.63 (t, 2H, J = 78.6 Hz), 3.49 (s, 2H), 3.02 (s, 3H), 2.04 (s, 3H); 13C-NMR (100 MHz, 
CDCl3) δ (ppm): 11.89, 32.21, 38.41, 44.61, 69.77, 113.06, 113.44, 115.90, 120.71, 125.59, 
127.10, 130.66, 130.71, 131.30, 131.83, 136.12, 138.23, 169.45. Anal. (C22H22FN3O6S) C, H, N; 
MS-ESI: m/z 475.12 [M+H]+.  
N-[3-(Nitroxy)propyl] 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (5b). Obtained with the same procedure as (5a), using (29b) as coupling 
partner. Yellowish powder (yield 76%), m.p. 125 °C; FT-IR (neat, cm-1): 3310, 1642, 1597, 1515, 
1280, 899; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.73 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.40 (s, 1H), 
6.12 (s broad, 1H), 4.59 (t, 2H, J = 7.6 Hz), 3.63 (t, 2H, J = 78.6 Hz), 3.49 (s, 2H), 3.02 (s, 3H), 2.04 
(s, 3H), 1.88 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 11.78, 31.10, 32.20, 38.35, 44.55, 
69.70, 113.09, 113.50, 115.81, 120.66, 125.43, 127.17, 130.46, 130.21, 131.270, 131.80, 136.32, 
138.41, 169.49; Anal. (C23H24FN3O6S) C, H, N; MS-ESI: m/z 489.14 [M+H]+.  
N-[2-(Nitroxy)ethyl] 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (5c). Obtained with the same procedure as (5a), using (17c) as coupling 
partner. Yellowish powder (yield 81%), mp 135 °C; FT-IR (neat, cm-1): 3300, 1640, 1520, 1278, 
1595, 865; 1H-NMR (400 MHz, CDCl3) ppm: 7.70 (d, 2H, J = 8.6 Hz), 7.23 (m, 6H), 6.43 (s, 1H), 
6.12 (s broad, 1H), 4.59 (t, 2H, J = 7.6 Hz), 3.63 (t, 2H, J = 7.6 Hz), 3.49 (s, 2H), 3.02 (s, 3H), 2.09 
(s, 3H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.77, 32.31, 38.27, 44.59, 69.60, 112.81,113.66, 
115.71, 120.28, 124.45, 130.09, 130.69, 131.33, 135.07, 136.80, 138.110, 139.35, 169.60; Anal. 
(C22H22FN3O6S) C, H, N; MS-ESI: m/z 475.12 [M+H]+.  
N-[3-(Nitroxy)propyl] 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (5d). Obtained with the same procedure as (5a), using (17c) and (29b) 
as coupling partners. Yellowish powder, m.p. 125 °C (yield 76%). FT-IR cm-1: 3310, 1642, 1597, 
1515, 1280, 899. 1H-NMR (400 MHz, CDCl3) ppm: 7.67 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.44 (s, 
1H), 6.15 (s broad, 1H), 4.61 (t, 2H, J = 7.6 Hz), 3.65 (t, 2H, J = 7.6 Hz), 3.47 (s, 2H), 3.00 (s, 3H), 
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2.07 (s, 3H), 1.89 (m, 2H). 13C-NMR (400 MHz, CDCl3)  δ (ppm): 11.80, 30.15, 32.21, 38.25, 44.61, 
69.60, 112.81, 113.66, 115.71, 120.25, 124.45, 130.12, 130.69, 131.30, 135.11, 136.81, 138.11, 
139.30, 169.57; Anal. (C23H24FN3O6S) C, H, N; MS-ESI: m/z 489.14 [M+H]+.  
 N-[2-(Hydroxy)ethyl] 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (6a).  
 
Ethanolamine (28a) (1.0 mmol), HOBt (0.9 mmol), and EDCI (1.2 mmol) were added in 
sequence to a solution of 1,5-diarylpyrrole-3-acetic acid (17b) (0.7 mmol) in dichloromethane 
(20 mL), under nitrogen atmosphere. An excess of TEA (2.0 mmol) was added dropwise and the 
reaction was stirred at rt for 3h. Then the mixture was quenched with water and extracted with 
chloroform. The organic layer was washed with 1N HCl, NaHCO3 saturated solution, brine and 
dried over Na2SO4. After filtration and concentration of the organic phase a crude material was 
obtained. The material was then purified by chromatography on silica gel using petroleum 
ether/chloroform/ethyl acetate, 3:2:1 (v/v/v), as the eluent to give the desired product in good 
yield. Yellowish powder (77% yield), mp 97 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.69 (d, 2H, J 
= 8.6 Hz), 7.40 (m, 1H), 7.19 (d, 2H, J = 8.6 Hz), 7.13 (m, 1H), 6.96 (m, 1H), 6.87 (m, 1H), 6.47 (s, 
1H), 6.40 (s broad, 1H), 3.70 (t, 2H, J = 7.4 Hz), 3.48 (s, 2H), 3.40 (m, 2H), 3.00 (s, 3H), 2.70 (s 
broad, 1H), 2.04 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 11.89, 32.21, 36.41, 44.61, 60.17, 
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113.08, 113.54, 115.88, 120.31, 125.61, 127.12, 130.56, 130.44, 131.37, 131.85, 136.32, 138.63, 
169.47; Anal. (C22H23FN2O4S) C, H, N;  MS-ESI: m/z 430.14 [M+H+].  
N-[3-(Hydroxy)propyl] 2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (6b). Obtained with the same procedure as (6a), using (28b) as coupling 
partner. Yellowish powder (yield 76%), m.p. 99 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 
2H, J = 8.6 Hz), 7.17 (m, 6H), 6.45 (s, 1H), 6.37 (s broad, 1H), 3.67 (t, 2H, J = 7.4 Hz), 3.50 (m, 2H), 
3.49 (s, 2H), 3.00 (s, 3H), 2.00 (s, 3H), 1.79 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 11.67, 
31.10, 32.00, 38.27, 44.55, 60.11, 113.09, 113.53, 115.73, 120.56, 125.48, 127.27, 130.46, 
130.21, 131.270, 131.56, 136.33, 138.40, 169.39; Anal. (C23H25FN2O4S) C, H, N;  MS-ESI: m/z 
444.15 [M+H]+.  
N-[2-(Hydroxy)ethyl] 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (6c). Obtained with the same procedure as (6a), using (17c) as coupling 
partner. Yellowish powder (yield 81%), mp 102 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.76 (d, 
2H, J = 8.6 Hz), 7.20 (m, 6H), 6.40 (s, 1H), 6.33 (s broad, 1H), 3.69 (t, 2H, J = 7.4 Hz), 3.49 (s, 2H), 
3.40 (m, 2H), 3.02 (s, 3H), 2.09 (s, 3H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.77, 32.21, 38.20, 
44.39, 60.06, 112.77, 113.46, 116.01, 121.18, 124.50, 130.10, 130.70, 131.43, 135.17, 136.11, 
138.18, 139.35, 169.41; Anal. (C22H23FN2O4S) C, H, N;  MS-ESI: m/z 430.15 [M+H]+.   
N-[3-(Hydroxy)propyl] 2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-
pyrrol-3yl]acetamide (6d). Obtained with the same procedure as (6a), using (17c) and (28b) 
as coupling partners. Yellowish powder (yield 76%), m.p. 105 °C; 1H-NMR (400 MHz, CDCl3) δ 
(ppm): 7.68 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.41 (s, 1H), 6.35 (s broad, 1H), 3.68 (t, 2H, J = 7.6 
Hz), 3.47 (s, 2H), 3.40 (m, 2H), 3.00 (s, 3H), 2.07 (s, 3H), 1.79 (m, 2H); 13C-NMR (100 MHz, 
CDCl3)  δ (ppm): 11.69, 30.15, 32.01, 38.25, 44.61, 60.02, 112.85, 113.70, 115.82, 120.33, 124.50, 
130.23, 130.59, 131.70, 135.10, 136.81, 138.11, 139.40, 169.47; Anal. (C23H25FN2O4S) C, H, N;  
MS-ESI: m/z 444.15 [M+H]+. 
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 (R,S)-2-[2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-nitroxypropanoic acid (7a). 
 
PyBop (0.93 mmol) and TEA (3 mmol) are added in sequence to a solution of (17b) (0.78 
mmol) in THF (20 mL) at rt and the mixture stirred for 1h. Then (31a) (1.5 mmol) was added 
over 5 minutes. After 4 h the reaction is concentrated in vacuo and the oily residue is treated 
with KOH 1N (10 mL). The solution is filtered through a paper filter. The liquid is collected, 
cooled to 0 °C and HCl 5N was added dropwise till a white precipitate is formed. The solid 
obtained is filtered and dried. After recrystallization from ethanol/petroleum ether 7a is 
obtained in quite good yield. Yellow powder (yield 80%), mp 110°C; FT-IR (neat, cm-1): 3310, 
1734, 1640, 1595, 1520, 1278,  865; 1H-NMR (400 MHz, CDCl3) δ (ppm): 11.13 (s broad, 1H), 
7.70 (d, 2H, J = 8.5 Hz), 7.20 (m, 6H), 6.73 (s broad, 1H), 6.50 (s, 1H), 4.79 (m, 1H), 4.62 (m, 2H), 
3.51 (s, 2H), 3.10 (s, 3H), 2.09 (s, 3H).  13C-NMR (100 MHz, CDCl3) δ (ppm): 11.80, 32.21, 38.41, 
55.71, 70.18, 113.22, 113.43, 115.98, 120.56, 125.59, 127.00, 130.66, 130.71, 131.30, 131.80, 
136.13, 138.50, 169.67; Anal. (C23H22FN3O8S) C, H, N; MS-ESI: m/z 519.17 [M+H]+.  
(R,S)-2-[2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-nitroxybutanoic acid (7b). Obtained with the same procedure as (7a), using 
31b as coupling partner. Yellowish powder (79% yield), m.p. 112 °C; FT-IR (neat, cm-1): 3320, 
1735, 1642, 1589, 1524, 1282,  871; 1H-NMR (400 MHz, CDCl3): δ 11.13 (s broad, 1H), 7.70 (d, 
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2H, J = 8.6 Hz), 7.30 (m, 4H), 7.23 (m, 2H), 6.70 (s broad, 1H), 6.51 (s, 1H), 4.80 (m, 1H), 4.67 (m, 
2H), 3.54 (s, 2H), 3.01 (s, 3H), 2.07 (s, 3H), 1.79 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 
11.80, 30.19, 33.01, 38.49, 55.79, 70.08, 113.22, 113.43, 115.98, 120.56, 125.59, 127.11, 130.67, 
130.71, 131.34, 131.75, 136.13, 138.54, 169.60; Anal. (C24H24FN3O8S) C, H, N; MS-ESI: m/z 
533.21 [M+H]+.  
(R,S)-2-[2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-nitroxypropanoic acid (7c). Obtained with the same procedure as (7a), 
using 17c as coupling partner. Yellowish powder (81% yield), mp 109 °C; FT-IR (neat, cm-1): 
3323, 1735, 1642, 1589, 1524, 1282,  871; 1H-NMR (100 MHz, CDCl3) δ (ppm): 11.10 (s broad, 
1H), 7.70 (d, 2H, J = 8.6 Hz), 7.23 (m, 6H), 6.50 (s, 1H), 4.79 (m, 1H), 4.62 (m, 2H), 3.51 (s, 2H), 
3.10 (s, 3H), 2.09 (s, 3H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.66, 32.31, 38.27, 55.59, 70.60, 
112.67, 113.34, 115.19, 120.39, 124.45, 130.32, 130.19, 131.36, 135.11, 136.80, 138.01, 139.39, 
169.57; Anal. (C23H22FN3O8S) C, H, N; MS-ESI: m/z 519.17  [M+H]+.   
(R,S)-2-[2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-nitroxybutanoic acid (7d). Obtained with the same procedure as (7a), using 
17c and 31b as coupling partners. Yellowish powder (76% yield), m.p. 116 °C; FT-IR (neat, cm-
1): 3310, 1642, 1597, 1515, 1280, 899; 1H-NMR (400 MHz, CDCl3) δ (ppm): 11.14 (s broad, 1H), 
7.60 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.72 (s broad, 1H), 6.51 (s, 1H), 4.80 (m, 1H), 4.67 (m, 2H), 
3.55 (s, 2H), 3.03 (s, 3H), 2.07 (s, 3H), 1.79 (m, 2H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.77, 
30.22, 33.17, 38.51, 55.839, 70.10, 112.80, 113.57, 115.70, 120.27, 124.55, 130.12, 130.48, 
131.27, 135.10, 136.80, 138.11, 139.30, 169.50; Anal. (C24H24FN3O8S) C, H, N; MS-ESI: m/z 
533.21 [M+H] +. 
(R,S)-2-[2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-hydroxypropanoic acid (8a). Obtained with the same procedure as (7a), 
using 30a as coupling partner. Yellow powder (80% yield), mp 118°C; 1H-NMR (400 MHz, 
CDCl3) δ (ppm): 11.17 (s broad, 1H), 7.71 (d, 2H, J = 8.5 Hz), 7.23 (m, 6H), 6.78 (s broad, 1H), 
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6.51 (s, 1H), 4.77 (m, 1H), 4.12 (m, 2H), 3.51 (s, 2H), 3.10 (s, 3H), 2.76 (s broad, 1H), 2.09 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ (ppm): 11.84, 32.20, 38.41, 55.34, 65.25, 113.25, 113.40, 115.89, 
120.45, 125.69, 127.01, 130.76, 130.70, 131.41, 131.77, 136.21, 138.50, 169.72; Anal. 
(C23H23FN2O6S) C, H, N; MS-ESI: m/z 474.12 [M+H]+. 
(R,S)-2-[2-[1-(3-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-hydroxybutanoic acid (8b). Obtained with the same procedure as (7a), using 
30b as coupling partner. Yellowish powder (79% yield), m.p. 128 °C; 1H-NMR (400 MHz, CDCl3) 
δ (ppm):  11.18 (s broad, 1H), 7.73 (d, 2H, J = 8.6 Hz), 7.33 (m, 4H), 7.22 (m, 2H), 6.72 (s broad, 
1H), 6.50 (s, 1H), 4.76 (m, 1H), 4.17 (m, 2H), 3.54 (s, 2H), 3.01 (s, 3H), 2.67 (s broad, 1H), 2.07 (s, 
3H), 1.79 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 11.67, 30.22, 33.10, 38.38, 55.81, 60.08, 
113.32, 113.29, 115.88, 120.51, 125.53, 127.14, 130.69, 130.70, 131.34, 131.70, 136.20, 138.55, 
169.68; Anal. (C24H25FN2O6S) C, H, N; MS-ESI: m/z 488.14 [M+H]+. 
(R,S)-2-[2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-hydroxypropanoic acid (8c). Obtained with the same procedure as (7a), 
using (17c)  and (30a) as coupling partners. Yellowish powder (81% yield), mp 113 °C; 1H-NMR 
(400 MHz, CDCl3) δ (ppm): 11.10 (s broad, 1H), 7.73 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.51 (s, 
1H), 4.79 (m, 1H), 4.12 (m, 2H), 3.51 (s, 2H), 3.10 (s, 3H), 2.65 (s broad, 1H), 2.09 (s, 3H); 13C-
NMR (400 MHz, CDCl3)  δ (ppm): 11.60, 32.30, 38.25, 55.44, 60.55, 112.60, 113.30, 115.09, 
120.32, 124.40, 130.30, 130.29, 131.16, 135.10, 136.57, 138.07, 139.19, 169.49; Anal. 
(C23H23FN2O6S) C, H, N;  MS-ESI: m/z 474.12 [M+H]+.  
(R,S)-2-[2-[1-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-
yl]acetamide]-4-hydroxybutanoic acid (8d). Obtained with the same procedure as (7a), using 
17c and 30b as coupling partners. Yellowish powder (76% yield), m.p. 126 °C; 1H-NMR (400 
MHz, CDCl3) δ (ppm): 11.14 (s broad, 1H), 7.60 (d, 2H, J = 8.6 Hz), 7.20 (m, 6H), 6.73 (s broad, 
1H), 6.51 (s, 1H), 4.75 (m, 1H), 4.17 (m, 2H), 3.58 (s, 2H), 3.05 (s, 3H), 2.62 (s broad, 1H), 2.09 (s, 
3H), 1.81 (m, 2H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 11.77, 30.20, 33.21, 38.44, 55.89, 60.10, 
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112.81, 113.66, 115.70, 120.27, 124.52, 130.10, 130.37, 131.27, 135.10, 136.81, 138.11, 139.33, 
169.48; Anal. (C24H25FN2O6S) C, H, N; MS-ESI: m/z 533.21 [M+H]+.  
2-(Nitroxy)ethylamine nitrate salt (29a).  
 
Nitric acid (3 mL) was added to dichloromethane in a 100 mL round-bottomed flask. The 
solution was allowed to reach 0 °C and then ethanolamine (28a) (16 mmol) was added 
dropwise. After 50 minutes of stirring, acetic anhydride (2 mL) is added dropwise over 2 
minutes. After 45 minutes a precipitate was formed and then filtered. The solid is then 
crystallised with hot chloroform/ethanol to give (29a) as nitrate salt. Off-white crystals (90% 
yield), mp 89 °C; FT-IR (neat, cm-1): 1636, 889; 1H-NMR (400 MHz, MeOH-d4) δ (ppm):  4.80 (t, 
2H, J = 7.4 Hz), 3.40 (t, 2H, J = 7.4 Hz); 13C-NMR (100 MHz, CDCl3) δ (ppm): 38.49, 69.17.  
2-(Nitroxy)propylamonium nitrate (29b). Off-white crystals (80% yield), mp 90 °C; FT-IR 
(neat, cm-1): 1641, 880; 1H-NMR (400 MHz, MeOH-d4) δ (ppm):  4.78 (t, 2H, J = 7.4 Hz), 3.60 (t, 
2H, J = 7.4 Hz), 2.10 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 30.12, 38.44, 69.17.  
2-Amino-3-(nitroxy)propanoic acid nitric salt (31a). Off-white crystals (80% yield), mp 109 
°C; FT-IR (neat, cm-1): 3160, 1723, 1630, 877; 1H-NMR (400 MHz, MeOH-d4) δ (ppm): 8.31 
(broad s, 3H), 4.99-4.77 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 35.67, 68.97, 170.34. 
2-Amino-4-(nitroxy)butanoic acid nitric salt (31b). Off-white crystals (88% yield), mp 104 
°C; FT-IR (neat, cm-1): 3165, 1730, 1625, 880; 1H-NMR (400 MHz, MeOH-d4) δ (ppm):  8.71 
(broad s, 3H), 4.73 (m, 2H), 4.14 (m, 1H), 2.37 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ (ppm): 
30.87, 35.67, 69.08, 170.21. 
N-[2-(Nitroxy)ethyl] (R,S)-2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetamide (9a). Obtained following the same 
procedure as (3a). Yellowish powder (81% yield), m.p. 144°C; FT-IR (neat, cm-1) v: 3330, 2890, 
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1654, 1590, 1300, 1147, 1102, 899; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.67 (d, 2H, J = 8.4 Hz), 
7.28 (d, 2H, J = 8.4 Hz), 7.12 (m, 3H, J = 8.4 Hz), 7.04 (m, 1H), 6.78 (s broad, 2H), 6.51 (s, 1H), 
4.67 (t, 2H, J = 7.4 Hz), 3.47 (m, 2H), 3.00 (s, 3H), 2.20 (s, 3H); 13C-NMR (100 MHz, CDCl3):  δ 
(ppm) 169.33, 159.91, 145.23, 144.51, 141.22, 138.00, 131.32, 129.55, 127.91, 126.19, 122.45, 
121.20, 116.09, 68.34, 58.18, 43.07, 33.15, 11.06; Anal. (C22H23FN4O6S) C, H, N; MS-ESI: m/z 
491.14 [M+H]+. 
N-[3-(Nitroxy)propyl] (R,S)-2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetamide (9b). Obtained following the same 
procedure as (3a). Yellowish powder (83% yield), m.p. 131°C; FT-IR (neat, cm-1) v: 3340, 2889, 
1638, 1581, 1289, 1142, 1105, 877;  1H-NMR (400 MHz, CDCl3): δ (ppm) 7.68 (d, 2H, J = 8.4 Hz), 
7.25 (d, 2H, J = 8.4 Hz), 7.11 (m, 3H, J = 8.4 Hz), 7.05 (m, 1H), 6.83 (s broad, 2H), 6.53 (s, 1H), 
4.69 (t, 2H, J = 7.4 Hz), 3.45 (m, 2H), 3.08 (s, 3H), 2.17 (s, 3H), 1.88 (m, 2H); 13C-NMR (100 MHz, 
CDCl3):  δ (ppm) 169.53, 159.88, 145.64, 144.50, 141.23, 138.10, 131.38, 129.52, 127.90, 
126.22, 122.15, 121.10, 116.03, 68.31, 58.17, 43.01, 33.12, 31.12, 11.00; Anal. (C23H25FN4O6S) C, 
H, N; MS-ESI: m/z 515.13 [M+H]+. 
N-[2-(Hydroxy)ethyl] (R,S)-2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetamide (10a). Obtained following the same 
procedure as (13a). Yellowish powder, m.p. 109°C (>95% yield); 1H-NMR (400 MHz, DMSO-d6): 
δ (ppm) 7.65 (d, 2H, J = 8.4 Hz), 7.22 (d, 2H, J = 8.4 Hz), 7.10 (m, 3H, J = 8.4 Hz), 7.05 (m, 1H), 
6.76 (s broad, 2H), 6.53 (s, 1H), 4.12 (t, 2H, J = 7.4 Hz), 3.45 (m, 2H), 3.02 (s, 3H), 2.15 (s, 3H); 
13C-NMR (100 MHz, DMSO-d6):  δ (ppm) 169.37, 159.63, 145.33, 144.78, 141.51, 138.00, 131.32, 
129.25, 128.00, 126.20, 122.48, 121.53, 116.12, 62.10, 58.21, 44.07, 33.23, 11.06; Anal. 
(C22H24FN3O4S) C, H, N; MS-ESI: m/z 446.16 [M+H]+. 
N-[3-(Hydroxy)propyl] (R,S)-2-amino-2-[1-(3-fluorophenyl)-2-methyl-5-[4-
(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetamide (10b). Obtained following the 
procedure as (13a). Yellowish powder, m.p. 115°C (>95% yield); 1H-NMR (400 MHz, DMSO-d6): 
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δ (ppm) 7.66 (d, 2H, J = 8.4 Hz), 7.26 (d, 2H, J = 8.4 Hz), 7.09 (m, 3H, J = 8.4 Hz), 7.04 (m, 1H), 
6.79 (s broad, 2H), 6.51 (s, 1H), 4.15 (t, 2H, J = 7.4 Hz), 3.48 (m, 2H), 3.09 (s, 3H), 2.17 (s, 3H), 
192 (m, 2H); 13C-NMR (100 MHz, DMSO-d6):  δ (ppm) 169.40, 159.12, 145.31, 144.71, 141.49, 
138.06, 131.44, 129.23, 127.00, 126.29, 122.42, 121.47, 116.10, 62.10, 58.11, 44.07, 33.23, 
30.12, 11.06; Anal. (C23H26FN3O4S) C, H, N; MS-ESI: m/z 460.15 [M+H]+. 
N-[2-(Nitroxy)ethyl] (R,S)-2-[(tert-butyl)oxycarbonyl]amino-[2-(1-(3-fluorophenyl)-2-
methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)]acetamide (32a). Obtained 
following the same procedure as (7a), using (23a) as carboxylic acid partner. White solid (70% 
yield), m.p. 102°C; FT-IR (neat, cm-1) v: 3330, 2895, 1688, 1645, 1579, 1228, 1155, 1101, 867; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.73 (d, 2H, J = 8.4 Hz), 7.26 (m, 4H), 7.15 (d, 2H, J = 8.4 Hz), 
6.63 (s, 1H), 6.52 (s broad, 1H), 5.59 (m, 1H), 4.69 (t, 2H, J = 7.3 Hz), 4.19 (t, 2H, J = 7.3 Hz), 3.05 
(s, 3H), 2.15 (s, 3H), 1.46 (s, 9H). 13C-NMR (100 MHz, CDCl3) δ (ppm):  169.24, 168.70, 159.20, 
138.70, 135.63, 134.18, 132.43, 129.18, 127.11, 126.66, 123.00, 123.13, 120.18, 117.33, 81.91, 
60.05, 58.34, 44.03, 32.21, 30.50, 27.82, 11.24; Anal. (C27H31FN4O8S) C, H, N; MS-ESI: m/z 591.18 
[M+H]+. 
N-[3-(Nitroxy)propyl] (R,S)-2-[(tert-butyl)oxycarbonyl]amino-[2-(1-(3-fluorophenyl)-2-
methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)]acetamide (32b). Obtained 
following the same procedure as (7a), using (23b) and (29b) as coupling partners. White solid 
(71% yield), m.p. 100°C; FT-IR (neat, cm-1): 3335, 2893, 1687, 1646, 1577, 1225, 1152, 1100, 
869; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.70 (d, 2H, J= 8.4 Hz), 7.23 (m, 4H), 7.16 (d, 2H, J= 8.4 
Hz), 6.60 (s, 1H), 6.52 (s broad, 1H), 5.59 (m, 1H), 4.67 (t, 2H, J = 7.3 Hz), 4.17 (t, 2H, J = 7.3 Hz), 
3.05 (s, 3H), 2.15 (s, 3H), 1.46 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ (ppm):  170.27, 168.88, 
154.23, 141.40, 138.07, 136.29, 134.52, 130.01, 128.13, 126.68, 123.12, 121.43, 117.32, 117.06, 
118.11, 108.31, 81.93, 62.85, 60.56,  54.82, 43.83, 28.51, 27.31, 10.90; Anal. (C28H33FN4O8S) C, H, 
N; MS-ESI: m/z 615.17 [M+H]+. 
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N-[2-(Nitroxy)ethyl] (R,S)-[(benzyloxy)carbonyl]amino-2-(1-(3-fluorophenyl)-2-methyl-
5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)acetamide (33a). Obtained following the 
same procedure as (7a), using (26a) as carboxylic acid partner. White solid (75% yield), 138 °C; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 7.71 (d, 2H, J = 8.4 Hz), 7.30 (m, 9H), 7.16 (d, 2H, J = 8.4 Hz), 
6.88 (s broad, 1H) 6.60 (s, 1H), 5.54 (d, 1H, J = 7.7 Hz), 5.32 (d, 1H, J = 7.7 Hz), 5.10 (s, 2H), 4.70 
(t, 2H, J = 6.8 Hz), 3.49 (m, 2H), 3.03 (s, 3H), 2.14 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ (ppm):  
169.23, 168.66, 159.78, 143.23, 139.01, 135.82, 134.65, 132.43, 131.80, 127.98, 127.49, 127.29, 
127.17, 126.89, 123.45, 123.22, 119.05, 116.92, 115.88, 70.82, 60.09, 58.32, 44.03, 32.80, 11.04; 
Anal. (C30H29FN4O8S) C, H, N; MS-ESI: m/z 625.16 [M+H]+. 
N-[3-(Nitroxy)propyl] (R,S)-[(benzyloxy)carbonyl]amino-2-(1-(3-fluorophenyl)-2-
methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)acetamide (33b). Obtained following 
the same procedure as (7a), using (26b) and (29b) as carboxylic acid partner. White solid (70% 
yield), 135 °C; 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.71 (d, 2H, J = 8.4 Hz), 7.30 (m, 9H), 7.16 (d, 
2H, J = 8.4 Hz), 6.88 (s broad, 1H) 6.60 (s, 1H), 5.54 (d, 1H, J = 7.7 Hz), 5.32 (d, 1H, J = 7.7 Hz), 
5.10 (s, 2H), 4.70 (t, 2H, J = 6.8 Hz), 3.49 (m, 2H), 3.03 (s, 3H), 2.14 (s, 3H), 193 (m, 2H); 13C-NMR 
(100 MHz, CDCl3) δ (ppm):  169.5, 168.67, 159.71, 143.20, 139.21, 135.12, 134.51, 132.31, 
131.83, 127.78, 127.52, 127.29, 127.37, 126.91, 123.44, 123.31, 117.05, 116.92, 115.88, 70.82, 
60.09, 58.32, 44.03, 32.80, 30.12, 11.04; Anal. (C31H31FN4O8S) C, H, N; MS-ESI: m/z 639.17 
[M+H]+. 
 
Biology and Pharmacology.  
In Vitro Anti-Inflammatory Study. The in vitro profiles of all the compounds were evaluated 
through a cell-based assay employing murine monocyte/macrophage J774 cell lines. The cell 
line was grown in DMEM supplemented with 2 mM glutamine, 25 mM HEPES, 100 units/mL 
penicillin, 100 μg/mL streptomycin, 10% fetal bovine serum (FBS), and 1.2% sodium pyruvate. 
Cells were plated in 24-well culture plates at a density of 2.5 x 105 cells/mL or in 60 mm 
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diameter culture dishes (3x106 cells per 3mL per dish) and allowed to adhere at 37 °C in 5% CO2 
for 2 h. Immediately before the experiments, culture medium was replaced with fresh medium 
and cells were stimulated as described previously.44 The evaluation of COX-1 inhibitory activity 
was achieved by pre-treating cells with test compounds (10 μM) for 15 min and then incubating 
them at 37 °C for 30 min with 15 μM arachidonic acid to activate the constitutive COX. For the 
compounds with COX-1 % inhibition higher than 50% (at 10 μM), the cells were treated also 
with lower concentrations (0.01-1 μM). At the end of the incubation, the supernatants were 
collected for the measurement of prostaglandin E2 (PGE2) levels by a radioimmunoassay (RIA). 
To evaluate COX-2 activity, cells were stimulated for 24 h with Escherichia coli 
lipopolysaccharide (LPS, 10 μg/mL) to induce COX-2, in the absence or presence of test 
compounds (0.01-10 μM). Celecoxib was utilized as a reference compound for the selectivity 
index. The supernatants were collected for the measurement of PGE2 by means of RIA. 
Throughout the time the experiments lasted, triplicate wells were used for the various 
conditions of treatment. Results are expressed as the mean, for three experiments, of the 
percent inhibition of PGE2 production by test compounds with respect to control samples. The 
IC50 values were calculated with GraphPad Instat, and the data fit was obtained using the 
sigmoidal dose-response equation (variable slope) (GraphPad). 
Ex Vivo Vasorelaxing Activity. All the experimental procedures were carried out following the 
guidelines of the European Community Council Directive 86-609. The effects of the compounds 
were tested on isolated thoracic aortic rings of male normotensive Wistar rats (250-350 g). 
After a light ether anaesthesia, rats were sacrificed by cervical dislocation and bleeding. The 
aortae were immediately excised, freed of extraneous tissues and the endothelial layer was 
removed by gently rubbing the intimal surface of the vessels with a hypodermic needle. Five 
mm wide aortic rings were suspended, under a preload of 2 g, in 20 mL organ baths, containing 
Tyrode solution (composition of saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 1.05; 
NaH2PO4 0.41; NaHCO3 11.9; Glucose 5.5), thermostated at 37 °C and continuously gassed with a 
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mixture of O2 (95%) and CO2 (5%). Changes in tension were recorded by means of an isometric 
transducer (Grass FTO3), connected with a computerised system (Biopac). After an equilibration 
period of 60 minutes, the endothelium removal was confirmed by the administration of 
acetylcholine (ACh) (10 µM) to  KCl (30 mM)-precontracted vascular rings. A relaxation < 10% 
of the KCl-induced contraction was considered representative of an acceptable lack of the 
endothelial layer, while the organs, showing a relaxation  10% (i.e. significant presence of the 
endothelium), were discarded. From 30 to 40 minutes after the confirmation of the endothelium 
removal, the aortic preparations were contracted by a single concentration of KCl (30 mM) and 
when the contraction reached a stable plateau, 3-fold increasing concentrations of compounds 
(1nM-10 M) were added. Preliminary experiments showed that the KCl (30 mM)-induced 
contractions remained in a stable tonic state for at least 40 minutes. The same experiments 
were carried out also in the presence of a well-known GC inhibitor: ODQ 1 µM which was 
incubated in aortic preparations after the endothelium removal confirmation. The vasorelaxing 
efficacy was evaluated as maximal vasorelaxing response (Emax), expressed as a percentage 
(%) of the contractile tone induced by KCl 30 mM. When the limit concentration 10 M (the 
highest concentration, which could be administered) of the tested compounds did not reach the 
maximal effect, the parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by KCl 30 mM, evoked by this limit 
concentration. The parameter of potency was expressed as pIC50, calculated as negative 
logarithm of the molar concentration of the tested compounds evoking a half reduction of  the 
contractile tone induced by KCl 30 mM. The pIC50 could not be calculated for those compounds 
showing an efficacy parameter lower than 50%.  The parameters of efficacy and potency were 
expressed as mean  standard error, for 6-10 experiments. Two-way ANOVA was selected as 
statistical analysis, P < 0.05 was considered representative of significant statistical differences. 
Experimental data were analysed by a computer fitting procedure (software: GraphPad Prism 
4.0).  
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Ex vivo determination of the formation of nitrites and nitrates, in rat liver homogenate. The 
experimental procedures were carried out following the guidelines of the European Community 
Council Directive 86-609. The liver homogenates were obtained from male normotensive 
Wistar rats (250−350 g). After a light ether anesthesia, rats were sacrificed by cervical 
dislocation and bleeding. The portal vein was immediately cannulated and the liver was 
perfused with 4 °C-cold homogenation buffer (composition: K2HPO4 100 mM; EDTA 1 mM; KCl 
15 mM; sucrose 0.25 M and Ethanol 0.1%, pH 7.4). After about 5 min of slow perfusion, the liver 
was minced with scissors and washed with cold homogenation buffer. Then, it was dried with 
filter paper, weighted and resuspended (1:5 w/v) in cold homogenation buffer. The sample was 
finally homogenated in Turrax. In a vial, 400 µl of the above homogenate were mixed with 500 
µl of assay buffer (composition: K2HPO4 100mM; EDTA 1mM; pH 7.4), containing glutathione, 
NADH and NADPH (all at the final concentration of 1mM). The vials were then thermostated at 
37 °C, and 100 µl of a DMSO solution of the tested NO-donor were added (final concentration of 
the tested compound = 1 mM), allowing the release of NO, which in turn is rapidly converted to 
the stable inorganic metabolites, i.e. nitrites and nitrates. Aliquots (100 µl) of the above medium 
were collected at selected intervals (5, 15, 30, 60 and 120 min) and added into a beaker 
containing 1.9 ml of an aqueous solution of H2SO4 (0.1 M) and KI (0.1 M). This solution allows 
nitrite ions to be exhaustively and instantaneously reduced to NO, which is amperometrically 
titrated by a NO-selective electrode connected to an Apollo 4000 free radical analyzer (World 
Precision Instrument), allowing us to determine the concentration of the nitrites previously 
formed in the biological sample. In parallel experiments, a Nitrate Reductor (World Precision 
Instrument) was constantly kept immerged into the vial. This tool allowed nitrates to be 
constantly converted to nitrites. The concentration of nitrites in these sample is defined as NOx, 
which reflects the sum of all the nitrites and nitrates previously derived from NO. Opportune 
calibration curves were previously obtained with standard solutions of sodium nitrite. 
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Ex vivo Human Whole Blood (HWB) Assay. Three healthy volunteers (2 females and 1 male, aged 
29 +3  years) were enrolled to participate in the study after its approval by the Ethical 
Committee of the University of Chieti. Informed consent was obtained from each subject.  
Compounds 11c (0.05 -50 mM) and 12c (0.05 - 50 mM) were dissolved in DMSO. Aliquots of the 
solutions (2 μL) or vehicle were pipetted directly into test tubes to give final concentrations of 
0.1 - 100 μM in whole blood samples. To evaluate COX-2 activity, 1 mL aliquots of peripheral 
venous blood samples containing 10 IU of sodium heparin were incubated in the presence of 
LPS (10 μg/mL) or saline for 24 h at 37 °C, as previously described.36 The contribution of 
platelet COX-1 was suppressed by pretreating the subjects with aspirin (300 mg, 48 h) before 
sampling. Plasma was separated by centrifugation (10 min at 2000 rpm) and kept at -80 °C until 
assayed for PGE2 as an index of monocyte COX-2 activity. Moreover, peripheral venous blood 
samples were drawn from the same donors when they had not taken any NSAID during the 2 
weeks preceding the study. Aliquots (1 mL) of whole blood were immediately transferred into 
glass tubes and allowed to clot at 37 °C for 1 h. Serum was separated by centrifugation (10 min 
at 3000 rpm) and kept at -80 °C until assayed for TXB2. Whole blood TXB2 production was 
measured as a reflection of maximally platelet COX-1 activity in response to endogenously 
formed thrombin.45 Analysis of PGE2 and TXB2. PGE2 and TXB2 concentrations were measured by 
previously described and validated radioimmunoassays.45 Unextracted plasma and serum 
samples were diluted in the standard diluent of the assay (0.02 M phosphate buffer, pH 7.4) and 
assayed in a volume of 1.5 mL at a final dilution of 1:50-1:30000. [3H]PGE2 or [3H]TXB2 (3000 
cpm, specific activity >100 Ci/mmol, 1:100000 dilution) and anti-TXB2 (1:120000 dilution) sera 
were used. The least detectable concentration was 1-2 pg/mL for both prostanoids. 
In Vivo Analgesic and Anti-Inflammatory Study. Male Swiss albino mice (23-25 g) and Sprague-
Dawley or Wistar rats (150-200 g) were used. The animals were fed with a standard laboratory 
diet and tap water ad libitum and kept at 23 (1 °C with a 12 h light/dark cycle, light on at 7 a.m.) 
The paw pressure test was performed by inducing an inflammatory process by the intraplantar 
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(ipl) carrageenan administration 4 h before the test. in the administered intraplantar (ipl) 
carrageenan 4 h before the test. The carrageenan-induced paw edema test was also performed, 
evaluating the paw volume of the right hind paw 4 h after the injection of carrageenan and 
comparing it with saline/carrageenan-treated controls. The analgesic activity of compounds 
was also assessed by performing the abdominal constriction test, using mice into which a 0.6% 
solution of acetic acid (10 mL/kg) had been injected intra-peritoneal (ip). The number of 
stretching movements was counted for 10 min, starting 5 min after administration. 
Solubility and stability assessment.  
Solubility assessment in phosphate buffered saline (PBS) and simulated gastric fluid (SGF). Stock 
solutions of test compounds (20 mM) were prepared in DMSO. A standard phosphate buffered 
saline (PBS) 0.01 M (pH 7.4) was used to determine the solubility in neutral pH conditions; a 
simulated gastric fluid (SGF) 0.05 M solution without pepsin (pH was adjusted to 1.5 using 
concentrated HCl) was instead used to check the solubility of compounds in acid medium. Seven 
point calibration standards (1, 5, 10, 25, 50, 100 and 200 µM) were prepared from each 20 mM 
solution stock by serial dilution. 2 µL of each test compound (stock solution 20 mM in DMSO) 
were added to 198 µL of PBS and SGF in two duplicate wells in multiscreen solubility filter plate, 
covered and shaken for 90 minutes at 300 rpm using a Multi-pulse Vortexer (Glas-Col). The 
sample was filtered using a Millipore manifold filter assembly and collected in an acceptor plate 
and then analysed on HPLC together with the standards solutions (HPLC-Waters Separations 
Module 2695 with photodiode array detector). 
Stability assessment in phosphate buffer saline (PBS), simulated gastric fluid (SGF) and rat plasma. 
Stock solutions of test compounds (1mM) were prepared in DMSO. A standard phosphate 
buffered saline (PBS) 0.01 M (pH 7.4) was used to determine the stability in neutral pH 
conditions; a simulated gastric fluid (SGF) 0.05M solution without pepsin (pH was adjusted to 
1.5 using concentrated HCl) was instead used to check the stability of compounds in acid 
medium. Rat plasma (Sprague Dawley rat) was used to underline the sensitivity of test 
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compounds to plasma enzymes; in this case, Na2EDTA dehydrate was used as anticoagulant for 
the experiment. An aliquot of each medium of 588 µL is taken and stored in a 2 mL eppendorf 
vial. Afterwards, 12 µL of 1 mM solution of each test compound is added to each medium. The 
samples are incubated in an hybridisation oven. At each time point (0, 30, 60, 120 min.), a 100 
µL aliquote is taken and quenched immediately with 300 µL of 100% ice cold acetonitrile 
(containing 60 ng/mL of internal standard, i.e. phenacetine) and stored at -80 °C. All the sample 
then are centrifuged at 14000 rpm for 5 min. The supernatant is transferred into an HPLC vial 
and analysed by LC-MS/MS (Shimadzu-API4000).  
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Introduction 
Flow chemistry. The term flow chemistry refers to a method of performing chemical reactions 
as a progressively flowing process.1 Although batch chemistry is still widely used, automated 
platforms where a reaction is operated as a flow-through process are becoming increasingly 
popular due to the distinctive advantages offered by this mode of working (Figure 1). 
 
Figure 1. Uniqsis FlowSyn and Vapourtec R2/R4+ flow platforms 
A machine-assisted flow process can offer several benefits including improved safety, 
automation, better real-time control over a range of parameters, enhanced mass and heat 
transfer, the ability to increase reaction temperatures far above the solvent’s boiling point and 
easier integration with diagnostic techniques (Figure 2).2-8 
 
Figure 2. Integration of a flow platform. 
Multi-step processes can be arranged in a continuous sequence,9-12 allowing in-situ generation 
and use of unstable, toxic, or air-sensitive intermediates.13 Furthermore, multi-phase reactions 
can be easily elaborated14-17 and scale-up of a proven reaction can be easily achieved by simply 
operating the reactor for a longer period of time.18 
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The application of flow chemistry in research laboratories has been an exponentially 
growing phenomenon which has stimulated the development of much custom-designed and 
commercially available equipment. Modular flow systems built from components based upon 
flow chips, mixers, capillaries, packed bed columns, and/or dedicated reactors that perform 
certain types of chemistry or specific unit operations allow a broad range of transformations. 
Flow reactors are constructed from a variety of materials including metal, glass, silica, ceramics, 
and polymers, and their designs range from simple capillaries to complex micro-structured 
devices. These laboratory scale flow reactors generally involve the processing of solution phase 
chemistry through channels ≤1 mm i.d., such that reactions are carried out continuously on 
small scale. One of most important aspects of bench top flow platforms is that they can allow 
rapid scale up of developed reactions, reducing the requirement for routes to be redesigned 
before entering production. Indeed, the micro-environment inside a flow reactor can be seen as 
a steady state scenario where reaction parameters such as temperature, concentration and 
composition of reactants established for a small scale flow process can be directly transferred to 
larger flow reactors, without substantial alteration.  
The discovery and development of new drugs for human diseases is a major scientific 
priority of modern society. However, the process of discovery and development is impeded by 
challenges that make it difficult, expensive and protracted. One of the most addressed issues in 
the pharmaceutical field is represented by key synthetic challenges of performing scalable, 
reliable and robust processes. Over the years chemists have tremendously improved 
methodology (transition-metal catalysis, asymmetric catalysis, etc.) but in contrast the 
technology of performing chemistry has remained more or less the same. Although process 
chemists are well aware of most of the aspects of performing chemical reactions, (such as heat 
and mass transfer, mixing and thermodynamic phaenomena) these concepts are quite 
underestimated in small research laboratories. In this context, the pharmaceutical industry is 
searching for new technologies to speed up the whole process of drug discovery and 
development.19-21 
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Neurotensin. Neurotensin (NT) (Figure 3) is a tridecapeptide highly distributed throughout the 
central nervous system (CNS), especially in the hypothalamus, amygdala and nucleus 
accumbens, which was first isolated from bovine hypothalamii in 1973.22  
 
 
Figure 3. Neurotensin  
Numerous studies have shown that NT is likely to be involved in cancer and neurodegenerative 
diseases,23-28 thus a deeper understanding of its functions and downstream effects related to the 
activation of its receptors is urgently required. This process has been aided by the development 
of small molecular probes. Investigations employing NT itself are hampered by a number of 
challenges. NT is a peptide and is, therefore, extremely susceptible to metabolism; its size also 
makes the absorption into the brain troublesome. Antagonists targeting these receptors are also 
required to build a complete picture.  
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Meclinertant. In the early 90’s Sanofi-Aventis researchers identified SR-45398 (1), a compound 
able to bind selectively to NT receptor 1 (NTR1) in the Guinea pig brain (IC50 = 40 uM) (Figure 
4).  
 
Figure 4. Molecular structure of SR-45398 (1) and SR-48692 (2) 
In an effort to develop a novel and more active molecule, they generated SR-48692 or 
Meclinertant (2), an antagonist with outstanding binding properties towards NTR1 (Ki = 
2.6±0.2 nM) but also capable of binding to NTR2 (Ki = 418±82.2 nM) and NTR3 (Ki = 238±46 
nM) at higher concentrations. The research laboratories of Sanofi Aventis reported two main 
routes to SR-48692.29,30 
In the first approach, a Claisen condensation between ketone (3) and diethyl oxalate gave access 
to the tricarbonyl compound (4). This was followed by a condensation of (4) and hydrazine (5) 
and subsequent saponification of the resultant ester (6) to yield acid (7). Activation of the acid 
and coupling with amino acid (8) afforded the desired product Meclinertant (2) (Scheme 1).  
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Scheme 1. Routes to Meclinertant reported by Sanofi Aventis 
 
 
Their second route affords Meclinertant (2) through activation of acid (7) and coupling with 
amino acid (8) using pyridine: DCM as the solvent system and then treating the intermediate 
with TFA:DCM. The publication gives very limited experimental procedures and data, making 
reproduction of this work extremely difficult. Previous studies on the batch synthesis of 
Meclinertant (carried out by Dr Matthew O. Kitching, University of Cambridge) highlighted that 
one the most problematic part of the process is the synthesis of the amino acid (8) (2-
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aminoadamantane-2-carboxylic acid).31,32 In addition, all the steps characterising the synthesis 
of Meclinertant were poorly reproducible, especially when scaling up to multi-gram scale. For 
these reasons, we decided to pursue a reliable, robust, machine assisted flow procedure for the 
synthesis of Meclinertant. Work began with the development of a novel procedure of the amino 
acid (8).20,33 Since the idea was to develop the whole process in flow, we envisaged that ketone 
(5) could be obtained from cheap starting materials using enabling technologies, and then the 
following stages could  be adapted to the flow platform to achieve automation and 
reproducibility on a multi-gram scale.34 
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The synthesis of 2-aminoadamantane-2-carboxylic acid 
(Battilocchio, C.; Baxendale, I.R.; Biava, M.; Kitching, M.O.; Ley, S.V. Org. Process Res. Dev. 2012, 16(5), 798-
810. Ref. 18; Battilocchio, C.; Baxendale, I.R.; Biava, M.; Ley, S.V. Org. Syn. Submitted for publication. Ref. 
33) 
A novel approach to amino acid (8), based on a five-step sequence, was investigated. We 
anticipated that each step would be both high yielding and readily scalable under flow 
conditions. The sequence commences with a Grignard addition to 2-adamantanone (10) 
followed by conversion of the resulting propargylic alcohol (11) to the acyl-propargylamide 
(12) via a Ritter reaction. Next, a 5-enol-exo-dig cyclisation furnishes the oxazolidine 
intermediate (13), which is transformed to the azalactone (14)35 by ozonolysis and then 
hydrolytically cleaved to the desired amino acid (8) (Figure 6).36 
 
 
Figure 6. Novel five-step sequence to the amino acid (8) 
The reversibility of the Grignard addition under basic conditions was anticipated so a screen of 
cryogenic conditions was conducted in batch.37 It was observed that upon scale-up under batch 
conditions, substantial quantities of the ketone starting material were isolated when the 
propargylic alcohol anion was quenched at temperatures above -10 °C. The reaction was 
therefore run at -20 °C employing a cryo-flow reactor (“Polar Bear” reactor, Figure 7) equipped 
with a 52 mL PFA (perfluoroalkoxy polymer) reactor coil and two 1 mL PFA pre-cooling loops.38  
A 0.5 M solution of 2-adamantanone (10) in THF and a 0.5 M THF solution of ethynylmagnesium 
bromide, each delivered at a flow rate of 0.2 mLmin-1 through the pre-cooling loops, were 
combined in a T-piece and then passed through the reactor coil.  
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Figure 7. Polar Bear reactor developed by Cambridge Reactor Design (CRD) and connected to a Uniqsis 
FlowSyn platform, used to run reaction under cryogenic conditions 
Under this set-up, an approximate 40% yield was obtained when processing 10 mmol of the 
substrate (Figure 8). Further attempt to optimise the reaction (increasing the residence time or 
altering the relative stoichiometries of the reagents) failed to increase the yield.  
 
 
Figure 8. Grignard  reaction in flow under cryogenic conditions  
 
Eventually it was found that the cryogenic conditions were actually detrimental to the reaction 
progress under flow processing. Indeed, carrying out the reaction at a higher temperature of 40 
°C using a 14 mL reactor coil on a Uniqsis FlowSyn platform (0.5 M solution of 2-adamantanone 
(5) in THF at 0.18 mL min-1 and 0.5 M solution of ethynylmagnesium bromide in THF at 0.2 
mLmin-1), resulted in an 80% isolated yield of the 2-ethynyl-2-adamnatanol on a 300 mmol 
scale after a standard aqueous extraction (Figure 9).  
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Figure 9. Grignard  reaction in flow at 40 °C on a 300 mol scale 
This difference was attributed to the improved stability of the intermediate in the flow 
processing regime where the ionic concentration of the reaction mixture remains relatively 
constant. In the batch scenario the pH of the reaction media steadily increases eventually 
favoring the retro reaction. This was observed in batch reactions where higher relative 
conversion to the desired product was achieved using lower stoichiometries of the Grignard. 
Also higher final isolated yields were obtained when the reaction was worked up immediately 
following the Grignard addition. Since the product has the potential to liberate acetylene, we 
investigated the stability of this key alkyne intermediate (11). A differential scanning 
calorimetry (DSC) study was used to determine the behavior of this compound (Figure 10).39  
 
Figure 10. DSC machine from Mettler-Toledo 
An exothermic event was observed at temperatures above 160 °C which was thought to be due 
to liberation of acetylene. The identity of the suspected degradation product, 2-adamantanone 
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(10), was confirmed repeating the scan on the same sample (following cooling). The results of 
this scan convincingly matched the profile obtained from authentic 2-adamantanone (10). It 
was concluded that the high temperature heating caused the de-ethynylation of 2-
ethynyladamantan-2-ol (11) (Figure 11).  
 
 
 
Figure 11. DSC of 2-ethynyladamantan-2-ol (left), 2-adamantanone and degradation product of 2-
ethynyladamantan-2-ol (right) 
Due to the inherent reversibility of the prop-2-yn-1-olate formation and knowledge that the 
acidic work-up of this anion is exothermic, it was reasoned that the use of flow micro-mixing 
could prevent any overheating when conducting the quenching step. Consequently, a 
straightforward modification of the original set-up was made to incorporate an in-line 
quenching step using a saturated solution of NH4Cl. This was achieved by the incorporation of a 
second T-piece. However, this initially proved problematic due to the rapid precipitation of 
magnesium salts which accumulated over time in the T-connector and eventually resulted in the 
blockage of the reactor. A simple solution to this problem was to use pulsed sonication where 
the T-piece connector and a short length (10 cm) of the subsequent tubing were submerged in 
the water bath of a standard laboratory sonicator.40 This completely eliminated build-up of 
precipitates enabling steady-state operation. The product could then be processed continuously 
(longest run 660 mol) giving an improved isolated yield of 90% (Figure 12). 
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Figure 12. Scheme of the set-up for the optimised Grignard reaction in flow with in-line quenching (left) 
and  a picture of the set-up itself (right) 
Ritter reactions in microfluidic flow devices have already been convincingly described by Wirth 
and coworkers, demonstrating that even at mild temperatures, ranging from 45-85 °C 
depending on the substrate, high conversions could be realized in only 10 minutes residence 
time.41 Building upon these results the conditions for the adamantane substrate (11) were 
rapidly established. Two different nitriles were chosen, namely benzonitrile and acetonitrile, to 
generate amides with differing electronic natures thereby influencing the subsequent 
cyclisation and also the potential ease of their eventual deprotection at the final stage. The 
reaction set up was made possible due to the use of an acid resistant Uniqsis FlowSyn platform. 
The preliminary reaction set-up employed two injection loops (3 mL internal volume each), one 
filled with a mixture of the alcohol (11) along with the nitrile, the other containing neat 
concentrated sulfuric acid (>95%). These were simultaneously switched into the main flow 
stream (glacial acetic acid/acetic anhydride 10/1 [v/v]) combining at a T-piece before 
progressing into a 14 mL PFA continuous flow coil (CFC).  It was quickly determined that the 
temperature was a crucial parameter; all attempts to perform the reaction at temperatures 
exceeding 40 °C gave substantial byproduct formation. This compound was later identified as 
arising from a Meyer-Schuster rearrangement followed by a subsequent 1,2-hydride migration 
(Wagner-Meerwein rearrangement) (Figure 13).  
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Figure 13. Byproduct obtained when running the Ritter reaction at temperatures above 40 °C 
At an operating temperature of 30 °C this byproduct was only present in trace amounts allowing 
the desired adduct to be isolated in yields of around 85% on a 3 mmol scale. Since the use of 
large volumes of concentrated sulfuric acid resulted in work up issues, especially when scaling 
up, we further investigated the performance of the reaction using different solvent 
compositions and additives. The best results were obtained using a mixture of 
H2SO4/AcOH/Ac2O 5:11:5 (v/v/v). Under these optimized conditions a solution of 
nitrile/AcOH/(11) were introduced to the system at a flow rate of 1.0 mLmin-1. A corresponding 
solution of H2SO4/AcOH/Ac2O also at a flow rate of 1.0 mLmin-1 was directed to meet the first 
stream at a mixing-T piece prior to entering a 14 mL PFA CFC maintained at 30 °C. The output 
stream was collected into a continuously stirred tank reactor which was continuously quenched 
and neutralized by an auxiliary feed line delivering a solution of aqueous KOH (3 M). The flask 
was periodically exchanged and the solution extracted with DCM allowing isolation of the Ritter 
product (12) (Figure 14).  
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Figure 14. Ritter reaction set-up in flow 
 
The lower overall yield obtained in the case of amide (12b) is a consequence of its problematic 
separation. Determination of the crude conversion to benzamide (12b) indicated > 95% by 1H-
NMR and LC-MS. However, upon scale-up the excess benzonitrile and its resulting hydrolysis 
by-product (benzamide) created considerable issues with regards to the efficient and clean 
extraction of the product from the reaction media. Some success was eventually realized by 
reducing the excess of benzonitrile (to 1.7 equiv.) and increasing the residence time, thereby 
allowing isolation of an improved 85% of the desired amide product (12b). Unfortunately, 
isolation still remained a significant issue at larger scales (i.e. > 25 g) with no satisfactory 
alternative work-up conditions being readily identified. 
In order to rapidly scope out the potential options for the formal 5-enol-exo-dig cyclisation we 
evaluated a series of batch conditions in parallel. Attempts to catalyze the cyclisation of the 
propargyl amides (12) with various metal salts such as silver and copper were only partially 
successful (Table 1).42 
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Table 1. Investigations of metal salts for the catalytic 5-enol-exo-dig cyclisation to (13) 
Entry Catalyst Solvent/additive T(°C), Time Conversion 
1 CuI Benzene/TEA (1:1) reflux, 12 h - 
2 AgNO3 n-butyl acetate reflux, 20 h 20% 
3 AgSbF6 dichloromethane rt, 30 min 65% 
4 NaOH 
Toluene/water 
/TBACl* 
reflux, 6 h 50% 
*tetrabutylammonium chloride. 
The best results were obtained using silver hexafluoroantimonate (DCM, rt) leading to a 65% 
conversion although we were discouraged from its use at scale due to its cost (Table 1, entry 3). 
The use of gold was avoided for the same reason. Interestingly, using sodium hydroxide in a 
biphasic toluene/water mixture in the presence of tetrabutylammonium chloride as a phase 
transfer catalyst (PTC) allowed isolation of the product (13) in a 50% yield. Further 
optimisation of the reaction by screening various bases, concentrations, temperatures and 
reaction times highlighted a combination of potassium hydroxide in ethanol as an improved 
medium. It was found that when a ~ 3:1 molar ratio of KOH/starting material (12) in EtOH (1.3 
M) was microwave irradiated at 100 °C for 2 h, a high isolated yield of the desired products 
could be obtained (R = Me; 13a, 91% yield and R = Ph; 13b, 92% yield). At higher temperatures 
the reaction produced larger quantities of an unidentified by-product (Figure 15). Interestingly, 
the tailored conditions of the flow procedure allowed the use of an elevated temperature 
window with a correspondingly shorter reaction time without observing any byproduct 
formation. 
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Figure 15. Relationship between yield and temperature in batch reactions 
Under the optimised conditions, the flow cyclisation of the benzoyl propargylamide derivative 
(12b) occurred within a residence time of 24 min at 120 °C (1:16 molar ratio amide (12b) to 
KOH). The corresponding acetyl derivative (12a) was less amenable to cyclisation and so 
required a prolonged residence time (48 min) to achieve complete conversion to the desired 
product (13a) under the same reaction conditions (Figure 16).  
 
Figure 16. Flow set-up for the 5-enol-exo-dig cyclisation 
In both cases an overall high yield of the cyclised products could be realised following a very 
trivial organic extraction of the reactor output. It was reasoned that the basic quenching step 
used in the Ritter process (Figure 14) could be adapted to deliver the material directly through 
to the subsequent cyclisation step (Figure 16) as a single integrated flow process. In addition, 
to shorten the sequence and reduce the manual workup it was anticipated that the basic 
conditions could facilitate easier extraction of the final product. In the Ritter reaction the major 
problem was due to issues of extraction and isolation of the product from any residual nitrile 
(due to the excess used in the Ritter reaction, especially for (12b)) and the corresponding 
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partially hydrolysed by-product amide (acetamide or benzamide). This was particularly 
troublesome when benzonitrile was used at scale. However, under the strongly basic conditions 
and higher reaction temperature of the cyclisation step, complete hydrolysis of the nitrile (and 
amide) to the carboxylate should occur making extraction of (13) far easier. The flow reactor 
set-up established to test this process is shown in (Figure 17). 
 
 
 
Figure 17. Telescoped Ritter and 5-enol-exo-dig cyclisation in flow 
Under the telescoped conditions, a solution of nitrile/AcOH/(11) and a corresponding mixture 
of H2SO4/AcOH/Ac2O were combined (at a T-piece) and introduced into a 14 mL PFA CFC 
maintained at 30 °C. The exiting flow stream was coupled with a second T-connector supplying 
a solution of KOH in EtOH/H2O (3 M, 40:1 v/v). Any resulting precipitate was directly removed 
by in-line filtration (glass wool) and the solution collected into a storage vessel. Following a 
suitable delay (dependent on the flow rate of the two steps) the eluent was progressed using a 
second HPLC pump through a heated PFA CFC (120 °C).  The solution from the reactor was 
readily extracted to give the final product in good yield and excellent purity. This abridged 
process proved particularly effective for processing larger quantities of material significantly 
reducing the work-up burden. 
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The oxidizing properties of ozone are well-known, especially for its use in industrial 
applications spanning chemical synthesis to waste treatment and water purification. Although it 
has a minimal environmental impact and low cost, there are safety issues relating to the 
generation of unstable and highly energetic ozonide intermediates.43 Consequently, any system 
using ozone should be simple, high-performance and safe for the processing of larger quantities 
of substrate.44 We established a flow based ozonolysis device of our own creating. The first flow 
set-up (Figure 14) used a Knauer K100 HPLC pump to deliver a sprayed stream of the substrate 
(0.2 M solution in DCM) into the gas flow (O2/O3, 500 mL min-1) via an infusion T-piece (Figure 
18).  
 
 
Figure 18. Infusion T-piece and coil 
The combined stream then progressed through a reaction coil (20 mL, 2.5 mm i.d.) with a 
residence time of 5 min (Figure 18 and 19). The resulting output stream was collected into a 
vented chamber with the excess ozone being eliminated by gently flushing argon into the 
solution. The purged solution was then pumped through a packed bed cartridge containing an 
excess of polymer-supported thiourea inducing reductive cleavage of the ozonide.45,46 The 
output stream was periodically tested for residual ozone (Ozone Test Kit OZ-2 – Camlabs Part 
No. HH/20644-00) and the presence of unreacted ozonide (via LC-MS by Ph3P oxidation against 
an internal standard of 2,3-dimethoxynaphthalene). The output solution was finally evaporated 
under reduced pressure to give the desired compound (14). 
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Figure 19. Ozonolysis system and quenching reactor (polymer-supported thiourea) 
During the oxidative process we tried to identify the flow pattern in order to help with the 
optimisation of the reaction conditions: the very first portion of the reactor coil (5 cm) was 
characterized by formation of small liquid droplets along the inner surface of the tubing. This 
was accompanied by an instantaneous bleaching of the solution (from light yellow to colourless) 
and a sharp drop in temperature (rt→4 °C as detected by IR measurements at the outer surface 
of the reactor). Then a wavy/annular pattern was observed along the reactor tubing (Figure 
20). It was speculated that the endothermic process occurring was related to the “spraying 
effect” (latent heat of evaporation) that occurred as the liquid phase entered the fast moving gas 
flow. 
 
Figure 20. Flow pattern observed during the ozonolysis 
Having observed the immediate colour change at the start of the reactor we wanted to 
determine the composition of the reaction mixture at this stage. Sampling the flow stream after 
only 18 cm of tubing (1 mL internal volume) showed total consumption of the starting material 
which upon treatment with the thiourea resin gave the desired product (14) in quantitative 
Fluid flow
Gas flow
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conversion. Wishing to take advantage of this “spraying” phenomenon we envisaged the 
assembly of a short path reactor unit with a residence time of only 15 s. In addition to facilitate 
rapid reaction processing and self-controlled cooling the spray dispersion phenomenon would 
also assist flushing excess ozone from the reaction stream by showering the output feed into an 
argon (or nitrogen) blanketed purge vessel (Figure 21).  
 
Figure 21. Picture of the ozonolysis set-up (left) and the 1-mL reactor for ozonolysis (right) 
At this stage a secondary pump could then be used to advance the ozonide solution through the 
previously developed resin quenching process. This set-up was readily achieved and 
successfully used to process larger quantities of material (Figure 22).   
 
 
Figure 22. Final scheme for the ozonolysis in flow. 
Another useful feature of this set-up was the very small stoichiometric excess of ozone required, 
ranging from only 1.5 to 2 equivalents. Under optimised conditions it was possible to achieve a 
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throughput of 6.6 g/h, equating to over 200 g of product per day when processing in a 
continuous fashion.  
Next applying the hydrolysis conditions used by Edward et al. in batch32 the phenyl derivative 
14b was quantitatively converted to the corresponding amino acid 8 after 80 h at reflux in 70% 
isolated yield on a 10 mmol scale. Surprisingly, a much faster reaction was observed for the 
corresponding methyl derivative 14a which required only 28 h (96 % isolated yield). However, 
in each case the product obtained as its hydrochloride salt was a match for the authentic 
material. The transferal of the general hydrolysis procedure to flow was quite straightforward. 
The first set-up employed two injection loops (3 mL per loop), one loaded with the azalactone 
(14) in acetic acid and the other containing a mixture of AcOH/H2O/HCl 9/1.8/1 (v/v/v). The 
two channels were simultaneously switched into the main flow stream of AcOH/HCl 40/1 (v/v) 
and combined at a T-piece before progressing into a 14 mL PFA CFC. Once again temperature 
was found to be a principle parameter: reaction temperatures below 130 °C gave substantial 
quantities of the N-acylamino acid derivatives (15a) and (15b) (Figure 23).  
 
Figure 23. Structure of 15a and 15b. 
Any attempt to increase the flow rate beyond 0.80 mLmin-1 per channel (residence time 9 min) 
gave incomplete hydrolysis. The final optimised conditions involved processing a solution of the 
azalactone (14) in AcOH continuously introduced to the system at a fixed flow rate (0.40 
mLmin-1 for (14a); 0.25 mLmin-1 for (14b) equating to residence times of 18 min and 28 min 
respectively) to meet at a standard T-connector with a solution of HCl/AcOH/H2O (1/1.8/9 
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v/v/v equal flow rate). The combined solution was then directed into a 14 mL PFA CFC heated 
at 150 °C (Figure 24). 
 
Figure 24. Final set-up for the cleavage in flow 
The exiting reaction mixture was collected and concentrated in vacuo to obtain an off-white 
solid which was first triturated with hot Et2O. Bulk recrystallization from methanol (0 °C, 
overnight), gave 2-aminoadamantane-2-carboxylic acid (8) as the hydrochloride salt in very 
good yield (94% from (14a) and 87% from (14b)). 
 
It must be noted that the isolation at each stage of the process has been achieved without 
recourse to column chromatography, in high yield and giving quality material ready for 
telescoping into the subsequent step. The overall yield for the route to the methyl derivative 
(14a) was 76% whereas a lower final yield of 70% was attained for the phenyl derivative (14b) 
(Figure 25).20,30 
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Figure 25. Flow sequence to the amino acid (8). 
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Meclinertant in flow 
(Battilocchio, C.; Deadman, B.J.; Nikbin, N.; Ley, S.V.; Baxendale, I.R. Chem. Eur. J. Submitted for publication 
Ref. 34) 
Synthesis of 2,6-dimethoxyacetophenone. The approach to the development of the machine-
assisted route to 2,6-dimethoxyacetophenone (3) progressed through a four-step synthesis. It 
was envisaged that beginning from 1,3-cyclohexadione (16) an 
iodination/aromatisation/methylation tandem reaction would yield the intermediate (17) and, 
subsequently, a Sonogashira coupling (18) followed by deprotection (19) and hydration would 
afford the desired acetophenone (3) (Figure 26). 
 
 
 
Figure 26. Envisaged route to the acetophenone 3 
 
The batch reaction for the initial step showed that the selection of the solvent was a crucial 
parameter. Indeed, reacting iodine and compound (16) in the presence of an excess of trimethyl 
orthoformate (TMOF), as reported in the literature,47 gave only a 20-30% yield on a 1 mmol 
scale. After screening many different reaction conditions, it was noticed that addition of 
methanol, as solvent, improved the conversion of the starting material to the product to 90%. 
Increasing the temperature above 30 °C led to the formation of several by-products, the two 
principle identified by-products are shown in (Figure 27). 
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 Figure 27. By-products generated when raising the temperature above 30 °C 
 
When the reaction was transferred to the flow platform it was found that the micro-mixing 
effect, in those conditions, was not beneficial at all. Indeed, when a solution of 1,3-
cyclohexadione (16) in methanol and a methanol solution of iodine were delivered at a flow 
rate of 0.10 mL/min and then combined (T-connector) thereafter in the reactor coil (14 mL) at 
rt, only a 50% conversion was obtained (when processing 10 mmol of substrate). Attempts to 
optimise the reaction by increasing the residence time or changing the temperature failed to 
appreciably change the resulting yield. We speculate this is the result of multiple competing 
equilibria that in a micro-environment are controlled by reversible processes. The next step was 
to evaluate other iodonium donors. N-iodosuccinimide (NIS) is a fairly-known iodinating agent 
and it is known to generate in situ iodonium ions in the presence of an activating agent (usually 
a Brønsted acid).48 Indeed, using NIS as iodonium source we were able to isolate the final 
product in a very good yield (87%). Consequently a solution of 1,3-cyclohexadione (16) in 
methanol and a solution of NIS and para-toluene sulfonic acid (PTSA) in methanol were 
delivered at a flow rate of 0.10 mL/min and combined thereafter in a reactor coil (14 mL) via a 
T-connector at rt. Attempts to increase the temperature and reduce the reaction time were 
detrimental to the reaction yield, giving access to almost quantitative conversion to the non-
iodinated derivative 20 (Figure 27 and Figure 28).  
 
 
 Figure 28. Aromatisation/Iodination with NIS 
 
Chapter 2: A Machine-Assisted Flow Procedure for Meclinertant, a Neurotensin Receptor Probe 
Page 150 of 195 
 
The succinimide by-product was easily removed from the reaction stream by passing the 
mixture through a cartridge packed with strongly basic polymer supported beads (Ambersep-
OH 900 strongly basic, purchased from Sigma Aldrich), which after removal of the solvent in 
vacuo, gave access to compound (17) (Figure 29). 
 
Figure 29. Succinimide trapped on Ambersep 900 (strong basic ion-exchange resin). 
Having successfully prepared the iodo intermediate we next turned our attention to the 
coupling sequence. A series of different reaction conditions for the Sonogashira cross-coupling 
were first screened in batch.49 The reactions highlighted that the use of polymer supported 
catalysts (Pd En-cat, Cu on Quadrapure, etc.) was not ideal for these particular pairings of 
substrates with yields ranging between 10% to 30%.50 After screening different Pd and Cu 
sources, optimised conditions employing bis(triphenylphosphine) palladium chloride and 
copper iodide in methanol with tetramethylguanidine as base gave full conversion to the 
product (18) after 1 h under microwave irradiation at 100 °C (Figure 30).  
 
Figure 30. Sonogashira-coupling 
The flow set-up was easily arranged with a nearly quantitative conversion to (18) being 
attained. Since we wanted to use the product directly in the next stage, we investigated an in-
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line workup using polymer supported scavengers. Unfortunately, this scavenging process 
proved to be detrimental to the reaction yields dropping them to 30-45% (Figure 31). 
 
Figure 31. Sonogashira-coupling in flow 
While the route had been successful up to this point, there were few concerns about its cost-
effectiveness, especially when scaling-up the procedure. To overcome this, an alternative route 
based on a four step sequence was proposed. The synthesis commences with an O-acylation of 
the cyclohexadione (16) followed by rearrangement of (22) to the triketone derivative (23). A 
subsequent aromatisation with iodine in methanol would furnish the mono-
methoxyacetophenone (24). A final methylation step using dimethyl carbonate and 1,2-
dimethylimidazole would give access to the product (3) (Figure 32).  
 
 
Figure 32. Second route retrosynthesis. 
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A series of batch reactions for the O-acylation were evaluated in parallel and the best conditions 
found to be using acetyl chloride and diisopropylamine. Pleasingly, the optimised conditions for 
the corresponding flow procedure allowed for a very short reaction time (0.54 mL/min per 
channel, residence time 14 min) and high yield (92% isolated) without the need for further 
purification. We then turned our attention to the rearrangement step from O-acyl (22) to the 
corresponding C-acyl (23). In the literature this kind of reaction is usually carried out with the 
use of Lewis acid (especially AlCl3).51 However, most Lewis acids are poorly soluble in most 
organic solvents and there were safety issues that could be a problem to overcome. Prompted 
by the need to come up with a different approach to this rearrangement, we then focused on the 
use of dimethylaminopyridine (DMAP) as catalyst.52 The use of molecular DMAP in batch gave 
complete conversion to the C-acyl product (23) (1 mmol scale with 20 mol% of catalyst) when 
the reaction was run overnight at rt. It was therefore decided to use a polymer supported 
version of DMAP catalyst which would be amenable to recycling, especially if applied in a flow 
process. Running the reaction in toluene at 120 °C we obtained a complete conversion in 4 
hours (20 mol% of catalyst using a polymer with loading of 3-6 mmol/g of polymer) on a 2 
mmol scale. Nonetheless, as expected with polymer catalyzed reactions in batch, we found that 
increasing the amount of starting material prolonged the reaction times: starting from 100 
mmol of O-acyl (22) derivative, complete conversion to the C-acyl (23) was only obtained after 
5 days. This was seen as an opportunity to use flow chemistry to reduce the reaction time. A 
first set of reactions were set up packing the polymer in an glass column and heating at different 
temperatures ranging from 50 to 120 °C. Unfortunately, the conversion was low (less than 30%) 
at temperature below 80 °C, even with very slow flow rates. Increasing the temperature led to 
blockages of the system due to the swelling of the polymer. Attempts to reduce the density of 
the packing gave similar results. Unfortunately this approach seemed unlikely to be successful. 
However, the use of monolithic reactors has proven to be beneficial in expediting flow process 
and overcoming synthetic problems such as waste disposal and byproduct formation. A 
monolith is a single continuous piece of macroporous material prepared by precipitation 
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polymerisation within a column or cartridge. These systems have a permanent porous structure 
and can be made at a range of shapes and sizes (Figure 33).53 
 
 
 
Figure 33. Picture of a monolith. 
Their porosity can be tailored to allow proper flow of solvents and reagents at reasonable 
pressures (up to 25 bar) through the system. Monolithic polymers do not exhibit the same levels 
of swelling and shrinking when treated with different solvents, so the generation of a monolithic 
polymer containing a DMAP functional catalyst was evaluated. The resulting synthesis of the 
monomer was easily achieved through a simple single step reaction (Figure 34).54 
 
  
Figure 34. Reaction for the synthesis of the DMAP monomer 
The monolith was prepared using a mixture of divinylbenzene (15%), styrene (15%) and 
monomer (26) (10%) in the presence of dodecanol (60%) as porogen and aza-
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bis(cyclohexanecarbonitrile) (ACHC, 2 mol% of the monomer). Using this method a monolith 
with very good physical properties for use in a flow process was obtained.  
Utilizing this structure in the flow transformation of starting material (22) to compound (23) 
was next evaluated. Under optimised flow conditions, two grams of the precursor (22) were 
processed with the column heated at 100 °C, delivering the solution of (22) at a flow rate of 50 
µLmin-1 (residence time of 20 min), achieving full conversion to (23).  In order to telescope the 
material from the very first step, each step must be performed in the same solvent. Having 
found that the use of toluene as solvent is of extreme importance for the rearrangement using 
the DMAP monolith, we were pleased to find that the O-acylation reaction could also be run in 
toluene. After the O-acylation step, the reaction output stream was dispensed onto a filtering 
surface to eliminate the eventual solids formed and the solution directed to a glass column 
containing the DMAP monolith. Collection and concentration of the solution gave the triketone 
(23) as a reddish liquid, in 94% yield on a 20 mmol scale (Figure 35).  
 
 
 
Figure 35. Telescoped-flow acylation/rearrangement using the DMAP monolith 
 
Having successfully obtained the triketone (23) via a flow reaction, we turned our attention to 
the aromatization and methylation steps.  
After screening various modified conditions based upon the original iodination/aromatisation 
chemistry described above, a flow set-up was established that used a solution of compound (23) 
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in methanol and a methanolic solution of iodine, each stream delivered at a flow rate of 0.20 
mLmin-1 and combined at a T-connector. Thereafter the solution passed into a CFC reactor (14 
mL) which was maintained at 80 °C; the output stream was then directed to a glass column 
packed with a mixture of calcium carbonate to scavenge the hydroiodic acid formed and sand as 
a packing agent. The flow stream was then directed to second packed column containing 
thiosulfate beads mixed with Celite to scavenge any excess of iodine in solution. The output was 
collected and concentrated in vacuo to obtain the mono-methoxyacetophenone (24) in 68 % 
yield (Figure 36). The reduced yield was speculated to be a result of the interaction of the 
triketone (23) or the product (24) with the calcium carbonate, since no other material was 
identified in the outlet. Alternative strategies to remove the hydroiodic acid formed during the 
reaction proved detrimental, leading to further decrease of the yield. This step is still under 
investigation. 
  
 
 Figure 36. Flow synthesis of the mono-methyl intermediate. 
The final step of the sequence was carried out using a recently reported procedure, employing 
dimethylcarbonate (DMC) and 1,2-dimethylimidazole (DMI).55 A solution of  acetophenone (24) 
in DMF (flow rate 1.00 mLmin-1) and a solution of DMI in DMC (flow rate 1.00 mLmin-1) were 
combined in a T-piece and  then directed into a CFC reactor (14 mL) heated at 150 °C to obtain 
(3) in quantitative yield after trivial extraction procedures. We found that DMC decomposes in 
Chapter 2: A Machine-Assisted Flow Procedure for Meclinertant, a Neurotensin Receptor Probe 
Page 156 of 195 
 
the presence of strong acid and DMI can be scavenged by strongly acid media an immobilized 
acid scavenger allowed a complete in-line workup. Mindful of our objective to telescope the flow 
process further, it was noticed that methanol proved to be as effective in the reaction as DMF. 
Indeed, when performing the reaction in this solvent a quantitative conversion was achieved by 
reducing the flow rate, each channel being 0.7 mL/min (Figure 37). The solution stream was 
then directed to a QP-SA containing cartridge to scavenge the imidazole and decompose DMC 
successfully. 
 
Figure 37. Final step for the flow synthesis of the final product 
 
Following the procedure previously outlined, the material (a solution of 24 in methanol) from 
the aromatisation step was then directed in a second reactor were it was combined with the 
solution of dimethylcarbonate and 1,2-dimethylimidazole. Eventually, we were able to achieve a 
63% overall yield of 3 (two steps), employing a flow rate (for the final methylation step) of 0.80 
mL/min (Figure 38).  
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Figure 38. Telescoped flow aromatisation/methylation. 
The pyrazole core. With the acetophenone (3) in hand, we began to investigate the Claisen 
condensation31,32 to obtain the 1,3-dicarbonyl compound (4) (this step of the work has been 
done in collaboration with Benjamin J. Deadman, University of Cambridge). Screening a number 
of conditions under microwave irradiation indicated that the reaction could be driven to 
completion after just 30 min at 80 °C, using ethanol as solvent. However, the set-up for the flow 
reaction proved quite troublesome, due to blockages caused by precipitation of the product. It 
was identified that with higher concentrations of sodium ethoxide these problems were 
amplified, but at lower concentration the reaction proved to be sluggish. A compromise was 
chosen whereby the concentration of the reagent input was lowered and the solvent system was 
changed to ethanol/THF. Under these conditions, a solution of acetophenone and diethyl 
oxalylester in a mixture of ethanol/THF (1:1, v/v) was combined in a T-piece with a 0.25 M 
solution of sodium ethoxide in ethanol. Both solutions were delivered at a flow rate of 0.40 
mL/min, and reacted at 60 °C in a 25 mL stainless steel coil. The product was obtained in a 
sufficient yield (around 50%) without blockages, but did not justify the use of flow technology 
in this instance. Indeed, the batch reaction under these conditions indicated a 70% yield. After 
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various test reactions in batch, we came up with the solution whereby reducing the proportion 
of THF in the solvent mixture and increasing the temperature to 100 °C gave a quantitative 
transformation of the starting material. At this point the challenge was to set up a platform 
which could handle suspensions under high pressure. This was overcome by employing a gas-
pressurised system (developed previously within the group) instead of using a 1mm i.d. BPR, 
which we thought would be the primary cause of blockages, and a wider PFA coil (10 mm i.d.) to 
prevent the solid building up inside the reactor (Figure 39).  
 
 
Figure 39. Flow step for the Claisen condensation. 
The pressure chamber applied a pressure of 5 bar to the system and this allowed the reaction to 
be easily run without any problem. Additionally, we wrapped an electric heating system around 
the chamber which helped to keep the material in solution. Under these optimized conditions, a 
solution of acetophenone and diethyl oxalyl ester in ethanol (flow rate 1.20 mL/min) was 
combined in a T-piece with a solution 1M of sodium ethoxide in ethanol (flow rate 1.20 
mL/min) and heated to at 115 °C in a 52 mL PFA coil (10 mm i.d.) (Figure 40). 
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Figure 40. Claisen reaction using the pressure chamber. 
The material was then telescoped to the following stage where cyclisation with a substituted 
hydrazine gave access to the pyrazole core (6). Investigations of the reaction conditions under 
microwave irradiation led to the choice of ethanol as solvent (condition identified by Dr 
Matthew O. Kitching, University of Cambridge). Adapting these conditions to a flow system 
proved troublesome due to the insolubility of both compounds (4) and (5). We therefore went 
back to the microwave conditions to screen different solvents that could solve the solubility 
issue. The best choice of solvent turned out to be DMF. Using this solvent, the product could be 
synthesised under microwave conditions by heating the mixture at 140 °C for 1.5 h.  Under flow 
conditions, a mixture of (4) and (5) in DMF were delivered to a T-piece to meet a solution of 
sulfuric acid (conc.) in DMF; afterwards the mixture was heated in a 52 mL PFA coil (10 mm i.d.) 
at 140 °C. Collection, extraction and concentration of the output afforded the pyrazole ester 6 in 
a very good yield (89%) without requiring chromatography (Figure 41). 
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Figure 41. Flow step for the pyrazole ring formation. 
Penultimately hydrolysis of the pyrazole ester was achieved by reacting a THF solution of (6) 
with a solution of KOH (3 M). Two delivery channels were used set at a flow rate of 0.5 mLmin-1 
to combine at a T-piece, the mixture was then progressed through a 14 mL PFA CFC which was 
maintained at 140 °C. The reactor output was collected and THF was removed in vacuo; then 
HCl was used to precipitate the acid (7) (pH 3) (Figure 42). 
 
 
Figure 42. Flow set-up for the hydrolysis. 
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The final coupling. The flow end-game to Meclinertant was achieved using a strategy 
previously described for other applications.40b The carboxylic acid (7) was transformed to the 
corresponding acid chloride (27) using the Ghosez reagent. Under the optimised conditions, a 
solution of acid (7) in DCM was reacted with a solution of the Ghosez reagent also in DCM. The 
two solutions were combined at a flow rate of 0.10 mLmin-1 and passed into a 14 mL CFC 
reactor at 80 °C. The solution was directly taken into the next stage where it reacted with a 
solution of (8) in pyridine/DCM. Each flow channel was set at 0.10 mLmin-1 with the solutions 
combining at a T-connector and passing into a heated (80 °C) PFA CFC. After collection and 
extraction, Meclinertant was obtained in a satisfactory yield of 20% (over the last two steps and 
after crystallization from ethanol/hexanes) (Figure 43).31 
 
 
Figure 43. End-game to Meclinertant. 
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Conclusions 
 To date only one poorly documented synthesis of Meclinertant has been reported. In this study 
we have succeded in developing a novel machine-assisted synthesis of this molecule.  
This process allowed the preparation of Meclinertant without the need for any chromatography 
procedures for the intermediates. The process proved to be robust, reliable and amenable to 
scaling up and it represents a valuable example of a flow synthesis of a commercially significant 
molecule. We have demonstrated that flow chemistry procedures and concepts have gone 
beyond the proof of concept stage and can now be used to solve synthetic challenges. 
Further work to fully automate the flow platform and integrating a screening device would 
enable Meclinertant, and any analogue, to be synthesised and screened in a single process.56  
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Experimental procedures 
Chemistry. 1H-NMR spectra were recorded on a Bruker Avance DPX-400 spectrometer with the 
residual solvent peak as the internal reference (CDCl3 = 7.26 ppm, d6-DMSO = 2.50 ppm). 1H 
resonances are reported to the nearest 0.01 ppm. 13C-NMR spectra were recorded on the same 
spectrometers with the central resonance of the solvent peak as the internal reference (CDCl3 = 
77.16 ppm, d6-DMSO = 39.52 ppm). All 13C resonances are reported to the nearest 0.1 ppm. 
DEPT 135, COSY, HMQC, and HMBC experiments were used to aid structural determination and 
spectral assignment. The multiplicity of 1H signals are indicated as: s = singlet, d = doublet, t = 
triplet, m = multiplet, br. = broad, or combinations of thereof. Coupling constants (J) are quoted 
in Hz and reported to the nearest 0.1 Hz. Where appropriate, averages of the signals from peaks 
displaying multiplicity were used to calculate the value of the coupling constant. Infrared 
spectra were recorded neat on a PerkinElmer Spectrum One FT-IR spectrometer using 
Universal ATR sampling accessories. Letters in parentheses refer to the relative absorbency of 
the peak: w = weak, less than 40% of the most intense peak; m = medium, ca. 41-69% of the 
most intense peak; s = strong, greater than 70% of the most intense peak. Unless stated 
otherwise, reagents were obtained from commercial sources and used without purification. 
Laboratory reagent grade EtOAc, petroleum ether 40-60, and DCM were obtained from Fischer 
Scientific and distilled before use. Unless stated otherwise, heating was conducted using 
standard laboratory apparatus. The removal of solvent under reduced pressure was carried out 
on a standard rotary evaporator, a Genevac EZ-2 Plus personal evaporator, or a Vapourtec V-10 
evaporator. Melting points were performed on either a Stanford Research Systems MPA100 
(OptiMelt) automated melting point system and are uncorrected. High resolution mass 
spectrometry (HRMS) was performed using a Waters Micromass LCT Premier™ spectrometer 
using time of flight with positive ESI, or conducted by Mr Paul Skelton on a Bruker BioApex 47e 
FTICR spectrometer using positive ESI or EI at 70ev to within a tolerance of 5 ppm of the 
theoretically calculated value. LC-MS analysis was performed on an Agilent HP 1100 series 
chromatography (Mercury Luna 3u C18 (2) column) attached to a Waters ZQ2000 mass 
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spectrometer with ESCi ionization source in ESI mode. Elution was carried out at a flow rate of 
0.6 mL min-1 using a reverse phase gradient of acetonitrile and water containing 0.1% formic 
acid. Retention time (Rt) is given in min to the nearest 0.1 min and the m/z value is reported to 
the nearest mass unit (m.u.). X-ray crystal structures were determined by Dr John Davies at the 
Department of Chemistry, University of Cambridge. CIF numbers are reported as part of 
compound characterization. Elemental analyses within a tolerance of ±0.3% of the theoretical 
values were determined by Mr Alan Dickerson and Mrs Patricia Irele in the microanalytical 
laboratories at the Department of Chemistry, University of Cambridge. 
2-Ethynyl adamantan-2-ol (11).  
 
Batch reaction. A solution of ethynyl magnesium bromide (0.5 M in THF, 100 mL) was added 
dropwise to a stirred solution of adamantanone (10) (0.042 mol, 6.25 g in 300 mL of THF) at -
78 °C in a dry ice/acetone bath. After 2 h the dry ice bath was removed and the reaction further 
stirred for 16 h at room temperature. The reaction was quenched gently with NH4Cl solution at 
0 °C and the two phases separated; the water solution was washed twice with Et2O and the 
organic layer dried over sodium sulfate. After concentration, the solid obtained was crystallized 
from hexane to obtain 2-ethynyl adamantan-2-ol (11) as white solid (0.033 mol, 5.81 g, yield 
79.2 %). 
Flow reaction. A solution of 2-adamantanone (10) (100.0 g, 660 mmol, 0.5 M in THF, flow rate 
0.18 mL min−1, pump A) and  a solution of ethynyl magnesium bromide (0.5 M in THF, flow rate 
0.20 mL min−1, pump B) were combined at a T-piece using a Uniqsis Flowsyn (residence time 37 
min) and passed through a 14 mL PFA CFC heated at 40 °C. After exiting the CFC the flow stream 
was quenched with a saturated solution of NH4Cl solution (flow rate 0.18 mL min−1, pump C) 
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mixed at a second T-piece. The T-piece was sonicated to avoid blockages due to formation of 
insoluble magnesium salts. The combined biphasic output was collected and the two phases 
were separated; the water phase was washed once with Et2O and then the organic solution 
obtained dried over sodium sulfate. Evaporation of the solvent and subsequent crystallization 
from hexane furnished the desired product 2-ethynyl adamantan-2-ol (11) as a white solid 
(105.5 g, 590 mmol, yield 90 %, mp 101.7 °C); LC-MS: retention time 4.63 min, m/z [M+H]+ = 
159.00. FT-IR (neat, cm-1) v: 3366 (m), 3181 (m), 2898 (m), 2159 (w), 754 (m); 1H-NMR (400 
MHz, CDCl3): δ/ppm = 2.53 (s, 1H), 2.18-2.13 (m, 4H), 1.96-1.96 (m, 3H), 1.82-1.77 (m, 4H), 1.70 
(br. s, 2H), 1.55-1.58 (m, 3H); 13C-NMR (100 MHz, CDCl3): δ/ppm = 88.51, 72.70, 72.50, 39.31, 
37.60, 35.37, 31.54, 26.40, 26.23. HRMS: calculated for [C12H17O]+ 177.2550, found 177.2558.  
2-Ethynyl-2-acetamido adamantane (12a).  
 
Batch reaction. To a cooled (0 °C) solution of 2-ethynyl adamantan-2-ol (11) (1.5 g, 8.5 mmol), 
MeCN (5 mL) and acetic acid (3 mL), sulfuric acid (1.7 mL, 95% v/v) is added dropwise over 1 
minute. Subsequently, the reaction is allowed to reach room temperature and stirred for further 
2 h. Then the mixture is cooled again (sub-zero temperature) and quenched gently with NaOH 
solution 1M (60 mL). The suspension obtained is extracted with Et2O (4 × 100 mL) and washed 
with brine. The organic layer is dried over sodium sulfate and concentrated to obtain a crude 
material that after trituration with hexane gave the desired 2-ethynyl-2-acetylamino 
adamantane (12a) as a white solid (1.54 g, 7.0 mmol, yield 83 %). 
Flow reaction. EXPT A (small scale). A solution of 2-ethynyl adamantan-2-ol (11) (0.3 g, 1.7 
mmol), MeCN (1.6 mL) and AcOH (2 mL), loaded in a 3mL injection loop (A), and neat conc. 
sulfuric acid (3 mL), loaded in a 3 mL injection loop (B), were simultaneously switched into the 
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main flow stream of glacial acetic acid/acetic anhydride 10/1 (v/v) (flow rate of 1.00 mL min−1 
per channel) combining at a T-piece before progressing into a 14 mL PFA CFC heated at 30 °C 
(residence time 7 min). After exiting the CFC this flow stream was quenched with a third stream 
containing KOH solution (3 M, pump C at a flow rate 3 mL min−1) and the salts formed were 
filtered and washed with DCM. After separation of the two phases the organic layer was dried 
over sodium sulfate and concentrated to obtain a crude material that after trituration with 
hexane gave the title compound (12a) as a white solid (0.3 g, 1.4 mmol, yield 86 %); EXPT B 
(scale-up). A solution of 2-ethynyl adamantan-2-ol (11) (20.0 g, 113.6 mmol, pump A), MeCN 
(80 mL) and AcOH (88 mL) and a mixture of conc. sulfuric acid (40 mL, pump B),  acetic acid (88 
mL) and acetic anhydride (40 mL) were pumped using a Uniqsis Flowsyn at a flow rate of 1.00 
mL min−1 per channel (residence time 7 min) through a 14 mL PFA CFC heated at 30 °C. After 
exiting the CFC this flow stream was quenched with a third stream containing KOH solution (3 
M, pump C at a flow rate 3 mL min−1) and the salts formed were filtered and washed with DCM. 
After separation of the two phases the organic layer was dried over sodium sulfate and 
concentrated to obtain a crude material that after trituration with hexane gave the title 
compound (12a) as a white solid (21.8 g, 99.0 mmol, yield 91 %, mp 147 °C); LC-MS: retention 
time 4.39 min, m/z [M+H]+ = 218.14. FT-IR (neat, cm-1) v: 3287 (m), 2903 (m), 2166 (w), 1645 
(s), 1537 (s), 670 (m); 1H-NMR (400 MHz, CDCl3): δ/ppm = 5.41 (br. s, 1H), 2.46 (s, 1H), 2.40 (br. 
s, 2H), 2.35 (br. s, 1H), 2.31 (br. s, 1H), 2.01 (s, 3H), 1.82-1.77 (m, 4H), 1.70 (br. s , 2H), 1.55-1.58 
(m, 3H); 13C-NMR (400 MHz, CDCl3): δ/ppm = 169.12, 86.18, 71.73, 56.47, 37.64, 35.06, 34.37, 
32.18, 27.24, 26.76, 24.23. HRMS: calculated for [C14H20NO]+ 218.1545, found  218.1548. 
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2-Ethynyl-2-benzamido adamantane (12b).  
 
Batch reaction. To a cooled (0 °C) solution of 2-ethynyl adamantan-2-ol (11) (1.42 g, 8.0 mmol), 
benzonitrile (2.22 mL) and acetic acid (3 mL), sulfuric acid (1.7 mL, 95% v/v) is added dropwise 
over 1 min. Subsequently, the reaction is allowed to reach room temperature and stirred for 
further 4 h.  Then the mixture is cooled again (sub-zero temperature) and quenched gently with 
NaOH solution 1 M (60 mL). The suspension obtained is extracted with Et2O (4 × 100 mL) and 
washed with brine. The organic layer is dried over sodium sulfate and concentrated to obtain a 
crude material that after trituration with hexane gave the desired product (12b) as a white 
needles (1.8 g, 6.5 mmol, yield 81 %). 
Flow reactions. EXPT A (small scale). A solution of 2-ethynyl adamantan-2-ol (11) (0.3 g, 1.7 
mmol), benzonitrile (0.8 mL, 7.8 mmol, 4.6 equiv.) and AcOH (2.1 mL), loaded in a 3mL injection 
loop (A), and neat conc. sulfuric acid (3 mL), loaded in a 3 mL injection loop (B), were 
simultaneously switched into the main flow stream of glacial acetic acid/acetic anhydride 10/1 
(v/v) (flow rate of 1.00 mL min−1 per channel) combining at a T-piece before progressing into a 
14 mL PFA-CFC heated at 30 °C (residence time 7 min). After exiting the CFC this flow stream 
was quenched with a third stream containing KOH solution (3 M, pump C at a flow rate 3 mL 
min−1) and the salts formed were filtered and washed with DCM. After separation of the two 
phases the organic layer was dried over sodium sulfate and concentrated to obtain a crude 
material that after trituration with hexane gave the title compound (14b) as a white solid (0.38 
g, 1.3 mmol, yield 77 %); EXPT B (scale-up). A solution of 2-ethynyl adamantan-2-ol (11) (50.0 g, 
280 mmol, pump A), benzonitrile (98 mL, 0.95 mol, 3.4 equiv.) and acetic acid (196 mL) and a 
mixture of concentrated sulfuric acid (98 mL, pump B),  acetic acid (215 mL) and acetic 
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anhydride (98 mL) were pumped using a Uniqsis FlowSyn at a flow rate of 1.00 mL min−1 per 
channel (residence time 7 min) through a 14 mL PFA CFC maintained at 30 °C. After exiting the 
CFC this flow stream was quenched with 3 M aqueous KOH solution (pump C, flow rate 3 mL 
min−1) and the salts formed were filtered off washing with DCM. After separation of the phases 
the organic one is dried over sodium sulfate and concentrated to obtain a crude oily material 
that after trituration with hexane gave the title compound (12b) as white solid (50.1 g, 174 
mmol, yield 64 %); EXPT C (scale-up modified conditions). A solution of 2-ethynyl adamantan-2-
ol (11) (50.0 g, 0.28 mol, pump A), benzonitrile (49 mL, 0.475 mol, 1.7 equiv.) and acetic acid 
(196 mL) and a mixture of concentrated sulfuric acid (98 mL, pump B),  acetic acid (215 mL) 
and acetic anhydride (98 mL) were pumped using a Uniqsis FlowSyn at a flow rate of 0.60 mL 
min−1 per channel (residence time 11.6 min) through a 14 mL PFA CFC maintained at 30 °C. 
After exiting the CFC this flow stream was quenched with 3 M aqueous KOH solution (pump C, 
flow rate 1.8 mL min−1) and the salts formed were filtered off washing with DCM. After 
separation of the phases the organic one is dried over sodium sulfate and concentrated to obtain 
a crude oily material that after trituration with hexane gave the title compound (12b) as white 
needles (66.5 g, 231 mmol, yield 85 %, mp 189 °C); LC-MS: retention time 4.98 min, m/z [M+H]+ 
= 280.15. FT-IR (neat, cm-1) v: 3400 (m), 3281 (m), 2905 (m), 1645 (s), 1537 (s), 690 (s); 1H-
NMR (400 MHz, CDCl3): δ/ppm = 7.96 (d, 2H, J = 6.8 Hz), 7.49 (m, 1H), 7.40 (m, 2H), 6.14 (br. s, 
1H),  2.56 (s, 2H), 2.49 (s, 1H), 2.40 (d, 2H, J = 11.2 Hz), 2.00 (d, 2H, J = 11.2 Hz), 1.89-1.70 (m, 
9H); 13C-NMR (100 MHz, CDCl3): δ/ppm = 166.26, 135.27, 131.47, 128.60, 126.94, 86.04, 71.99, 
56.63, 37.66, 35.28, 34.06, 32.01, 26.92, 26.48. HRMS: calculated for [C19H22NO]+ 280.1701, 
found  280.1691. 
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2-Methyl-4-(adamantane-2’-spiro)-5-methylidene oxazoline (13a). 
 
Batch reaction. A solution of 2-ethynyl 2-acetylamino adamantane (12a) (0.640 g, 3 mmol) and 
KOH (0.45 g, 8 mmol) in EtOH (6 mL) was heated at 100 °C for 2 h employing a microwave 
apparatus system. Then the mixture was quenched with brine (100 mL), extracted with DCM (4 
x100 mL) and washed with brine (100 mL). Then the organic layer obtained was dried over 
sodium sulfate and concentrated to obtain the title compound (13a) as a yellowish solid (0.58 g, 
2.6 mmol, yield 91 %). 
Flow reaction. A solution of 2-ethynyl 2-acetylamino adamantane (12a) (9.0 g, 41.3 mmol, flow 
rate 0.20 mL min-1, pump A) in EtOH (400 mL) and a solution of potassium hydroxide (13.0 g, 
flow rate 0.10 mL min-1, pump B) in EtOH (200 mL) were pumped using a Uniqsis Flowsyn 
(residence time 47 min) through a 14 mL PFA CFC heated at 125 °C using a 100 psi BPR. After 
exiting the CFC this flow stream was collected and the solution concentrated in vacuo. The solid 
obtained was quenched with distilled water (ice bath to avoid any retro-reaction) and extracted 
with DCM. After drying over sodium sulfate, the solvent was evaporated and the title compound 
(13a) isolated as a yellowish solid (8.2 g, 37.6 mmol, yield 91 %, mp 61.5 °C). 
Telescoped Ritter/5-enol exo-dig cyclisation flow procedure. A solution of 2-ethynyl adamantan-
2-ol (11) (2.0 g, 11 mmol, pump A), MeCN (8.0 mL) and AcOH (9 mL) and a mixture of conc. 
sulfuric acid (4.0 mL, pump B),  acetic acid (9 mL) and acetic anhydride (4.0 mL) were pumped 
using a Uniqsis Flowsyn at a flow rate of 1.00 mL min−1 per channel (residence time 7 min) 
through a 14 mL PFA CFC heated at 30 °C. After exiting the CFC the flow stream was directed to 
a T-piece to meet a further solution of KOH (3M) in EtOH/H2O 40:1 (v/v) (pump C, flow rate 3.0 
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mL min−1) then filtered in-line (column packed with glass wool) to remove any precipitate 
(column packed with glass wool) to remove any precipitate (eluent collected in a filter flask). 
The resultant solution was pumped into a PFA CFC and heated to 120 °C (residence time 48 min, 
flow rate 0.30 mL min−1). After exiting the CFC the flow stream was collected and the solution 
concentrated in vacuo. The solid obtained was quenched with distilled water (ice bath to avoid 
any retro-reaction), extracted with DCM, dried over sodium sulfate and the solvent evaporated. 
The title compound (13a)  was obtained as a yellowish solid (2.2 g, 10 mmol, yield 91 %). LC-
MS: retention time 3.70 min, m/z [M+H]protonated = 219.05; time 4.49 min, m/z [M+H]+ = 218.07. 
FT-IR (neat, cm-1) v: 2906 (s), 1686 (s), 1654 (s), 1262 (s), 1199 (s), 1063 (s), 965 (s), 834 (s). 
1H-NMR (400 MHz, CDCl3): δ/ppm = 4.79 (d, 1H, J = 2.4 Hz), 4.52 (d, 1H, J = 2.4 Hz), 2.44 (d, 2H, J 
= 12.4 Hz), 2.21 (d, 2H, J = 12.4 Hz), 2.03 (s, 3H), 1.86 (broad s, 3H), 1.74 (s , 2H), 1.69-1.55 (m, 
5H); 13C-NMR (100 MHz, CDCl3): δ/ppm = 166.00, 158.66, 87.91, 76.02, 38.70, 37.08, 34.06, 
31.40, 28.03, 26.76, 14.43. HRMS: calculated for [C14H20NO]+ 218.1545, found 218.1541.  
 
CCDC860429 
The structure was unambiguously confirmed by single X-ray crystallography and deposited at 
Cambridge University (Crystallographic Data Centre) with the unique reference CCDC860429; 
space group P21/c; a = 6.6834 (2), b = 7.0945 (2), c = 23.8587 (8), β = 90.449 (2). 
 
 
 
 
Chapter 2: A Machine-Assisted Flow Procedure for Meclinertant, a Neurotensin Receptor Probe 
Page 171 of 195 
 
 
2-Phenyl-4-(adamantane-2’-spiro)-5-methylidene oxazoline (13b). 
 
Batch reaction. A solution of 2-ethynyl 2-benzamidoadamantane (12b) (0.56 g, 2 mmol) and 
KOH (0.29 g, 5.2 mmol) in EtOH (4 mL) was heated at 100 °C for 2 h employing a microwave 
apparatus system. Then the mixture was quenched with brine (100 mL), extracted with DCM (4 
x100 mL) and washed with brine (100 mL). Then the organic layer obtained was dried over 
sodium sulfate and concentrated to obtained 2-phenyl-4-(adamantane-2’-spiro)-5-methylidene 
oxazoline (13b) as a yellowish solid (0.53 g, 1.9 mmol, yield 95 %). 
Flow reaction. A solution of 2-ethynyl 2-benzamido adamantane (12b) (17.5 g, 63 mmol, flow 
rate 0.40 mL min-1, pump A) in EtOH (800 mL) and a solution of potassium hydroxide (20.0 g, 
flow rate 0.20 mL min-1, pump B) in EtOH (400 mL) were pumped using a Uniqsis Flowsyn 
(residence time 24 min) through a 14 mL PFA CFC heated at 120 °C using a 100 psi BPR. After 
exiting the CFC this flow stream was collected and the solution concentrated in vacuo. The solid 
obtained was quenched with distilled water (ice bath to avoid any retro-reaction) and extracted 
with DCM. After drying over sodium sulfate and evaporating the solvent, the title compound 
(13b)  was obtained as a yellowish solid (16.2 g, 53 mmol, yield 92 %, mp 67 °C). 
Telescoped Ritter/5-enol exo-dig cyclisation flow procedure. A solution of 2-ethynyl adamantan-
2-ol (11) (5.0 g, 28 mmol, pump A), benzonitrile (4.9 mL, 47.5 mmol, 1.7 equiv.) and acetic acid 
(20 mL) and a mixture of concentrated sulfuric acid (9.8 mL, pump B),  acetic acid (21.5 mL) and 
acetic anhydride (9.8 mL) were pumped using a Uniqsis FlowSyn at a flow rate of 0.60 mL min−1 
per channel (residence time 11.6 min) through a 14 mL PFA CFC maintained at 30 °C.  After 
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exiting the CFC the flow stream was directed to a T-piece to meet a further solution of KOH (3M) 
in EtOH/H2O 40:1 (v/v) (pump C, flow rate 1.8 mL min−1) then filtered in-line (column packed 
with glass wool) to remove any precipitate (eluent collected in a filter flask). The resultant 
solution was pumped into a PFA CFC and heated to 120 °C (residence time 24 min, flow rate 
0.60 mL min−1). After exiting the CFC the flow stream was collected and the solution 
concentrated in vacuo. The solid obtained was quenched with distilled water (ice bath to avoid 
any retro-reaction), extracted with DCM, dried over sodium sulfate and the solvent evaporated. 
The title compound (13b)  was obtained as a yellowish solid (7.0 g, 25 mmol, yield 90 %). LC-
MS: retention time 6.05 min, m/z [M+H]+ = 280.08. FT-IR (neat, cm-1) v: 2899 (s), 1666 (s), 1644 
(s), 1056 (s). 1H-NMR (400 MHz, CDCl3): δ/ppm = 8.01 (d, 2H, J = 6.8 Hz ), 7.49-7.40 (m, 3 H), 
4.99 (d, 1H, J = 2.4 Hz), 4.65 (d, 1H, J = 2.4 Hz), 2.63 (d, 2H, J = 11.2 Hz), 2.29 (d, 2H, J = 11.2 Hz), 
1.95 (m, 2H), 1.74 (s, 2H), 1.69-1.55 (m, 6H);  13C-NMR (100 MHz, CDCl3): δ/ppm = 166.04, 
157.63, 131.98, 128.81, 128.12, 126.97, 88.45, 77.14, 38.73, 37.68, 34.14, 31.51, 27.96, 26.54. 
HRMS: calculated for [C19H22NO]+ 280.1701, found 218.1704. 
 
CCDC860430 
The structure was unambiguously confirmed by single X-ray crystallography and deposited at 
Cambridge University (Crystallographic Data Centre)  with the unique reference CCDC860430; 
space group Pbca: a = 20.3254 (3), b = 12.2093 (1), c = 23.7513 (3). 
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2-Methyl-4-(adamantane-2’-spiro)-oxazolin-5-one (14a). 
 
Batch reaction. EXPT A. A solution of 2-methyl-4-(adamantane-2’-spiro)-5-methylidene 
oxazoline (13a) (0.436 g, 2 mmol) in DCM (20 mL) was cooled to -78 °C with acetone/dry ice 
bath and then ozone was bubbled inside the mixture till the solution turns to light blue. 
Afterwards the excess of ozone was removed from the solution blowing argon and then the 
reaction was quenched employing supported polymer thiourea. After filtering off the polymer 
and concentrating the solution, 2-methyl-4-(adamantane-2’-spiro)-oxazolin-5-one (14a) was 
obtained as a white solid (0.418 g, 1.90 mmol, yield 95 %); EXPT B. Ozone was bubbled (20 min) 
inside a solution of 2-methyl-4-(adamantane-2’-spiro)-5-methylidene oxazoline (13a) (0.44 g, 2 
mmol) in DCM (20 mL) at room temperature until the solution turned colourless. Afterwards 
the excess of ozone was removed from the solution blowing argon and then the reaction was 
quenched employing polymer-supported thiourea. After filtering off the polymer and 
concentrating the solution, the title compound (14a) was obtained as a white solid (0.410 g, 
1.86 mmol, yield 93 %). 
Flow reaction. A solution of 2-methyl-4-(adamantane-2’-spiro)-5-methylidene oxazoline (13a) 
(9.0 g, 41.3 mmol, flow rate 4.00 mL min-1, pump A) in DCM (400 mL) and a stream of ozone (0.5 
bar, flow rate 500 mL min-1) were combined in a T-piece and directly through a 1 mL PTFE tube 
reactor (180 mm, 2.5 mm i.d., ~ 15 s residence time). After exiting the tube this flow stream was 
collected and the excess of ozone was blown out with argon. The solution was then directly 
delivered to a scavenger cartridge containing QP-TU (3.00 mL min -1, pump B). The collection of 
the output stream and the concentration of the solution gave the title compound (14a) as a 
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white solid (8.7 g, 39.4 mmol, yield 95 %, mp 138 °C); LC-MS: retention time 4.32 min, m/z 
[M+H] decarboxylated = 192.09, m/z [M-H]acid = 236.07. FT-IR (neat, cm-1) v: 2907 (s), 1789 (m), 1693 
(s), 1448 (m), 1232 (s), 1174 (s), 1046 (s), 971 (s), 900 (s). 1H-NMR (400 MHz, CDCl3): δ/ppm =  
2.51 (d, 2H, J = 12 Hz), 2.35 (d, 2H, J = 11.2 Hz), 2.19 (s, 3H), 1.94 (s, 2H), 1.71-1.60 (m, 8H);  13C-
NMR (100 MHz, CDCl3): δ/ppm = 179.12, 159.27, 72.28, 37.79, 35.04, 33.61, 31.09, 27.48, 26.31, 
15.33. HRMS: calculated for [C13H18NO2]+ 220.1339, found  220.1347.  
 
CCDC860432 
The structure was unambiguously confirmed by single X-ray crystallography and deposited at 
Cambridge University (Crystallographic Data Centre) with the unique reference CCDC860432; 
space group P21/m: a = 6.8926 (4), b = 6.5463 (4), c = 12.267 (2), β = 98.997 (2). 
2-Phenyl-4-(adamantane-2’-spiro)-oxazolin-5-one (14b).  
 
Batch reaction. EXPT A. A solution of 2-phenyl-4-(adamantane-2’-spiro)-5-methylidene 
oxazoline (13b) (0.56 g, 2 mmol) in DCM (20 mL) was cooled to -78 °C with acetone/dry ice 
bath and then ozone was bubbled through the mixture (5 min) until the solution turned light 
blue in colour. The excess of ozone was removed from the solution by blowing argon and then 
the reaction was quenched employing supported polymer thiourea. After filtering off the 
polymer and concentrating the solution, 2-phenyl-4-(adamantane-2’-spiro)-oxazolin-5-one 
(14b) was obtained as a white off solid (0.558 g, 1.98 mmol, yield 99 %); EXPT B. Ozone was 
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bubbled (20 min) inside a solution of 2-phenyl-4-(adamantane-2’-spiro)-5-methylidene 
oxazoline (13b) (0.56 g, 2 mmol) in DCM (20 mL) at room temperature until the solution turned 
colourless. Afterwards the excess of ozone was removed from the solution blowing argon and 
then the reaction was quenched employing supported polymer thiourea. After filtering off the 
polymer and concentrating the solution, the title compound (14b) was obtained as a white solid 
(0.530 g, 1.9 mmol, yield 95 %). 
Flow reaction. A solution of 2-phenyl-4-(adamantane-2’-spiro)-5-methylidene oxazoline (13b) 
(10.0 g, 35.8 mmol, flow rate 4.00 mL min-1, pump A) in DCM  (350 mL) and a stream of ozone 
(0.5 bar, flow rate 500 mL min-1) were combined in a T-piece and directly through a 1 mL PTFE 
tube reactor (180 mm, 2.5 mm i.d., ~15 s residence time). After exiting the tube this flow stream 
was collected and the excess of ozone was blown out with argon. The solution was then directly 
delivered to a scavenger cartridge containing QP-TU (3.00 mL min-1, pump B). The collection of 
the output stream and the concentration of the solution gave the title compound (14b) as a 
white solid (10.09 g, 35.7 mmol, yield 99.8 %, mp 109 °C); LC-MS: retention time 5.64 min, m/z 
[M+H]decarboxylated = 254.12, m/z [M-H]acid= 298.05. FT-IR (neat, cm-1) v: 2893 (s), 1796 (s), 1657 
(s), 1453 (m), 1292 (s), 1046 (s), 961 (s), 678 (s); 1H-NMR (400 MHz, CDCl3): δ/ppm = 8.03 (d, 
2H, J = 6.8 Hz ), 7.55-7.51 (m, 1H), 7.49-745 (m, 2H), 2.59 (d, 2H, J = 14 Hz), 2.54 (d, 2H, J = 14 
Hz), 1.99 (s, 2H), 1.87 (s, 2H), 1.82 (s, 2H), 1.70 (m, 4H); 13C-NMR (100 MHz, CDCl3): δ/ppm = 
179.04, 157.96, 132.25, 128.68, 127.87, 126.64, 72.79, 37.81, 35.51, 33.67, 31.20, 27.67, 26.39. 
HRMS: calculated for [C18H20NO2]+ 282.1494, found  218.1484.  
 
CCDC860431 
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The structure was unambiguously confirmed by single X-ray crystallography and deposited at 
Cambridge University (Crystallographic Data Centre) with the unique reference CCDC860431;  
space group P21/m: a = 12.6229 (9), b = 6.9172 (5), c = 17.039 (2), β = 109.380 (3). 
2-Aminoadamantane-2-carboxylic acid hydrochloride (8).  
 
Batch reaction. EXPT A. 2-methyl-4-(adamantane-2’-spiro)-oxazolin-5-one (14a) (1 g, 4.54 
mmol) was dissolved in conc. HCl (10 mL), H2O (50 mL) and acetic acid (230 mL) and heated at 
reflux (170°C) for 28 h, when the reaction was complete by NMR. The reaction mixture was 
concentrated in vacuo and the solid triturated with hot Et2O (2 × 100 mL), hot MeCN (2 × 50 
mL). The solid was then dissolved in the minimum volume of MeOH (20 mL), added to Et2O (200 
mL) and left to crystallise at 0 ºC overnight. The resulting solid was isolated by filtration to 
afford the title compound (8) as a white crystalline solid (1.00 g, yield 96 %); EXPT B. 2-Phenyl-
4-(adamantane-2’-spiro)-oxazolin-5-one (14a) (2 g, 7.12 mmol) was dissolved in conc. HCl (15 
mL), H2O (70 mL) and AcOH (350 mL) and heated at reflux (170 °C) for 80 h, when the reaction 
was complete by NMR. The reaction mixture was concentrated in vacuo and the solid triturated 
with hot Et2O (2 × 100 mL), hot MeCN (2 × 50 mL). The solid was then dissolved in the 
minimum volume of MeOH (20 mL), added to Et2O (200 mL) and left to crystallise at 0 ºC 
overnight. The resulting solid was isolated by filtration to afford the title compound (8) as a 
white crystalline solid (1.14 g, yield 70 %).        
Flow reactions. EXPT A. A solution of 2-methyl-4-(adamantane-2’-spiro)-oxazolin-5-one (14a) 
(1.15 g, 5.25 mmol, flow rate 0.40 mL min-1, pump A) in glacial acetic acid (150 mL) and a 
mixture of glacial acetic acid (90 mL), H2O (50 mL) and hydrochloric acid (10 mL, flow rate 0.40 
mL min-1, pump B) were combined in a T-piece and reacted through a 14 mL PFA reactor coil at 
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150°C (residence time ~18 min). After exiting the tube this flow stream was collected and the 
mixture was concentrated in vacuo. The solid obtained was washed with hot diethyl ether (50 
mL × 2) and hot acetonitrile (50 mL × 2) to obtain the product, that was crystallised from 
methanol (1.10 g, 4.8 mmol, yield 94 %); EXPT B. A solution of 2-phenyl-4-(adamantane-2’-
spiro)-oxazolin-5-one (14b) (1.50 g, 5.25 mmol, flow rate 0.25 mL min-1, pump A) in glacial 
acetic acid (150 mL) and a mixture of glacial acetic acid (90 mL), H2O (50 mL) and hydrochloric 
acid (10 mL) (flow rate 0.25 mL min-1, pump B) were combined in a T-piece and reacted 
through a 14 mL PFA reactor coil at 150°C (residence time ~28 min). After exiting the tube this 
flow stream was collected and the mixture was concentrated in vacuo. The solid obtained was 
washed with hot diethyl ether (50 mL × 2) and hot acetonitrile (50 mL × 2) to obtain the 
product, that was crystallised from methanol (1.05 g, 4.55 mmol, yield 87 %, mp > 258 °C 
decomposition); LC-MS: retention time 0.31 min, m/z [M+H]decarboxylated = 149.99, m/z 
[M+H]deaminated = 179.05, m/z [M+H] = 196.10,  m/z [M-H] = 194.06. FT-IR (neat, cm-1) v: 3220 
(w), 3168 (w), 2775 (s), 1725 (s), 1587 (s), 1506 (s), 1468 (s); 1H-NMR (400 MHz, CDCl3): 
δ/ppm = 8.70 (s br, 3H), 2.21 (s, 2H), 2.12 (d, 2H, J = 13.2 Hz), 1.92 (d, 2H, J = 13.2 Hz), 1.75-1.80 
(m, 4H), 1.62-1.66 (m, 2H); 13C-NMR (100 MHz, CDCl3): δ/ppm = 171.59, 63.92, 37.54, 34.40, 
32.24, 31.22, 26.28. HRMS: calculated for [C11H18NO2]+ 196.1338, found  196.1336. 
Microanalysis calculated (found) for C11H18NO2Cl: C 57.02 (56.90%), H 7.83 (7.97%), N 6.04 
(6.06%).  
 
CCDC860428 
The structure was unambiguously confirmed by x-ray crystallography and the structure 
deposited at Cambridge University (Crystallographic Data Centre) with the unique reference 
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CCDC860428; space group P21/c: a = 6.3862 (2), b = 11.4838 (3), c = 14.9079 (4), β = 95.392 
(2).  
2-Acetylamido adamantane-2-carboxylic acid (15a).  
 
Off-white solid; mp 210-213 °C; LC-MS: retention time 4.06 min, m/z [M-H] = 236.10. FT-IR 
(neat, cm-1) v: 3386 (m), 2907 (s), 1745 (s), 1632 (m), 1594 (s), 1248 (s), 1208 (s), 849 (m), 
721 (m); 1H-NMR (400 MHz, CDCl3): δ/ppm = 12.01 (br. s, 1H), 7.62 (s, 1H), 2.39 (s, 2H), 2.01 
(br.s, 4H), 1.82 (s, 3H), 1.73 (s, 2H), 1.62 (br. s, 4H), 1.49 (m, 2H); 13C-NMR (100 MHz, CDCl3): 
δ/ppm = 174.18, 169.44, 63.10, 38.02, 35.80, 32.50, 32.01, 26.99, 26.71, 23.40. HRMS: calculated 
for [C13H20NO3]+ 238.1718, found  238.1710.  
 
CCDC874390 
The structure was unambiguously confirmed by x-ray crystallography and the structure 
deposited at Cambridge University (Crystallographic Data Centre) with the unique reference 
CCDC874390; space group P-1 : a = 6.8572 (2), b = 8.1043 (3), c = 10.8425 (5), α = 90.434(2) °, β 
= 102.620(2) °, γ = 98.459(3) °.  
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2-Benzamido adamantane-2-carboxylic acid (15b).  
 
Off-white solid; mp 234-236 °C; LC-MS: retention time 4.28 min., m/z [M+H]+ = 322.14. FT-IR 
(neat, cm-1) v: 3389.7 (w), 2905.7 (m), 1740.0 (s), 1626.8 (m), 1526.3 (s); 1H-NMR (400 MHz, 
DMSO-d6): δ/ppm = 12.17 (br. s, 1H), 8.10 (s, 1H), 7.79 (d, 2H, J = 7.2 Hz), 7.52 (t, 1H, J = 7.2 Hz), 
7.44 (t, 2H, J = 7.2 Hz), 2.63 (s, 2H), 2.12 (m, 4H), 1.80 (s, 2H), 1.65-1.69 (m, 4H), 1.56 (d, 2H, J = 
12.7 Hz); 13C-NMR (100 MHz, DMSO-d6): δ/ppm = 173.8, 166.4, 135.1, 131.1, 128.1, 127.7, 63.1, 
37.5, 33.5, 32.8, 31.5, 26.5, 26.4; HRMS: calculated for [C18H21NO3Na]+ 322.1419, found 
322.1421.  
 
CCDC860427 
The structure was unambiguously confirmed by x-ray crystallography and the structure 
deposited at Cambridge University (Crystallographic Data Centre) with the unique reference 
CCDC860427; space group P21/n : a = 14.1635 (4), b = 6.7026 (2), c = 15.8379 (6), β = 99.395 
(1). 
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3-Acetyloxy 2-cyclohexen-1-one (22).  
 
Batch reaction. To a solution of 1,3-cyclohexandione 16 (2.0 g, 17.8 mmol) and  
diisopropylamine (4 mL) in anhydrous toluene/dichloromethane (30 mL/5 mL), acetyl chloride 
(1.4 mL) is added dropwise over 2 minutes. The reaction is stirred for 2 hours at rt. The salts 
formed are then filtered off to obtain a solution of the 1. For characterisation analyses, a small 
portion of the solution is extracted with ethyl acetate, washed with water, HCl 2N and brine. The 
organic fraction, dried and concentrated, affords the product as a yellowish oil in almost 
quantitative yield (2.45 g, 15.89 mmol, yield 89 %). LC-MS: retention time 1.21 min, m/z [M+H] 
= 154.48. FT-IR (cm-1, neat): 2954 (w), 1768 (s), 1669 (s), 1640 (m), 1363 (s), 1182 (s) 1115 
(s), 1007 (m), 919 (m), 878 (m); 1H-NMR (400 MHz, CDCl3) δ (ppm): 5.75 (s, 1H), 2.42 (t, 2H, J = 
6.9 Hz), 2.30 (t, 2H, J = 6.9 Hz), 2.21 (s, 3H), 1.94 (m, 2H, J = 6.9 Hz); 13C-NMR (100 MHz, CDCl3) δ 
(ppm): 199.55, 169.82, 167.30, 117.34, 36.61, 28.22, 21.16, 21.14.  HRMS for [C8H11O3]+ 
calculated 155.1110 ; found 155.1111. 
2-Acetyl 1,3-cyclohexandione (23).  
 
Batch reaction. To the solution containing 22 is added PS-DMAP (0.5 g, 3 mmol) and the mixture 
is microwave irradiated for 3 h. The reaction mixture is then filtered to remove the PS-DMAP 
and the solution washed with HCl 2N and brine. The organic fraction obtained is dried over 
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sodium sulfate, filtered and concentrated to obtain 23 as reddish oil. (2.30 g, 14.9 mmol, yield 
94 %). LC-MS: retention time 2.62 min, m/z [M+H] = 155.35. FT-IR (cm-1, neat): 2953 (w), 1660 
(s), 1550 (s), 1410 (s), 1351 (s) 1188 (s), 1007 (m), 919 (m), 841 (m).1H-NMR (400 MHz, CDCl3) 
δ (ppm): 15.75 (s, 1H), 2.65 (t, 2H, J = 6.9 Hz), 2.61 (s, 3H), 2.48 (t, 2H, J = 6.9 Hz), 1.97 (m, 2H, J 
= 6.9 Hz). 13C-NMR (100 MHz, CDCl3)  δ (ppm): 203.05, 198.69, 195.38, 108.18, 38.55, 33.21, 
28.74, 18.98. HRMS for [C8H11O3]+ calculated 155.0708 ; found 155.0705. 
2’-Hydroxy-6’-methoxy-acetophenone (24). 
 
Batch reaction. To a solution of 23 (2.0 g, 13 mmol) in methanol (30 mL), iodine (2 eq., 6.8 g) is 
added and the reaction mixture microwave irradiated for 9 h. The mixture is then passed 
through calcium carbonate (to remove excess of acid produced during the reaction) and a 
polymer supported sulfite resin (to eliminate excess of iodine). The organic fraction obtained is 
concentrated to obtain 24 as yellowish needles. (mp 55-59 °C, 1.75 g, 10.5 mmol, yield 80 %). 
LC-MS: retention time 4.51 min, m/z [M+H] = 167.37. FT-IR (cm-1, neat): 2944 (w), 1628 (m), 
1608 (s), 1483 (s),1367 (m), 1325 (s), 1211 (s), 1180 (m), 1035 (m), 962 (m), 838 (m), 782 
(m).1H-NMR (400 MHz, CDCl3) δ (ppm): 13.23 (s, 1H), 7.32 (t, 1H, J = 8.9 Hz), 6.55 (d, 1H, J = 8.9 
Hz), 6.34 (d, 1H, J = 8.9 Hz), 3.90 (s, 3H), 2.67 (s, 3H). 13C-NMR (100 MHz, CDCl3)  δ (ppm): 
205.17 (C), 164.65 (C), 161.55 (C), 136.09 (CH), 111.32 (CH), 101.15 (CH), 55.86 (CH3), 33.66 
(CH3). HRMS for [C9H11O3]+ calculated 167.0708 ; found 167.070. 
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2’,6’-Dimethoxyacetophenone (3). 
 
Batch reaction. A solution of 24 (1 mmol, 0.166 g) and 1,2-dimethylimidazole (1 mmol, 0.1 g)  in 
dimethyl carbonate (0.8 mL)/methanol (0.8 mL) is microwave irradiated for 1 h at 160°C. The 
reaction mixture is then passed through a QP-SA scavenger and the solution obtained is 
concentrated to obtain 3 as a yellowish solid (0.183 g, 0.96 mmol, 96% yield ). 
Telescoped flow reaction. A solution of 1,3-cyclohexadione (2.0 g, 17.8 mmol) and 
diisopropylamine (1.1 eq.) (flow rate 0.50 mL min-1, pump A) in toluene (30 mL) and a solution 
of acetyl chloride (1.4 mL, 19.5 mmol, flow rate 0.50 mL min-1, pump B) in toluene (30 mL) were 
reacted in a 14 mL CFC PFA at 40 °C after combining at a T-piece (~ 14 min residence time). 
After exiting the CFC the flow stream was dispensed onto a filter mat to remove any precipitate 
(eluent collected in a filter flask). The resultant solution was pumped through a monolith 
containing dimethylaminopyridine (DMAP) catalyst heated to 100 °C (residence time 20 min, 
flow rate 50 µL min−1). After exiting the CFC the flow stream was collected and the solution 
concentrated in vacuo (2.50 g, 16.7 mmol, yield 94%). A solution of the material obtained in 
methanol (30 mL) (flow rate 0.20 mL min-1, pump A) and a solution of iodine (8.00 g, 32.00 
mmol) in methanol (30 mL) (flow rate 0.20 mL min-1, pump B) were pumped through a CFC 
PFA at 80 °C after mixing at a T-piece. The solution was then directly delivered to a scavenger 
cartridge containing calcium carbonate and a polymer supported thiosulfate cartridge.. The 
resultant solution was delivered (flow rate 0.40 mL min−1, pump A) at a T-piece to meet a 
solution of 1,2-dimethylimidazole (2.10 g, 13.06 mmol) in dimethyl carbonate (30 mL) (flow 
rate 0.40 mL min−1, pump B) and reacted into a PFA CFC heated to 150 °C (residence time 14 
min). After exiting the CFC the flow stream was directed to a polymer-supported sulfonic acid 
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(QP-SA) cartridge and then silica. The collection of the output stream and the concentration of 
the solution gave the title compound (3) as a yellowish solid in good yield and purity (mp 67-71 
°C, 1.81 g, 10.00 mmol, yield 62%). LC-MS: retention time 4.20 min, m/z [M+H] = 181.37. FT-IR 
(cm-1, neat): 3000 (w), 2943 (w), 1696 (s), 1590 (s), 1471 (s), 1434 (s), 1358 (s), 1282 (m), 
1249 (s), 1107 (s), 781 (s), 759 (m), 735 (s); 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.26 (t, 1H,  J = 
8.7 Hz,), 6.55 (d, 2H, J = 8.7 Hz), 3.80 (s, 6H), 2.47 (s, 3H); 13C-NMR (100 MHz, CDCl3)  δ (ppm): 
202.77, 156.76, 130.63, 104.02, 77.26, 55.88, 32.33. HRMS for [C10H13O3]+ calculated 181.0865; 
found 181.0857. 
Ethyl 4-(2,6-dimethoxyphenyl)-2,4-dioxobutanoate (4).  
 
Batch reaction. A solution of 2’,6’-dimethoxy-acetophenone 3 (0.90 g, 4.90 mmol), diethyl 
oxalate (1.344 mL, 2 eq.) and a solution of sodium ethoxide (1M, 10mL) in ethanol (8 mL) is 
microwave irradiated for 25 min at 80°C. Hydrochloric acid (1M, 10 mL) is then added till pH 
reached 3. The product 4 crystallised overnight as an off-white solid (1.10 g, 3.93 mmol, 80% 
yield). 
Flow reaction. A solution of 2’,6’-dimethoxy-acetophenone 3 (1.126 g, 6.18 mmol) and diethyl 
oxalate (1.664 mL, 2 eq.) in ethanol (36 mL) (flow rate 1.30 mL min-1, pump A) and a solution of 
sodium ethoxide (1 M) (flow rate 1.30 mL min-1, pump B) were reacted in a 52 mL (10 mm i.d.) 
PFA reactor at 140 °C after combining at a T-piece (20 minutes residence time). After exiting the 
reactor, the solution was collected and hydrochloric acid (1M, 10 mL) was added till pH reached 
3. The product 4 crystallised overnight as an off-white solid (1.240 g, 4.57 mmol, 74% yield). mp 
102-104 ºC; LCMS: retention time = 4.19 min, m/z [M+Na]+= 302.83; FT-IR (neat, cm-1): 1735.66 
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(m), 1620=5.14 (m), 15486.82 (m), 1475.31 (m), 1257.47 (s); 1H-NMR (400 MHz, CDCl3): 14.33 
(br s, 1H), 7.34 (t, 1H, J = 8.4 Hz), 6.60 (s, 1H), 6.59 (d, 1H, J = 8.4 Hz), 4.35 (q, 2H, J = 7.1 Hz), 
3.81 (s, 6H), 1.37 (t, 3H, J = 7.1 Hz); 13C-NMR (100 MHz, CDCl3): 195.8, 164.0, 162.6, 158.0, 132.4, 
117.2, 106.4, 104.3, 62.5, 56.2, 14.2; HRMS: calculated for [C14H16O6Na]+ = 303.0845, found 
303.0847. Microanalysis: calculated (found) for C14H16O6: C  59.99% (59.99%), H 5.52% 
(5.75%),  
Ethyl 1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carboxylate (5).  
 
Batch reaction. A solution of ethyl 4-(2,6-dimethoxyphenyl)-2,4-dioxobutanoate (4) (0.14 g, 
0.50 mmol) and 1-(7-chloroquinolin-4-yl)hydrazine (0.12 g, 1.3 eq.) in dimethylformamide (3 
mL) was microwave irradiated at 140 °C for 3 h. Sodium hydrogencarbonate (2 g) is added and 
the mixture stirred until no more evolution of gas is noticed. The mixture is added with water 
(10 mL) and extracted with dichloromethane (4 x 15 mL). The organic fractions collected are 
dried over sodium sulfate, filtered and concentrated in vacuo. The oil obtained is stirred with 
hexane (10 mL) overnight to afford a solid which is recrystallized from ethanol/hexane to 
furnish the product as yellowish crystals (0.18 g, 0.43 mmol, 87% yield). 
Flow reaction. A solution of ethyl 4-(2,6-dimethoxyphenyl)-2,4-dioxobutanoate (4) (1.12 g, 4.0 
mmol) and 1-(7-chloroquinolin-4-yl)hydrazine (0.926 g, 1.2 eq., 4.8 mmol) in 
dimethylformamide (10 mL) (flow rate 0.50 mL min-1, pump A) and a solution of sulfuric acid 
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(1.2 mL) in dimethylformamide (10 mL) (flow rate 0.50 mL min-1, pump B) were reacted in a 
52 mL (10 mm i.d.) PFA reactor at 140 °C after combining at a T-piece (52 min residence time). 
After exiting the reactor coil the solution was collected, sodium hydrogencarbonate (5 g) was 
added and the mixture stirred until no more evolution of gas is noticed. The mixture is added 
with water (20 mL) and extracted with dichloromethane (4 x 20 mL). The organic fractions 
collected are dried over sodium sulfate, filtered and concentrated in vacuo. The oil obtained is 
stirred with hexane (20 mL) overnight to afford a solid which is recrystallized by 
ethanol/hexane to furnish the product as yellowish crystals (1.58 g, 3.58 mmol, 89% yield). mp 
147 -149 ºC; LCMS: retention time = 4.58 min, m/z [M+H]+ = 437.93; FT-IR (neat, cm-1): 1719.4 
(m), 1590.0 (m), 1476.6 (s), 1434.8 (m),  1232.7 (s); 1H- NMR (400 MHz, DMSO-d6): 8.91 (d, 1H, 
J = 4.5 Hz), 8.17 (d, 1H, J  = 1.8 Hz), 7.72 (dd, 1H, J = 9.0, 1.8 Hz), 7.68 (d, 1H, J = 9.0 Hz), 7.26 (t, 
1H, J= 8.4 Hz), 7.23 (d, 1H, J  = 4.5 Hz), 7.04  (s, 1H), 6.54 (d, 2H, J = 8.4 Hz), 4.35 (q, 2H,  J = 7.1 
Hz, H-1’), 3.40 (s, 6H), 1.33 (t, 3H,  J  = 7.1 Hz); 13C-NMR (100 MHz, DMSO-d6): 161.4, 157.5, 
151.7, 149.1, 144.5, 143.3, 139.2, 134.8, 132.0, 128.1, 127.7, 125.7, 122.1, 118.3, 111.6, 105.4, 
104.0, 60.6, 55.4, 14.2; HRMS: calculated for [C23H21N3O4Cl]+ = 438.1221, found 438.1219.  
Microanalysis: calculated (found) for  C23H20N3O4Cl;  C  63.09% (62.80%), H 4.60% (4.62%), N  
9.60% (9.53%). 
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1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carboxylic acid (6).  
 
Batch reaction. A solution of ethyl 1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-
pyrazole-3-carboxylate (5) (0.438 g, 1.0 mmol) in tetrahydrofuran (5 mL) was microwave 
irradiated in the presence of potassium hydroxide aqueous solution (0.5 M, 5 mL) for 2h at 120 
°C. The solution obtained was concentrated in vacuo and the mixture obtained filtered to 
eliminate any presence of solid. The solution obtained was then acidified to pH 2-3 with 
concentrated hydrochloric acid (6 M) in ice water bath. The solid obtained was filtered to afford 
the product as a yellowish solid (0.370 g, 0.90 mmol, 90% yield).  
Flow reaction. A solution of ethyl 1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-
pyrazole-3-carboxylate (6) (0.876 g, 2.0 mmol) in tetrahydrofuran (10 mL) (flow rate 0.25 mL 
min-1, pump A) and a solution of potassium hydroxide (0.56 g,  10 mmol) in water (10 mL) 
(flow rate 0.25 mL min-1, pump B) were reacted in a 14 mL PFA reactor at 120 °C after 
combining at a T-piece (28 min residence time). The solution obtained is concentrated in vacuo 
and the mixture obtained filtered to eliminate any presence of solid. The solution obtained is 
then acidified to pH 2-3 with concentrated hydrochloric acid (6 M) in ice water bath. The solid 
obtained is filtered to afford the product as a yellowish solid (0.75 g, 1.84 mmol, 92% yield). 
LCMS: retention time = 4.35 min, m/z [M+H]+ =  410.25; 1H- NMR (400 MHz, DMSO-d6): 13.08 (s, 
1H), 8.89 (d, 1H,  J = 4.6 Hz), 8.16 (d, 1H, J = 1.9 Hz), 7.73 (d, 1H, J = 9.0 Hz), 7.70 (dd, 1H, J = 9.0, 
1.9 Hz) , 7.26 (t, 1H, J  = 8.4 Hz), 7.20  (d, 1H, J = 4.6 Hz), 6.99 (s, 1H), 6.54 (d, 2H, J = 8.5 Hz), 3.39 
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(s, 6H); 13C- NMR (100 MHz,  DMSO-d6): 162.9, 157.5, 151.6, 149.1, 145.4, 143.3, 138.9, 134.7, 
131.8, 128.0, 127.7, 125.9, 122.1, 118.1, 111.7, 105.6, 104.0, 55.3; FT-IR (neat, cm-1): 1687.7 (m), 
1575.2 (s), 1479.2 (s), 1456.9 (m), 1434.7 (s); HRMS: calculated for [C12H17N3O4Cl]+ 410.0908, 
found 410.0921.  Microanalysis calculated (found) for C12H16N3O4Cl: C 61.54 (61.30%), H 3.94% 
(4.00%), N 10.25% (10.17%). 
2-[1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-
carboxamido]adamantane-2-carboxylic acid (2) 
 
Flow reaction. A solution of ethyl 1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-
pyrazole-3-carboxylic acid (7) (100 mg, 0.23 mmol) in dry DCM (10 mL) (flow rate 0.10 mL 
min-1, pump A) and solution of 1-chloro-N,N,2-trimethyl-1-propenylamine (Ghosez reagent)  
(40 µL, 0.30 mmol) in dry DCM (10 mL) (flow rate 0.10 mL min-1, pump B) were combined at a 
T-piece and heated in a 14 mL PFA coil at 80 °C (70 min residence time). A small portion of the 
output was analysed to check the acid chloride [LCMS: retention time = 5.00 min, m/z [M+H]+= 
428.06; FT-IR: 1758.7 (s), 1633.9 (m), 1593.8 (s), 1475.8 (m), 1444.1 (m); 1H  NMR (600 MHz, 
CDCl3): 9.23 (1H, d,  J  = 5.7 Hz, H-9), 8.92 (1H, d, J  = 1.7 Hz, H-16), 8.34 (1H, d,  J  = 9.2 Hz, H-13), 
7.88 (1H, dd,  J  = 9.2, 1.7 Hz, H-14), 7.59 (1H, d,  J  = 5.7 Hz, H-10), 7.37 (1H, t, J  =8.5 Hz, H-1), 
7.30 (1H, s, H-6), 6.53 (2H, d,  J  = 8.5 Hz, H-2), 3.52 (1H, s, H-3’); 13C NMR (150 MHz, CDCl3): 
161.8, 157.3, 150.6, 149.0, 144.6, 142.0, 141.2, 140.3, 133.1, 131.9, 127.2, 122.6, 121.0, 117.3, 
114.3, 104.1, 55.6; HRMS: Calculated for [C21H16N3O3Cl2]+ 428.0569, found 428.0571]. The 
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solution stream is then delivered to another T-piece where is combined with a solution of amino 
acid (65 mg, 0.28 mmol) in pyridine (10 mL) which is pumped at a flow rate of 0.2 mL/min was 
and then heated in a PFA reactor coil (14 mL, residence time = 35 min, 80 οC). The output 
solution obtained was extracted with dilute HCl and the organic phase was then dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. LC-MS analysis of this residue indicated 
that 50% conversion had been obtained. The residue was dry loaded onto silica and flash 
chromatographed (1-10% gradient of MeOH in DCM). A fraction containing pure meclinertant 
(2) was crystallised from ethanol/hexanes (29 mg, 20% yield). Mp: 219-222 ºC; LCMS: retention 
time = 5.86 min, m/z [M+H]+ = 643.42; FT-IR (neat, cm-1): 3413.7 (w), 2908.8 (w), 1743.8 (w), 
1731.9 (m), 1706.2 (w), 1685.8 (m), 1532.4 (m), 1100.9 (s); 1H- NMR (400 MHz, CDCl3): 8.76 (d, 
1H, J = 4.6 Hz), 8.13 (d, 1H, J = 2.0 Hz), 7.95 (d, 1H, J = 9.0 Hz), 7.48 (dd, 1H, J = 2.0, 9.0 Hz), 7.21 
(t, 1H, J = 8.0 Hz), 7.10 (br. s, 1H), 7.07 (s, 1H), 7.04 (d, 1H, J = 4.6 Hz), 6.39 (d, 2H, J = 8.0 Hz), 
3.39 (s, 6H), 2.66 (s, 2H), 2.14 (d, 2H, J = 12.9 Hz), 2.05 (d, 2H, J = 12.9 Hz), 1.65-1.87 (m, 8H), 
1.51 (s, 9H); 13C- NMR (100 MHz, CDCl3): 171.6, 160.6, 158.0, 151.0, 150.2, 148.6, 144.5, 139.4, 
136.0, 131.6, 128.5, 128.1, 126.4, 122.9, 117.5, 110.7,106.9, 103.8, 80.9, 64.1, 55.4, 38.1, 34.2, 
33.4, 33.0, 28.2, 27.2, 26.9; HRMS: calculated for [C36H40N4O5Cl]+ = 643.2687, found 643.2711. 
N-(4-vinylbenzyl)-N-methylpyridin-4-amine (26). 
 
To a vigorously stirred solution of N-methyl-4-aminopyridine (9.3 mmol, 1.0 g) in dry THF (20 
mL), under complete anhydrous conditions, NaH (1.3 eq, 0.5 g, 60% in mineral oil) is added at 
0°C. The suspension is stirred at 0°C for 10 min and then allowed to warm to rt. After 6h, the 
colourless suspension (n.b.: excess of sodium hydride can be noticed by the solution turning 
yellowish) is cooled to 0°C and 4-vinyl-benzyl chloride (1.1 mL, 0.8 eq) is added dropwise. After 
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10 minutes the reaction is warmed gently to rt and stirred for further 26h. The suspension is 
carefully filtered using filter paper, concentrated in vacuo and the oil obtained dissolved in DCM. 
The mixture is then washed twice with water, brine and then dried over sodium sulfate. The 
organic solution is filtered and concentrated to obtain a brown oil which is dissolved in 2 mL of 
DCM/hexane (1:1) and then passed through basic alumina. The solution is concentrated to 
obtain the product as a yellowish oil (yield 93%). LC-MS: retention time 3.20 min, m/z [M+H] = 
225.17. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.22 (d, J = 6.53 Hz, 2H), 7.37 (d, J = 8.13 Hz, 2H), 
7.13 (d, J = 8.08 Hz, 2H) , 6.70 (q, J = 10.89 Hz,  J = 17.60 Hz, 1H), 6.54 (d, J = 6.53 Hz, 2H), 5.73 
(d, J = 17.57, 1H), 5.24 (d, J = 10.93, 1H), 4.56 (s, 2H), 3.07 (s, 3H).13C-NMR (100 MHz, CDCl3)  δ 
(ppm): 154.10, 150.76, 137.63, 136.00, 127.34, 114.02, 107.26, 55.88, 38.33. HRMS for 
[C10H13O3]+ calculated 181.0865; found 181.0857. 
Dimethylaminopyridine monolith 
 
 
A stock solution was prepared by dissolving N-(4-vinylbenzyl)-N-methylpyridin-4-amine (26) 
(0.80 g) in 1-dodecanol (4.80 g) with gentle heating (<50°C) then adding divinylbenzene (1.60 
g), styrene (0.80 g) and 4,4’-azobis(4-cyanovaleric acid) (0.040 g). A 10 mm i.d./ 4 cm length 
glass column was filled to 2 cm with this sdtock soliution and both ends of the column were 
sealed with plugs (Vapourtec). The column was heated at 90 C using the Vapourtec R4 
convection heater, resulting in a rigid white monolith. Following polymerisation, the monolith 
was allowed to cool to room temperature and the end seals were changed for standard tubing 
connectors. In order to remove the porogen and any residual non-polymeric material, the 
monolith was heated to 60 °C and washed with THF at 0.25 mL/min for 5 h using the Vapourtec 
R4/R2+ flow system. Average pressure drop (THF, 0.25 mL/min, 60 C) = 8-10 bar. 
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